Bibliography: library/10665-381036

The reference for library/10665-381036 (who-iris) and any references extracted from it. library · All references.

Export these 1081 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

1081 shown

  1. World Health Organization (2025). WHO consolidated guidelines on tuberculosis: module 3: diagnosis: web annex B: evidence synthesis and analysis. World Health Organization.
    10665-381036 · catalogue · link · doi:https://doi.org/10.2471/B09341 · repository record · source: catalogue/records/10665-381036.dc.json · held: library/10665-381036
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Aguilera-Alonso, D.; Solis-Garcia, G.; Noguera-Julian, A.; Gonzalez-Martin, J.; Roman Cobena, A.; Baquero-Artigao, F.; Toro Rueda, C.; Rodriguez-Molino, P.; Bloise Sanchez, I.; Vallmanya, T.; Bernet-Sanchez, A.; Minguell Domingo, L.; Rubio, A.; Saavedra-Lozano, J.; Ruiz-Serrano, M. J.; Blazquez-Gamero, D.; Lopez-Roa, P.; Gomez-Pastrana, D.; Lopez Prieto, M. D.; Lopez Medina, E. M.; Gil-Brusola, A.; Martin Nalda, A.; Soriano-Arandes, A.; Tortola, T.; Falcon-Neyra, L.; Gonzalez Galan, V.; Tebruegge, M.; Santiago-Garcia, B.. Accuracy of Xpert Ultra for the diagnosis of paediatric tuberculosis in a low TB burden country: a prospective multicentre study. Thorax 2022;77(10):1023-1029.
    · extracted · source: references/10665-381036.page-036.1.json
  3. Berhanu RH, David A, da Silva P, Shearer K, Sanne I, Stevens W, et al. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018;56(12):12.
    · extracted · source: references/10665-381036.page-036.2.json
  4. Boyles TH, Nduna M, Pitsi T, Scott L, Fox MP, Maartens G. A clinical prediction score including trial of antibiotics and C-reactive protein to improve the diagnosis of tuberculosis in ambulatory people with HIV. Open forum infect. 2020;7(2) (no pagination)(ofz543).
    · extracted · source: references/10665-381036.page-036.3.json
  5. Calderwood CJ, Reeve BW, Mann T, Palmer Z, Nyawo G, Mishra H, et al. Clinical utility of C-reactive protein-based triage for presumptive pulmonary tuberculosis in South African adults. J Infect. 2023;86(1):24-32.
    · extracted · source: references/10665-381036.page-036.4.json
  6. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017;8(4):29.
    · extracted · source: references/10665-381036.page-036.5.json
  7. Chien JY, Lin CK, Yu CJ, Hsueh PR. Usefulness of Xpert MTB/RIF Ultra to Rapidly Diagnose Sputum Smear-Negative Pulmonary Tuberculosis Using Bronchial Washing Fluid. Front Microbiol. 2020;11:588963.
    · extracted · source: references/10665-381036.page-036.6.json
  8. Chilukutu L, Mwanza W, Kerkhoff AD, Somwe P, Kagujje M, Muyoyeta M. Prevalence and interpretation of Xpert Ultra trace results among presumptive TB patients. Public health action. 2022;12(1):28-33.
    · extracted · source: references/10665-381036.page-036.7.json
  9. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76-84.
    · extracted · source: references/10665-381036.page-036.8.json
  10. Jaganath D, Wambi P, Reza TF, Nakafeero J, Aben EO, Kiconco E, et al. A Prospective Evaluation of Xpert MTB/RIF Ultra for Childhood Pulmonary Tuberculosis in Uganda. J Pediatric Infect Dis Soc. 2021;10(5):586-92.
    · extracted · source: references/10665-381036.page-036.9.json
  11. Li M, Qiu Y, Guo M, Qu R, Tian F, Wang G, et al. Comparison of Xpert MTB/RIF Ultra with Xpert MTB/RIF for the detection of Mycobacterium tuberculosis and rifampicin resistance in a primary-level clinic in rural China. Tuberculosis (Edinb). 2023;142:102397.
    · extracted · source: references/10665-381036.page-036.10.json
  12. Liu XH, Xia L, Song B, Wang H, Qian XQ, Wei JH, et al. Stool-based Xpert MTB/RIF Ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: A prospective cohort study. J Infect. 2021;82(1):84-9.
    · extracted · source: references/10665-381036.page-036.11.json
  13. MacLean, E. L.; Villa-Castillo, L.; Espinoza-Lopez, P.; Caceres, T.; Sulis, G.; Kohli, M.; Pai, M.; Ugarte-Gil, C. Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study. Lancet Microbe 2023;4(6):e452-e460.
    · extracted · source: references/10665-381036.page-036.12.json
  14. Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med. 2020;8(4):368-82.
    · extracted · source: references/10665-381036.page-036.13.json
  15. Moodley, N.; Velen, K.; Saimen, A.; Zakhura, N.; Churchyard, G.; Charalambous, S.. Digital Chest Radiography Enhances Screening Efficiency for Pulmonary Tuberculosis in Primary Health Clinics in South Africa. Clinical Infectious Diseases 2022;74(9):1650-1658.
    · extracted · source: references/10665-381036.page-036.14.json
  16. standard Aguilera-Alonso 2022 Spain Aurilio 2022 Brazil Extrapulmonary Babo 2023 Ethiopia Barcellini Italy Chibolela de Haas 2022 Vietnam Enimil 2022 Retrospective Convenience Jaganath 2021 Uganda No/Yes aspirate, NPA Kabir 2020 Bangladesh Sputum, stool Liu 2021 China NCT03734172 (RaPaed 2023)
    · extracted · source: references/10665-381036.page-055.1.json
  17. South Africa, Tanzania, Malawi, India Variable extrapulmonary NCT04121026 HIV 2024)
    · extracted · source: references/10665-381036.page-055.2.json
  18. Côte d'Ivoire, NCT04203628 (Four stool processing methods 2019)
    · extracted · source: references/10665-381036.page-055.3.json
  19. Gastric aspirate, NPA, stool NCT04899076 (FIND 2021)
    · extracted · source: references/10665-381036.page-055.5.json
  20. India, Sputum,gastric and referral Nicol 2018
    · extracted · source: references/10665-381036.page-055.6.json
  21. Unclear Pradhan 2022 India Yes/No Single Sabi 2018 Tanzania Sputum Sabi 2022 Tanzania, Gambia, Mali Ssengooba Uganda Outpatient Yenew 2024 Ethiopia aspirate, stool Zar 2018-2023 South Africa Sputum, NPA, extrapulmonary
    · extracted · source: references/10665-381036.page-056.2.json
  22. CSF = cerebrospinal fluid; NPA= nasopharyngeal aspirate. Methodological quality Studies evaluating Xpert Ultra on sputum specimens (15 studies) In the patient selection domain, for MRS, we judged the risk of bias as low for most studies (13/15, 86.7%) and high for two studies (2/15, 13.3%) because in one study participants with definitive tuberculosis were excluded (Liu 2021) and in the other, the sampling method was retrospective and by convenience (Enimil 2022). Regarding applicability, we judged low concern for most studies (12/15, 80%). We judged high concern for two studies (2/15, 13.3%) because participants were enrolled exclusively as inpatients in tertiary care centers. We judged unclear concern for one study (1/15, 6.7%) because the setting was undefined.
    · extracted · source: references/10665-381036.page-056.3.json
  23. References to included studies Aguilera-Alonso 2022 Aguilera-Alonso D, Solís-García G, Noguera-Julian A. Accuracy of Xpert Ultra for the diagnosis of paediatric tuberculosis in a low TB burden country: a prospective multicentre study. Thorax BMJ July 28 2022;77:1023-1029. [DOI: 10.1136/thoraxjnl-2021-218378]
    · extracted · doi:10.1136/thoraxjnl-2021-218378 · source: references/10665-381036.page-077.1.json
  24. Aurilio 2022 Aurilio, R. B.; Ferreira, S.; Parente, Aaai; Sant'Anna, M. F. P.; Pereira, C. S.; Malaquias, Tdss; Kritski, A. L.; Sant'Anna, C. C.. Gene-Xpert Ultra for the diagnosis of extrapulmonary tuberculosis in children and adolescents. Journal of the São Paulo Institute of Tropical Medicine 10 January 2022;64:12-16. [DOI: http://doi.org/10.1590/S1678-9946202264012]
    · extracted · doi:10.1590/S1678-9946202264012 · source: references/10665-381036.page-077.2.json
  25. Babo 2023 Babo, Y.; Seremolo, B.; Bogale, M.; Bedru, A.; Wabe, Y.; Churako, H.; Bilat, A.; Degaga, T.; de Haas, P.; Tiemersma, E.; Jerene, D.. Comparison of Xpert MTB/RIF Ultra Results of Stool and Sputum in Children with Presumptive Tuberculosis in Southern Ethiopia. MDPI Tropical Medicine and Infectious Disease 30 June 2023;8:350. [DOI: https://doi.org/10.3390/tropicalmed8070350]
    · extracted · doi:10.3390/tropicalmed8070350 · source: references/10665-381036.page-077.3.json
  26. Barcellini 2019 Barcellini L, Borroni E, Cimaglia C, Girardi E, Matteelli A, Marchese V, et al. App-based symptoms screening with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: the E-DETECT TB intervention analysis. PLOS One 2019;14(7):e0218039. [CRS ID: 20771772]
    · extracted · source: references/10665-381036.page-077.4.json
  27. Chibolela 2023 M Chibolela, P de Haas, E Klinkenberg, B Kosloff, C Chunda-Liyoka, P Lungu, C Chabala . Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
    · extracted · source: references/10665-381036.page-077.5.json
  28. International Journal Tuberculosis Lung Disease 1 August 2023;27:612-618.
    · extracted · source: references/10665-381036.page-077.6.json
  29. de Haas 2022 de Haas, P.; Nhung, N. V.; Hng, N. T.; Hoa, N. B.; Loan, N. B.; Thanh, N. T. K.; Gebhard, A.; Slyzkyi, A.; Tue, P. Q.; NV, H. Ng; Hang, P. T.; Ngoc, K. T. T.; Tiemersma, E. W.. Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults. International Journal Lung Disease 23 May 2022;27(1):19-27. [DOI: http://dx.doi.org/10.5588/ijtld.22.0161]
    · extracted · doi:10.5588/ijtld.22.0161 · source: references/10665-381036.page-077.7.json
  30. Enimil 2022 Enimil, A. K.; Nuttall, J. J. C.; Centner, C. M.; Beylis, N.; Eley, B. S.. Xpert MTB/RIF Ultra and mycobacterial culture in routine clinical care at a paediatric hospital. Southern African Journal of Infectious Diseases 20 June 2022;2313-1810. [DOI: https://doi.org/10.4102/sajid.v37i1.398]
    · extracted · doi:10.4102/sajid.v37i1.398 · source: references/10665-381036.page-077.8.json
  31. Jaganath 2021 Jaganath D, Wambi P, Reza TF, Nakafeero J, Aben EO, Kiconco E, et al. A prospective evaluation of Xpert MTB/RIF Ultra for childhood pulmonary tuberculosis in Uganda. Journal of the Pediatric Infectious Diseases Society 2021;piaa159.
    · extracted · source: references/10665-381036.page-077.9.json
  32. Kabir 2020 Kabir S, Rahman SM, Ahmed S, Islam MS, Banu RS, Shewade HD, et al. Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children. Clinical Infectious Diseases 2020;ciaa583.
    · extracted · source: references/10665-381036.page-077.10.json
  33. Liu 2021 Liu XH, Xia L, Song B, Wang H, Qian XQ, Wei JH, Li T, Xi XH, Song YL, Li SQ. Stool-based Xpert MTB/RIF Ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: A prospective cohort study. Journal of Infection 2021;82(1):84-9.
    · extracted · source: references/10665-381036.page-077.11.json
  34. FIND 2021/ NCT04899076 Stool Processing Kit (SPK) Evaluation for Paediatric TB. https://clinicaltrials.gov/ct2/show/NCT04899076 NCT04203628 (first received 24 May 2021).
    · extracted · link · source: references/10665-381036.page-077.12.json
  35. NCT03734172 Olbrich, L.; Nliwasa, M.; Sabi, I.; Ntinginya, N. E.; Khosa, C.; Banze, D.; Corbett, E. L.; Semphere, R.; Verghese, V. P.; Michael, J. S.; Graham, S. M.; Egere, U.; Schaaf, H. S.; Morrison, J.; McHugh, T. D.; Song, R.; Nabeta, P.; Trollip, A.; Geldmacher, C.; Hoelscher, M.; Zar, H. J.; Heinrich, N.. Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis. Pediatric Infectious Disease Journal May 2023;42(5):353-360. [DOI: 10.1097/INF.0000000000003853]
    · extracted · doi:10.1097/INF.0000000000003853 · source: references/10665-381036.page-077.13.json
  36. NCT04121026 NCT04121026. Validation of a Tuberculosis Treatment Decision Algorithm in HIV-infected Children (TB-Speed HIV). clinicaltrials.gov/show/NCT04121026 (first received 9 October 9 2019).
    · extracted · source: references/10665-381036.page-077.14.json
  37. NCT04203628 Evaluation of four stool processing methods combined with Xpert MTB/RIF Ultra for diagnosis of intrathoracic paediatric tuberculosis. https://clinicaltrials.gov/ct2/show/NCT04203628 (first received 18 December 2019).
    · extracted · link · source: references/10665-381036.page-077.15.json
  38. NCT04240990 NCT04240990. Development of a diagnostic prediction sore for tuberculosis in hospitalized children with severe acute malnutrition (TB-Speed SAM). https://clinicaltrials.gov/show/NCT04240990 (first received 27 January 2020).
    · extracted · link · source: references/10665-381036.page-077.16.json
  39. Nicol 2018 Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. Accuracy of Xpert
    · extracted · source: references/10665-381036.page-077.17.json
  40. MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children. Paediatric Infectious Disease Journal 2018;37(10):e261-3. [CRS ID: 14396201]
    · extracted · source: references/10665-381036.page-077.18.json
  41. Parigi 2021 Parigi S, Venturini E, Galli L, Chiappini E. Xpert MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates. International Journal of Tuberculosis and Lung Disease 2021;25(1):75-7.
    · extracted · source: references/10665-381036.page-077.19.json
  42. Pradhan 2022 Pradhan, N. N.; Paradkar, M. S.; Kagal, A.; Valvi, C.; Kinikar, A.; Khwaja, S.; Dhage, R.; Chandane, J.; Ithape, M.; Bendre, M.; Madewar, R.; Nadgeri, V.; Nijampurkar, A.; Jain, D.; Gupte, N.; Gupta, A.; Mave, V.; Dooley, K. E.; Thakur, K. T.. Performance of Xpert MTB/RIF and Xpert Ultra for the diagnosis of tuberculous meningitis in children. International Journal of Tuberculosis and Lung Disease 1 April 2022;26(4):317-325. [DOI: https://doi.org/10.5588/ijtld.21.0388]
    · extracted · doi:10.5588/ijtld.21.0388 · source: references/10665-381036.page-077.20.json
  43. Sabi 2018 Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasamalo M, et al. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. Journal of Infection 2018;77(4):321-7. [CRS ID: 14396211]
    · extracted · source: references/10665-381036.page-077.21.json
  44. Sabi 2022 Sabi, I.; Olomi, W.; Nkereuwem, E.; Togun, T.; Gomez, M. P.; Sylla, M.; Diarra, B.; Sanogo, M.; Sichone, E.; Mahiga, H.; Njeleka, F.; Ebonyi, A. O.; Egere, U.; Ntinginya, N. E.; Hoelscher, M.; Heinrich, N.; Kampmann, B.; Reach4KidsAfrica, R. K. A. Consortium. Diagnosis of paediatric TB using Xpert (R) MTB/RIF Ultra on fresh respiratory samples. International Journal of Tuberculosis Lung Disease 17 March 2022;26(9):862-868. [DOI: http://dx.doi.org/10.5588/ijtld.22.0007]
    · extracted · doi:10.5588/ijtld.22.0007 · source: references/10665-381036.page-077.22.json
  45. Ssengooba 2020 Ssengooba W, de Dieu Iragena J, Nakiyingi L, Mujumbi S, Wobudeya E, Mboizi R, et al. Accuracy of Xpert Ultra in diagnosis of pulmonary tuberculosis among children in Uganda: a substudy from the SHINE trial. Journal of Clinical Microbiology 2020;58(9):e00410-20.
    · extracted · source: references/10665-381036.page-077.23.json
  46. Yenew 2024 Yenew B, de Haas P, Babo Y, et al. Diagnostic accuracy, feasibility and acceptability of stool-based testing for childhood tuberculosis. ERJ Open Res 2024; 0: 00710-2023 [DOI: 10.1183/23` 120541.00710-2023].
    · extracted · doi:10.1183/23` · source: references/10665-381036.page-077.24.json
  47. Zar 2019-2023 Zar HJ, Workman LJ, Prins M, Bateman LJ, Mbhele SP, Whitman CB, et al. Tuberculosis diagnosis in children using Xpert Ultra on different respiratory specimens. American Journal of Respiratory and Critical Care Medicine 2019;200(12):1531-8. [DOI: 10.1164/rccm.201904-0772OC; CRS ID: 14396239]
    · extracted · doi:10.1164/rccm.201904-0772OC · source: references/10665-381036.page-077.25.json
  48. References to excluded studies Biswas 2022 Biswas, S.; Uddin, M. K. M.; Paul, K. K.; Ather, M. F.; Ahmed, S.; Nasrin, R.; Kabir, S.; Heysell, S. K.; Banu, S. Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh. International Journal of Infectious Diseases 2022;114():244-251: 2022; DOI:
    · extracted · source: references/10665-381036.page-077.26.json
  49. 10.1016/j.ijid.2021.11.010; Unable to disaggregate data to children 0-9 years of age
    · extracted · doi:10.1016/j.ijid.2021.11.010 · source: references/10665-381036.page-077.27.json
  50. ChiCTR1800015075 Diagnositc accuracy of Xpert MTB/RIF Ultra assay on diagnosing pediatric pulmonary tuberculosis 2018;():2018; Data is unpublished and incomplete
    · extracted · source: references/10665-381036.page-077.28.json
  51. Christopher 2021 Christopher, D. J.; Coelho, V.; Ebby, G. S.; Shankar, D.; Gupta, R.; Thangakunam, B. Incremental yield of Xpert® MTB/RIF Ultra over Xpert® MTB/RIF in the diagnosis of extrapulmonary TB.
    · extracted · source: references/10665-381036.page-077.29.json
  52. International Journal of Tuberculosis and Lung Disease 2021;25(11):939-944; 2021; DOI: 10.5588/ijtld.21.0280; Adult study population
    · extracted · doi:10.5588/ijtld.21.0280 · source: references/10665-381036.page-077.30.json
  53. Cox 2022 Cox, H.; Workman, L.; Bateman, L.; Franckling-Smith, Z.; Prins, M.; Luiz, J.; Van Heerden, J.; Ah Tow Edries, L.; Africa, S.; Allen, V.; Baard, C.; Zemanay, W.; Nicol, M. P.; Zar, H. J.Oral Swab Specimens Tested With Xpert MTB/RIF Ultra Assay for Diagnosis of Pulmonary Tuberculosis in Children: A Diagnostic Accuracy Study. Clin Infect Dis;75(12):2145-2152; DOI: 10.1093/cid/ciac332; Index test is not studied on a specimen type included in the review
    · extracted · doi:10.1093/cid/ciac332 · source: references/10665-381036.page-077.31.json
  54. CTRI/2020/02/023317 2020 https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/02/023317 2020;():2020; Data is unpublished and incomplete
    · extracted · link · source: references/10665-381036.page-077.32.json
  55. de Haas 2021 de Haas, P.; Yenew, B.; Mengesha, E.; Slyzkyi, A.; Gashu, Z.; Lounnas, M.; Tesfaye, E.; Bedru, A.; Tiemersma, E.; Kremer, K.; Amare, M.; Diriba, G.; Zerihun, B.; Gudina, T.; Tegegn, B.; Bonnet, M.; Negeri, C.; Klinkenberg, E. The Simple One-Step (SOS) Stool Processing Method for Use with the Xpert MTB/RIF Assay for a Child-Friendly Diagnosis of Tuberculosis Closer to the Point of Care. J Clin Microbiol;59(8):e0040621; DOI: 10.1128/JCM.00406-21; Data duplicated in another publication
    · extracted · doi:10.1128/JCM.00406-21 · source: references/10665-381036.page-077.33.json
  56. Esmail 2020 Esmail, Aliasgar; Tomasicchio, Michele; Meldau, Richard; Makambwa, Edson; Dheda, Keertan.
    · extracted · source: references/10665-381036.page-077.34.json
  57. Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. International Journal of Infectious Diseases 2020;95():246-252 2020 DOI: 10.1016/j.ijid.2020.03.025; Adult study population
    · extracted · doi:10.1016/j.ijid.2020.03.025 · source: references/10665-381036.page-077.35.json
  58. Foster 2021 Foster, J.; Marais, B.; Martin, R. L.; Peniyamina, D.; Mendez, D.; Warner, J.; McBryde, E. Tuberculosis in the Torres Strait: the lady doth test too much. Rural Remote Health 0002;21(1):63170002; DOI: 10.22605/RRH6317; Index test is not studied on a specimen type included in the review
    · extracted · doi:10.22605/RRH6317 · source: references/10665-381036.page-077.36.json
  59. Gao 2021 Gao, S.; Wang, C.; Yu, X.; Teng, T.; Shang, Y.; Jia, J.; Dong, L.; Zhao, L.; Liu, S.; Chu, N.; Huang, H. Xpert MTB/RIF Ultra enhanced tuberculous pleurisy diagnosis for patients with unexplained exudative pleural effusion who underwent a pleural biopsy via thoracoscopy: A prospective cohort study. International Journal of Infectious Diseases 2021;106():370-375 2021 DOI: 10.1016/j.ijid.2021.04.011; Adult study population
    · extracted · doi:10.1016/j.ijid.2021.04.011 · source: references/10665-381036.page-077.37.json
  60. Hassane-Harouna 2023 Hassane-Harouna, S.; Braet, S. M.; Decroo, T.; Camara, L. M.; Delamou, A.; Bock, S.; Ortuno-
    · extracted · source: references/10665-381036.page-077.38.json
  61. Gutierrez, N.; Cherif, G. F.; Williams, C. M.; Wisniewska, A.; Barer, M. R.; Rigouts, L.; de Jong, B. C. Annals of Clinical Microbiology and Antimicrobials 2023;22(1) (no pagination)(81): 2023; DOI: 10.1186/s12941-023-00633-8; Adult study population
    · extracted · doi:10.1186/s12941-023-00633-8 · source: references/10665-381036.page-077.39.json
  62. Kagujje 2023 Kagujje, M.; Nyangu, S.; Maimbolwa, M. M.; Shuma, B.; Mutti, L.; Somwe, P.; Sanjase, N.; Chungu, C.; Kerkhoff, A. D.; Muyoyeta, M. Face mask sampling (FMS) for tuberculosis shows lower diagnostic sensitivity than sputum sampling in Guinea. PLoS ONE 2023;18(7 July) (no pagination)(e0288643): 2023; DOI: 10.1371/journal.pone.0288643; Not a diagnostic accuracy study
    · extracted · doi:10.1371/journal.pone.0288643 · source: references/10665-381036.page-077.40.json
  63. Lu 2021 Lu, C.; Jing, H.; Lu, Z.; Deng, Y. Comparison of different methods for the diagnosis of mycobacterium tuberculosis and rifampin-resistance. Clinical Laboratory 2021;67(7)():1691-1696; 2021; DOI: 10.7754/Clin.Lab.2020.200745; Adult study population
    · extracted · doi:10.7754/Clin.Lab.2020.200745 · source: references/10665-381036.page-077.41.json
  64. Manyelo 2019 Manyelo, C. M.; Solomons, R. S.; Snyders, C. I.; Mutavhatsindi, H.; Manngo, P.M.; Stanley, K.; Walzl, G.; Chegou, N. N. Potential of Host Serum Protein Biomarkers in the Diagnosis of Tuberculous Meningitis in Children. Front. Pediatr. 2019;7():12; 2019; DOI: 10.3389/fped.2019.00376; InsuFcient diagnostic accuracy data
    · extracted · doi:10.3389/fped.2019.00376 · source: references/10665-381036.page-077.42.json
  65. Marcy 2023 Marcy, O.; Wobudeya, E.; Font, H.; Vessiere, A.; Chabala, C.; Khosa, C.; Taguebue, J. V.; Moh, R.; Mwanga-Amumpaire, J.; Lounnas, M.; Mulenga, V.;Mavale, S.; Chilundo, J.; Rego, D.; Nduna, B.;Shankalala, P.; Chirwa, U.; DeLauzanne, A.; Dim, B.; Tiogouo Ngouana, E.; Folquet Amorrissani, M.; Cisse, L.; Amon Tanoh Dick, F.; Komena, E. A.; Kwedi Nolna, S.; Businge, G.;Natukunda, N.; Cumbe, S.; Mbekeka, P.; Kim, A.; Kheang, C.; Pol, S.; Maleche-Obimbo, E.; Seddon, J. A.; Mao, T. E.; Graham, S. M.; Delacourt, C.; Borand, L.; Bonnet, M.; Lancet Infect Dis 2023;23(3):341-351; 2023; DOI: 10.1016/S1473-3099(22)00668-5; Insufficient diagnostic accuracy data
    · extracted · doi:10.1016/S1473-3099(22)00668-5 · source: references/10665-381036.page-077.43.json
  66. Mekkaoui 2021 Mekkaoui, L.; Hallin, M.; Mouchet, F.; Payen, M. C.; Maillart, E.; Clevenbergh, P.; Georgala, A.; Van den Wijngaert, S.; Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium.
    · extracted · source: references/10665-381036.page-077.44.json
  67. PLoS ONE 2021;16(4):e0249734; 2021; DOI: 10.1371/journal.pone.0249734; Unable to disaggregate
    · extracted · doi:10.1371/journal.pone.0249734 · source: references/10665-381036.page-077.45.json
  68. Moodley 2022 Moodley, Nishila; Velen, Kavindhran; Saimen, Amashnee; Zakhura, Noor; Churchyard, Gavin; Charalambous, Salome; Digital Chest Radiography Enhances Screening Efficiency for Pulmonary Tuberculosis in Primary Health Clinics in South Africa. Clinical Infectious Diseases 2022;74(9): 2022; DOI: 10.1093/cid/ciab644; Adult study population
    · extracted · doi:10.1093/cid/ciab644 · source: references/10665-381036.page-077.46.json
  69. Motse 2021 Kouemo Motse, F. D.; Nsagha, D. S.; Teyim, P. M.; Adiogo, D.; Kojom Foko, L. P.; Kedy Koum, D. C.; Ngaba, G. P.; Assob Nguedia, J. C. Rifampicin resistance among Mycobacterium tuberculosis-infected individuals using GeneXpert MTB/RIF ultra: a hospital-based study. Trop Med Int Health 0002;26(2):159-1650002; DOI: 10.1111/tmi.13489; Unable to disaggregate data to children 0-9 years of age
    · extracted · doi:10.1111/tmi.13489 · source: references/10665-381036.page-077.47.json
  70. NCT03831906 NCT03831906. TB-Speed Pneumonia. clinicaltrials.gov/show/NCT03831906 (first received 6 February 2019); data were unpublished and incomplete
    · extracted · source: references/10665-381036.page-077.48.json
  71. NCT04038632 NCT04038632. TB-Speed Decentralisation Study. clinicaltrials.gov/show/NCT04038632 (first received 2 August 2019); data were unpublished and incomplete.
    · extracted · source: references/10665-381036.page-077.49.json
  72. NCT05818059 https://clinicaltrials.gov/show/NCT05818059 2023;(): 2023; Not a diagnostic accuracy study
    · extracted · link · source: references/10665-381036.page-077.50.json
  73. Nicol 2020 Nicol M, Schumacher S, Workman L, Broger T, Baard C, Prins M, et al. Accuracy of a novel urine test, Fujifilm SILVAMP TB LAM, for the diagnosis of pulmonary tuberculosis in children. Clinical Infectious Diseases 2020;72(9):e280-8; index text was not studied.
    · extracted · source: references/10665-381036.page-077.51.json
  74. Nicol 2021 Nicol, M. P.; Schumacher, S. G.; Workman, L.; Broger, T.; Baard, C.; Prins, M.; Bateman, L.; du Toit, E.; van Heerden, J.; Szekely, R.; Zar, H. J.; Denkinger, C. M. Accuracy of a Novel Urine Test, Fujifilm SILVAMP Tuberculosis Lipoarabinomannan, for the Diagnosis of Pulmonary Tuberculosis in Children. Clin Infect Dis ;72(9):e280-e288; DOI: 10.1093/cid/ciaa1052; Data duplicated in another publication
    · extracted · doi:10.1093/cid/ciaa1052 · source: references/10665-381036.page-077.52.json
  75. Opota 2019 Opota, O.; Zakham, F.; Mazza-Stalder, J.; Nicod, L.; Greub, G.; Jaton, K. Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting J Clin Microbiol 0002;57(2):020002; DOI: 10.1128/JCM.01717-18; Adult study population pagination): 2017 DOI: 10.1164/ajrccm-conference.2017.B28; Data duplicated in another publication
    · extracted · doi:10.1128/JCM.01717-18 · source: references/10665-381036.page-077.53.json
  76. Peng 2022 Peng, X.; Liao, Q.; Fang, M.; Zhu, Y.; Shi, Y.; Quan, S.; Wang, Y.; Duan, L.; Shi, X.; Liu, Y.; Wang, M.; Wei, Q.; Zhou, H.; Wu, X.; Yao, Y.; Sun, L.; Shen, A.; Wan, C.; Detection of pulmonary tuberculosis in children using the Xpert MTB/RIF Ultra assay on sputum: a multicenter study. Eur J Clin Microbiol Infect Dis 2022;41(2):235-243; 2022; DOI: 10.1007/s10096-021-04340-0; Unable to disaggregate data to children 0-9 years of age
    · extracted · doi:10.1007/s10096-021-04340-0 · source: references/10665-381036.page-077.54.json
  77. Penn-Nicholson 2021 Penn-Nicholson, Adam; Gomathi, Sivaramakrishnan N.; Ugarte-Gil, Cesar; Meaza, Abyot; Lavu, Evelyn; Patel, Pranav; Choudhury, Bandana; Rodrigues, Camilla; Chadha, Sarabjit; Kazi, Mubin; Mace, Aurelien; Nabeta, Pamela; Boehme, Catharina; Gangakhedkar, Raman R.; Sarin, Sanjay; Tesfaye, Ephrem; Gotuzzo, Eduardo; du Cros, Philipp; Tripathy, Srikanth; Ruhwald, Morten; Singh, Manjula; Denkinger, Claudia M.; Schumacher, Samuel G.; Truenat Trial, A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. Consortium European Respiratory Journal 2021;58(5):2100526 2021 DOI: 10.1183/13993003.00526-2021; Adult study population
    · extracted · doi:10.1183/13993003.00526-2021 · source: references/10665-381036.page-077.55.json
  78. Quan 2022 Quan, S.; Jiang, T.; Jiao, W.; Zhu, Y.; Liao, Q.; Liu, Y.; Fang, M.; Shi, Y.; Duan, L.; Shi, X.; Wang, Y.; Tian, X.; Wan, C.; Sun, L.; Shen, A. A Novel Cross-Priming Amplification-Based Assay for Tuberculosis Diagnosis in Children Using Gastric Aspirate. Frontiers in Microbiology 2022;13 (no pagination)(819654):2022; DOI: 10.3389/fmicb.2022.819654; Unable to disaggregate data to children 0-9 years of age
    · extracted · doi:10.3389/fmicb.2022.819654 · source: references/10665-381036.page-077.56.json
  79. Quan 2023 Quan, S.; Zou, T.; Duan, L.; Tian, X.; Wang, Y.; Zhu, Y.; Fang, M.; Shi, Y.; Wan, C.; Sun, L.; Shen, A.; Clinical Characteristics of Pulmonary Tuberculosis in Children Tested by Xpert MTB/RIF Ultra.
    · extracted · source: references/10665-381036.page-077.57.json
  80. Pediatr Infect Dis J ;42(5):389-395; DOI: 10.1097/INF.0000000000003866; Unable to disaggregate
    · extracted · doi:10.1097/INF.0000000000003866 · source: references/10665-381036.page-077.58.json
  81. Rekart 2023 Rekart, M. L.; Aung, A.; Cullip, T.; Mulanda, W.; Mun, L.; Pirmahmadzoda, B.; Kliescokova, J.; Achar, J.; Alvarez, J. L.; Sitali, N.; Sinha, A. Household drug-resistant TB contact tracing in Tajikistan. Int J Tuberc Lung Dis ;27(10):748-753 DOI: 10.5588/ijtld.23.0066; Not a diagnostic accuracy study
    · extracted · doi:10.5588/ijtld.23.0066 · source: references/10665-381036.page-077.59.json
  82. Rekart 2023 Rekart, M. L.; Mun, L.; Aung, A.; Gomez, D.; Mulanda, W.; Kliescikova, J.; Sitali, N.; Rajabov, A.; Azamova, S.; Pirmahmadzoda, B.; Achar, J.; Alvarez, J. L.; Greig, J.; Cros, P. D.; Sinha, A. Detection of Mycobacterium tuberculosis Complex Using the Xpert MTB/RIF Ultra Assay on the Stool of Pediatric Patients in Dushanbe, Tajikistan.Microbiol;11(1):e0369822; DOI: 10.1128/spectrum.03698-22; Unable to disaggregate data to children 0-9 years of age
    · extracted · doi:10.1128/spectrum.03698-22 · source: references/10665-381036.page-077.60.json
  83. Romdhane 2020 Romdhane, E.; Arfaoui, A.; Benabdessalem, C.; Ksentini, M.; Ferjani, A.; Dekhil, N.; Lahiani, R.; Bchiri, S.; Mardassi, H.; Barbouche, M. R.; Boutiba Ben Boubake, I.; Ben Salah, M.; Rammeh, S.Performance of GeneXpert ultra in the diagnosis of Tuberculous Cervical lymphadenitis in formalin fixed paraffin embedded tissues. Tuberculosis (Edinb) 0012;125():1020120012; DOI: 10.1016/j.tube.2020.102012; Adult study population
    · extracted · doi:10.1016/j.tube.2020.102012 · source: references/10665-381036.page-077.61.json
  84. Sabi 2019 Sabi, I.; Rachow, A.; Mapamba, D.; Clowes, P.; Ntinginya, N. E.; Sasamalo, M.; Kamwela, L.; Haraka, F.; Hoelscher, M.; Paris, D.; Saathoff, E.; Reither, K. Diagnostic Accuracy of Xpert Mtb/Rif Ultra for Pulmonary Tuberculosis in Children: A Multicentre Comparative Study. BMJ Global Health 2019;4(Supplement 3)():A2: 2019; DOI: 10.1136/bmjgh-2019-EDC.3; Data duplicated in another
    · extracted · doi:10.1136/bmjgh-2019-EDC.3 · source: references/10665-381036.page-077.62.json
  85. Sabi 2022 Sabi, I.; Sichone, E.; Mahiga, H.; Njeleka, F.; Mtafya, B.; Olomi, W.; Ntinginya, N. E.; Hoelscher, M.; Heinrich, N.; Kampmann, B. Diagnostic accuracy of xpert MTB/RIF ultra for the diagnosis of pulmonary TB in children. BMC Proceedings. Conference: 8th Tanzania Health Summit. Tanzania India 2022;16(Supplement 2): 2022; DOI: 10.1186/s12919-022-00231-0; Data duplicated in another
    · extracted · doi:10.1186/s12919-022-00231-0 · source: references/10665-381036.page-077.63.json
  86. Sharma 2023 Sharma, K.; Sharma, M.; Ayyadurai, N.; Dogra, M.; Sharma, A.; Gupta, V.; Singh, R.; Gupta, A. Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis. Ocular Immunology and Inqammation 2023;31(5)():914-920; 2023; DOI: 10.1080/09273948.2022.2064880; Adult study population
    · extracted · doi:10.1080/09273948.2022.2064880 · source: references/10665-381036.page-077.64.json
  87. Sun 2019 Sun L, Qi X, Liu F, Wu X, Yin Q, Guo Y, et al. A test for more accurate diagnosis of pulmonary tuberculosis. Pediatrics November 2019;144(5):e20190262; index test was not studied on the specimen type included in review.
    · extracted · source: references/10665-381036.page-077.65.json
  88. Bioneer Corporation. IRON-qPCR™. 2023. Available at: eng.bioneer.com/20-a-2600.html (accessed 19 September 2023).
    · extracted · source: references/10665-381036.page-125.1.json
  89. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-2.
    · extracted · source: references/10665-381036.page-125.2.json
  90. Global TB Report, 2023. WHO, Geneva, Switzerland Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;1:CD012768.
    · extracted · source: references/10665-381036.page-125.3.json
  91. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982-90.
    · extracted · source: references/10665-381036.page-125.4.json
  92. Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, Macaskill P. Chapter 10: Undertaking meta-analysis. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook-diagnostic-test-accuracy/currentTakwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Stat Methods Med Res. 2017;26(4):1896-1911.
    · extracted · link · source: references/10665-381036.page-125.5.json
  93. World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detention, 2021 update. Geneva: World Health Organization; 2021a. apps.who.int/iris/handle/10665/342369 (accessed 15 September 2023).
    · extracted · source: references/10665-381036.page-125.6.json
  94. [ISBN:9789240030589]. Included studies Alomatu Samuel, Vasaikar Sandeep, Thomas Kandathil, Dubula Thozama, Moeketsi Khulile. The Efficiency of TB LAM Antigen Test to Xpert MTB/RIF Ultra Test for the Diagnosis of Tuberculous Pericarditis Using Pericardial Fluid Samples. Pathogens 2023;12(9):. [DOI: 10.3390/pathogens12091175]
    · extracted · doi:10.3390/pathogens12091175 · ISBN 9789240030589 · source: references/10665-381036.page-125.7.json
  95. Antel K, Oosthuizen J, Malherbe F, Louw VJ, Nicol MP, Maartens G, et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases 2020;20(1):33. [CRS ID: 16196404]
    · extracted · source: references/10665-381036.page-125.8.json
  96. Antel Katherine, Oosthuizen Jenna, Brown Karryn, Malherbe Francois, Loebenberg Perry, Seaton Cylene, Baloyi Siphiwe, Simba Kudakwashe, Chetty Dharshnee, Louw Vernon J, Maartens Gary, Verburgh Estelle R. Focused investigations to expedite cancer diagnosis among patients with lymphadenopathy in a tuberculosis and HIV-endemic region. AIDS 2023;37(4).
    · extracted · source: references/10665-381036.page-125.9.json
  97. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases 2017;18(1):68-75. [CRS ID: 9074082]
    · extracted · source: references/10665-381036.page-125.10.json
  98. Bisognin Francesco, Lombardi Giulia, Felici Silvia, Monte Paola Dal. MYCO-TB: the first IVD kit suitable for the digestion and decontamination of extra-pulmonary specimens to detect Mycobacteria. Scientific Reports 2021/07/01;11(1):13706. [DOI: 10.1038/s41598-021-93182-z]
    · extracted · doi:10.1038/s41598-021-93182-z · source: references/10665-381036.page-125.11.json
  99. Boloko L, Schutz C, Sibiya N, Balfour A, Ward A, Shey M, Nicol MP, Burton R, Wilkinson RJ, Maartens G, Meintjes G, Barr DA. Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. Lancet Microbe 2022;3(7):e521-e532. [DOI: doi: 10.1016/S2666-5247(22)00062-3]
    · extracted · doi:10.1016/S2666-5247(22)00062-3 · source: references/10665-381036.page-125.12.json
  100. Chin JH, Musubire AK, Morgan N, Pellinen J, Grossman S, Bhatt JM, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology 2019;57(6):pii: e00249-19. [CRS ID: 16196410]
    · extracted · source: references/10665-381036.page-125.13.json
  101. Christopher DJ, Coelho V, Ebby GS, Shankar D, Gupta R, Thangakunam B. Incremental yield of Xpert® MTB/RIF Ultra over Xpert® MTB/RIF in the diagnosis of extrapulmonary TB. Int J Tuberc Lung Dis 2021;25(11):939-944. [DOI: 10.5588/ijtld.21.0280]
    · extracted · doi:10.5588/ijtld.21.0280 · source: references/10665-381036.page-125.14.json
  102. Cresswell FV, Tugume L, Bahr NC, Kwizera R, Bangdiwala AS, Musubire AK, et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease 2020;20(3):308-17. [CRS ID: 16196414]
    · extracted · source: references/10665-381036.page-125.15.json
  103. Cresswell Fiona V, Ellis Jayne, Kagimu Enock, Bangdiwala Ananta S, Okirwoth Michael, Mugumya Gerald, Rutakingirwa Morris, Kasibante John, Quinn Carson M, Ssebambulidde Kenneth, Rhein Joshua, Nuwagira Edwin, Tugume Lillian, Martyn Emily, Skipper Caleb P, Muzoora Conrad, Grint Daniel, Meya David B, Bahr Nathan C, Elliott Alison M, Boulware David R. Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. Open Forum Infect Dis 2020/04/01;7(4):ofaa100. [DOI: 10.1093/ofid/ofaa100]
    · extracted · doi:10.1093/ofid/ofaa100 · source: references/10665-381036.page-125.16.json
  104. Donovan J, Anh Thu DD, Phu NH, Dung VT, Quang TP, Nghia HDT, et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease 2020;20:299-307. [CRS ID: 16196416]
    · extracted · source: references/10665-381036.page-125.17.json
  105. Gao S, Wang C, Yu X, Teng T, Shang Y, Jia J, Dong L, Zhao L, Liu S, Chu N, Huang H. Xpert MTB/RIF Ultra enhanced tuberculous pleurisy diagnosis for patients with unexplained exudative pleural effusion who underwent a pleural biopsy via thoracoscopy: A prospective cohort study.. Int J Infect Dis. 2021;106:370-375. [DOI: 10.1016/j.ijid.2021.04.011]
    · extracted · doi:10.1016/j.ijid.2021.04.011 · source: references/10665-381036.page-125.18.json
  106. García-Rodríguez JF, Álvarez-Díaz H, Lorenzo-García MV, Mariño-Callejo A, Fernández-Rial Á, Sesma-Sánchez P. Extrapulmonary tuberculosis: epidemiology and risk factors. Enferm Infecc Microbiol Clin. 2011 Aug-Sep;29(7):502-9. doi: 10.1016/j.eimc.2011.03.005.
    · extracted · doi:10.1016/j.eimc.2011.03.005 · source: references/10665-381036.page-125.19.json
  107. Epub 2011 May 12. PMID: 21570159.
    · extracted · source: references/10665-381036.page-125.20.json
  108. Hoel Ida Marie, Sviland Lisbet, Syre Heidi, Dyrhol-Riise Anne Ma, Skarstein Ingerid, Jebsen Peter, Jørstad Melissa Davidsen, Wiker Harald, Mustafa Tehmina. Diagnosis of extrapulmonary tuberculosis using the MPT64 antigen detection test in a high-income low tuberculosis prevalence setting. BMC Infectious Diseases 2020/02/12;20(1):130. [DOI: 10.1186/s12879-020-4852-z]
    · extracted · doi:10.1186/s12879-020-4852-z · source: references/10665-381036.page-125.21.json
  109. Hoel Ida Marie, Syre Heidi, Skarstein Ingerid, Mustafa Tehmina. Xpert MTB/RIF ultra for rapid diagnosis of extrapulmonary tuberculosis in a high-income low-tuberculosis prevalence setting. Scientific Reports 2020/08/18;10(1):13959. [DOI: 10.1038/s41598-020-70613-x]
    · extracted · doi:10.1038/s41598-020-70613-x · source: references/10665-381036.page-125.22.json
  110. Huang Mailing, Wang Guirong, Sun Qing, Jiang Guanglu, Li Wensheng, Ding Zeyu, Jia Hongyan, Gao Mengqiu, Huang Hairong, Li Qi. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in a clinical practice setting of China. Diagnostic Microbiology and Infectious Disease 2021/05/01;100(1):115306. [DOI: https://doi.org/10.1016/j.diagmicrobio.2020.115306]
    · extracted · doi:10.1016/j.diagmicrobio.2020.115306 · source: references/10665-381036.page-125.23.json
  111. Jose RA et al. Diagnostic Accuracy of Truenat MTB Plus for the detection of Pulmonary and Extrapulmonary Tuberculosis. 2024 (Unpublished)
    · extracted · source: references/10665-381036.page-125.24.json
  112. Makambwa E, Maboreke HR, Fadul M, Meldau R, Dhansay M, Esmail A, Dheda K. Clinical characteristics that portend a positive Xpert Ultra test result in patients with pleural tuberculosis. Afr J Thorac Crit Care Med 2019;31. [DOI: 10.7196/AJTCCM.2019.v25i2.011]
    · extracted · doi:10.7196/AJTCCM.2019.v25i2.011 · source: references/10665-381036.page-125.25.json
  113. Mansfield M, McLaughlin AM, Roycroft E, Montgomery L, Keane J, Fitzgibbon MM, Rogers TR. Diagnostic Performance of Xpert MTB/RIF Ultra Compared with Predecessor Test, Xpert MTB/RIF, in a Low TB Incidence Setting: a Retrospective Service Evaluation. . Microbiol Spectr 2022;10(3):e0234521. [DOI: 10.1128/spectrum.02345-21]
    · extracted · doi:10.1128/spectrum.02345-21 · source: references/10665-381036.page-125.26.json
  114. Mekkaoui L, Hallin M, Mouchet M , Payen M, Maillart E, Clevenbergh P, GeorgalaI A, Van den Wijngaert S. Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium. PloS One 2021;16:e0249734.
    · extracted · source: references/10665-381036.page-125.27.json
  115. Minnies Stephanie, Reeve Byron WP, Rockman Loren, Nyawo Georgina, Naidoo Charissa C, Kitchin Natasha, Rautenbach Cornelia, Wright Colleen A, Whitelaw Andrew, Schubert Pawel, Warren Robin M, Theron Grant. Xpert MTB/RIF Ultra Is Highly Sensitive for the Diagnosis of Tuberculosis Lymphadenitis in a High-HIV Setting. Journal of Clinical Microbiology 2021;59(12):10.1128/jcm.01316-21. [DOI: 10.1128/jcm.01316-21]
    · extracted · doi:10.1128/jcm.01316-21 · source: references/10665-381036.page-125.28.json
  116. Ninan MM, Rupali P, Varghese GM, Shalini EB, Venkatesh K, Jesudason MR, Rebekah G, Michael JS. . Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls. Int J Tuberc Lung Dis 2022;26:441-445. [DOI: 10.5588/ijtld.21.0480]
    · extracted · doi:10.5588/ijtld.21.0480 · source: references/10665-381036.page-125.29.json
  117. Osei Sekyere John, Maphalala Nontobeko, Malinga Lesibana A, Mbelle Nontombi M, Maningi Nontuthuko E. A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens. Scientific Reports 2019/11/12;9(1):16587. [DOI: 10.1038/s41598-019-53086-5]
    · extracted · doi:10.1038/s41598-019-53086-5 · source: references/10665-381036.page-125.30.json
  118. Peñata Adrián, Zuluaga-Avendaño Shally, Castaño-Sepúlveda Tatiana, Bustamante-Mira Julián, Ospina Sigifredo. Performance of Real-Time Semi-Quantitative Polymerase Chain Reaction Assay for Optimum Diagnosis of Extrapulmonary Tuberculosis and Sensitivity to Rifampin in a Tertiary Care Center. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2021/05/17;73. [DOI: 10.24875/RIC.21000040]
    · extracted · doi:10.24875/RIC.21000040 · source: references/10665-381036.page-125.31.json
  119. Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F. Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology 2018;56(9):pii: e00659-18. [CRS ID: 16196430]
    · extracted · source: references/10665-381036.page-125.32.json
  120. Quinn Carson M, Kagimu Enock, Okirworth Michael, Bangdiwala Ananta S, Mugumya Gerald, Ramachandran Prashanth S, Wilson Michael R, Meya David B, Cresswell Fiona V, Bahr Nathan C, Boulware David R. Fujifilm SILVAMP TB LAM Assay on Cerebrospinal Fluid for the Detection of Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. Clin Infect Dis 2021/11/01;73(9):e3428-e3434. [DOI: 10.1093/cid/ciaa1910]
    · extracted · doi:10.1093/cid/ciaa1910 · source: references/10665-381036.page-125.33.json
  121. Shao L, Qiu C, Zheng L, Yang Y, Yang X, Liang Q, Zhang Y, Che N, Pang Y, Duan H. . Comparison of diagnostic accuracy of the GeneXpert Ultra and cell-free nucleic acid assay for tuberculous meningitis: A multicentre prospective study. Int J Infect Dis. 2020;98:441-446. [DOI: 10.1016/j.ijid.2020.06.076.]
    · extracted · doi:10.1016/j.ijid.2020.06.076 · source: references/10665-381036.page-125.34.json
  122. Sharma Kusum, Sharma Megha, Shree Ritu, Modi Manish, Goyal Manoj, Narang Dhawal, Sharma Aman, Lal Vivek, Sharma Navneet, Ray Pallab. Xpert MTB/RIF ultra for the diagnosis of tuberculous meningitis: A diagnostic accuracy study from India. Tuberculosis 2020/12/01;125:101990. [DOI: https://doi.org/10.1016/j.tube.2020.101990]
    · extracted · doi:10.1016/j.tube.2020.101990 · source: references/10665-381036.page-125.35.json
  123. Sharma K, Sharma M, Modi M, Singla N, Sharma A, Sharma A, Sharma N, Ray P. Comparative analysis of Truenat™ MTB Plus and Xpert Ultra in diagnosing tuberculous meningitis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2021;25(8):626-631. [DOI: 10.5588/ijtld.21.0156]
    · extracted · doi:10.5588/ijtld.21.0156 · source: references/10665-381036.page-125.36.json
  124. Sharma Kusum, Sharma Megha, Gupta Nalini, Modi Tanish, Joshi Himanshu, Shree Ritu, Sharma Aman. Determining the diagnostic potential of Truenat MTB Plus for Tubercular lymphadenitis and detection of drug resistance and a comparison with GeneXpert Ultra. Tuberculosis 2023/09/01;142:102379. [DOI: https://doi.org/10.1016/j.tube.2023.102379]
    · extracted · doi:10.1016/j.tube.2023.102379 · source: references/10665-381036.page-125.37.json
  125. Slail Mousa J, Booq Rayan Y, Al-Ahmad Ibrahim H, Alharbi Arwa A, Alharbi Shafi F, Alotaibi Mutlaq Z, Aljubran Abdulaziz M, Aldossary Ahmad M, Memish Ziad A, Alyamani Essam J, Tawfik Essam A, Binjomah Abdulwahab Z. Evaluation of Xpert MTB/RIF Ultra for the Diagnosis of Extrapulmonary Tuberculosis: A Retrospective Analysis in Saudi Arabia. Journal of Epidemiology and Global Health 2023/09/14. [DOI: 10.1007/s44197-023-00150-z]
    · extracted · doi:10.1007/s44197-023-00150-z · source: references/10665-381036.page-125.38.json
  126. Spener-Gomes Renata, Costa Allyson Guimarães, Melo Hilda Ferreira de, Souza Alexandra Brito de, Beraldi-Magalhães Francisco, Jesus Jaquelane Silva, Arriaga María B, Kritski Afrânio, Safe Izabella, Andrade Bruno B, Trajman Anete, Cordeiro-Santos Marcelo. Examination of respiratory specimens improves microbiological diagnosis of patients with presumptive extrapulmonary tuberculosis. International Journal of Infectious Diseases 2021/04/01;105:743-745. [DOI: https://doi.org/10.1016/j.ijid.2021.03.022]
    · extracted · doi:10.1016/j.ijid.2021.03.022 · source: references/10665-381036.page-125.39.json
  127. Wang G, Wang S, Jiang G, Yang X, Huang M, Huo F, et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection 2019;78(4):311-6. [CRS ID: 16196442]
    · extracted · source: references/10665-381036.page-125.40.json
  128. Wang G, Wang S, Yang X, Sun Q, Jiang G, Huang M, et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest 2020;157(2):268-75. [CRS ID: 16196444]
    · extracted · source: references/10665-381036.page-125.41.json
  129. Wu X, Tan G, Gao R, Yao L, Bi D, Guo Y, et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases 2019;81:91-6. [CRS ID: 16196446]
    · extracted · source: references/10665-381036.page-125.42.json
  130. Yadav Bhavana, Sharma Megha, Singla Neeraj, Shree Ritu, Goyal Manoj, Modi Tanish, Sharma Ananya, Sharma Aman, Sharma Navneet, Ray Pallab, Modi Manish, Sharma Kusum. Molecular diagnosis of Tuberculous meningitis: sdaA-based multi-targeted LAMP and GeneXpert Ultra. Tuberculosis 2023/05/01;140:102339. [DOI: https://doi.org/10.1016/j.tube.2023.102339]
    · extracted · doi:10.1016/j.tube.2023.102339 · source: references/10665-381036.page-125.43.json
  131. Yu Xia, Zhang Tingting, Kong Yaoyao, Wang Fen, Dong Lingling, Han Ming, Huang Hairong. Xpert MTB/RIF Ultra outperformed the Xpert assay in tuberculosis lymphadenitis diagnosis: a prospective head-to-head cohort study. International Journal of Infectious Diseases 2022;122:741-746. [DOI: 10.1016/j.ijid.2022.07.039]
    · extracted · doi:10.1016/j.ijid.2022.07.039 · source: references/10665-381036.page-125.44.json
  132. Appendix 1. Detailed search strategies Ovid MEDLINE(R) ALL <1946 to October 10, 2023>
    · extracted · source: references/10665-381036.page-125.45.json
  133. Tuberculosis, Multidrug-Resistant/Extensively Drug-Resistant Tuberculosis/exp Tuberculosis, Extrapulmonary/1 or 2 or 3 or 4 or 5 6 or 7 9 and 10 8 or 11 13 or 14 or 15 12 and 16 12 and 18 12 and 20 Embase <1996 to 2023 Week 40>
    · extracted · source: references/10665-381036.page-125.46.json
  134. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2017 International Bank for Reconstruction and Development / The World Bank.; 2017.
    · extracted · source: references/10665-381036.page-202.1.json
  135. World Health Organisation. Global tuberculosis report 2023 2023 [cited 2024 27 March]. Available from: https://www.who.int/publications/i/item/9789240083851.
    · extracted · link · source: references/10665-381036.page-202.2.json
  136. World Health Organisation. Global Tuberculosis Report 2022. 2022a [Available from: who.int/teams/global-tuberculosis-programme/tbreports/global-tuberculosis-report-2022.
    · extracted · source: references/10665-381036.page-202.3.json
  137. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402.
    · extracted · source: references/10665-381036.page-202.4.json
  138. Marais BJ. Childhood tuberculosis: epidemiology and natural history of disease. Indian J Pediatr. 2011;78(3):321-7.
    · extracted · source: references/10665-381036.page-202.5.json
  139. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120(4):316-53.
    · extracted · source: references/10665-381036.page-202.6.json
  140. World Health Organisation. Status update: Reaching the targets in the political declaration of the United Nations General Assembly High-level Meeting on the fight against tuberculosis 2023 [updated 24 September 2023. Available from: https://www.who.int/publications/m/item/WHO-UCN-TB-2023.4.
    · extracted · link · source: references/10665-381036.page-202.7.json
  141. World Health Organisation. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. 2020a [Available from: who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistanttuberculosis.
    · extracted · source: references/10665-381036.page-202.8.json
  142. World Health Organisation. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis–Rapid diagnostics for tuberculosis detection. 2022b.
    · extracted · source: references/10665-381036.page-202.9.json
  143. World Health Organisation. WHO operational handbook on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detention, 2021 update. 2021a [
    · extracted · source: references/10665-381036.page-202.10.json
  144. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424-35.
    · extracted · source: references/10665-381036.page-202.11.json
  145. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021;2:Cd009593.
    · extracted · source: references/10665-381036.page-202.12.json
  146. Penn-Nicholson A, Gomathi SN, Ugarte-Gil C, Meaza A, Lavu E, Patel P, et al. A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. Eur Respir J. 2021;58(5).
    · extracted · source: references/10665-381036.page-202.13.json
  147. Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, Shetty A, et al. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PLoS One. 2013;8(1):e51121.
    · extracted · source: references/10665-381036.page-202.14.json
  148. Nikam C, Kazi M, Nair C, Jaggannath M, M M, R V, et al. Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. Int J Mycobacteriol. 2014;3(3):205-10.
    · extracted · source: references/10665-381036.page-202.15.json
  149. Inbaraj LR DJ, Sathya Narayanan MK, Srinivasalu VA, Bhaskar A, Rajendran P, et al.,. TB-LAMP (loop-mediated isothermal amplification) for diagnosing pulmonary tuberculosis in children (Protocol). Cochrane Database Syst Rev 2023b.
    · extracted · source: references/10665-381036.page-202.16.json
  150. Dayal R, Yadav A, Agarwal D, Kumar M, Kamal R, Singh D, et al. Comparison of Diagnostic Yield of Tuberculosis Loop-Mediated Isothermal Amplification Assay With Cartridge-Based Nucleic Acid Amplification Test, Acid-Fast Bacilli Microscopy, and Mycobacteria Growth Indicator Tube Culture in Children With Pulmonary Tuberculosis. J Pediatric Infect Dis Soc. 2021;10(2):83-7.
    · extracted · source: references/10665-381036.page-202.17.json
  151. Fan L, Guan B, Cheng M, Liu C, Tian Y, Li R, et al. A Comprehensive Evaluation of a Loop-Mediated Isothermal Amplification Assay for the Diagnosis of Pulmonary Tuberculosis in Children Using Bronchoalveolar Lavage Fluid. Infect Drug Resist. 2022;15:975-87.
    · extracted · source: references/10665-381036.page-202.18.json
  152. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum samples. J Clin Microbiol. 2003;41(6):2616-22.
    · extracted · source: references/10665-381036.page-202.19.json
  153. Joon D, Nimesh M, Varma-Basil M, Saluja D. Evaluation of improved IS6110 LAMP assay for diagnosis of pulmonary and extra pulmonary tuberculosis. J Microbiol Methods. 2017;139:87-91.
    · extracted · source: references/10665-381036.page-202.20.json
  154. Haraka F, Kakolwa M, Schumacher SG, Nathavitharana RR, Denkinger CM, Gagneux S, et al. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. Cochrane Database Syst Rev. 2021;5(5):Cd012972.
    · extracted · source: references/10665-381036.page-202.21.json
  155. MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014;92(2):126-38.
    · extracted · source: references/10665-381036.page-202.22.json
  156. Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors),. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) 2023. Available from: http://www.training.cochrane.org/handbook.
    · extracted · link · source: references/10665-381036.page-202.23.json
  157. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.
    · extracted · source: references/10665-381036.page-202.24.json
  158. World Helath Organisation. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions 2020b [updated 24 September 2023. Available from: https://www.who.int/publications/i/item/9789240022195.
    · extracted · link · source: references/10665-381036.page-202.25.json
  159. Covidence. Covidence systematic review software Melbourne, Australia: Veritas Health Innovation; [Available from: www.covidence.org.
    · extracted · link · source: references/10665-381036.page-202.26.json
  160. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
    · extracted · source: references/10665-381036.page-202.27.json
  161. Higgins JPT ES, Li T,. Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane Syst. Rev; 2023. Available from: http://www.training.cochrane.org/handbook.
    · extracted · link · source: references/10665-381036.page-202.28.json
  162. Page MJ HJ, Sterne JAC,. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023): Cochrane Syst. Rev.; 2023. Available from: http://www.training.cochrane.org/handbook.
    · extracted · link · source: references/10665-381036.page-202.29.json
  163. GRADEpro GDT. McMaster University (developed by Evidence Prime) GRADEpro GDT McMaster University (developed by Evidence Prime) [Available from: gradepro.org.
    · extracted · source: references/10665-381036.page-202.30.json
  164. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6.
    · extracted · source: references/10665-381036.page-202.31.json
  165. Cattamanchi A, Reza TF, Nalugwa T, Adams K, Nantale M, Oyuku D, et al. Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. N Engl J Med. 2021;385(26):2441-50.
    · extracted · source: references/10665-381036.page-202.32.json
  166. Esmail A, Randall P, Oelofse S, Tomasicchio M, Pooran A, Meldau R, et al. Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial. Nat Med. 2023;29(4):1009-16.
    · extracted · source: references/10665-381036.page-202.33.json
  167. Reza TF, Nalugwa T, Farr K, Nantale M, Oyuku D, Nakaweesa A, et al. Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implement Sci. 2020;15(1):24.
    · extracted · source: references/10665-381036.page-202.34.json
  168. Marcy O, Wobudeya E, Font H, Vessière A, Chabala C, Khosa C, et al. Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial. Lancet Infect Dis. 2023;23(3):341-51.
    · extracted · source: references/10665-381036.page-202.35.json
  169. Mukoka M, Twabi HH, Msefula C, Semphere R, Ndhlovu G, Lipenga T, et al. Utility of Xpert MTB/RIF Ultra and digital chest radiography for the diagnosis and treatment of TB in people living with HIV: a randomised controlled trial (XACT-TB). Trans R Soc Trop Med Hyg. 2023;117(1):28-37.
    · extracted · source: references/10665-381036.page-202.36.json
  170. Leukes VN, Hella J, Sabi I, Cossa M, Khosa C, Erkosar B, et al. Study protocol: a pragmatic, cluster-randomized controlled trial to evaluate the effect of implementation of the Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania (TB-CAPT CORE). BMC Infect Dis. 2024;24(1):107.
    · extracted · source: references/10665-381036.page-202.37.json
  171. World Health Organisation. Global Tuberculosis Report 2021: Chapter 2.1: TB incidence: WHO; 2023 [cited 2023 07 December]. Available from: https://www.who.int/publications/digital/global-tuberculosis-report-2021/tb-disease-burden/incidence#:~:text=Geographically%2C%20in%202020%2C%20most%20TB%20cases%20were%20in,Mediterranean%20%288.3%25%29%2C%20the%20Americas%20%283.0%25%29%20and%20Europe%20%282.3%25%29.
    · extracted · link · source: references/10665-381036.page-202.38.json
  172. Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials? Trans R Soc Trop Med Hyg. 2016;110(8):432-44.
    · extracted · source: references/10665-381036.page-202.39.json
  173. Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P. Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial. Am J Respir Crit Care Med. 2017;196(7):901-10.
    · extracted · source: references/10665-381036.page-202.40.json
  174. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med. 2014;11(12):e1001766.
    · extracted · source: references/10665-381036.page-202.41.json
  175. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy and clinical impact of point-of-care xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: A multicentre, randomised controlled trial. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS. 2014;189(MeetingAbstracts).
    · extracted · source: references/10665-381036.page-202.42.json
  176. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: A cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health. 2015;3(8):e450-e7.
    · extracted · source: references/10665-381036.page-202.43.json
  177. Nct. Optimizing Clinical Outcomes in HIV-Infected Adults &amp; Children. 2014.
    · extracted · source: references/10665-381036.page-202.44.json
  178. Nct. Xpert Ultra and Xpert HIV-VL in People Living With HIV. 2017.
    · extracted · source: references/10665-381036.page-202.45.json
  179. Nct. Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa. 2016.
    · extracted · source: references/10665-381036.page-202.46.json
  180. Isrctn. Impact of a novel molecular tuberculosis (TB) diagnostic system in patients at high risk of TB mortality in rural South Africa. 2011.
    · extracted · source: references/10665-381036.page-202.47.json
  181. Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, et al. Xpert MTB/RIF Assay Shows Faster Clearance of <i>Mycobacterium tuberculosis</i> DNA with Higher Levels of Rifapentine Exposure. J Clin Microbiol. 2016;54(12):3028-33.
    · extracted · source: references/10665-381036.page-202.48.json
  182. Bassett IV, Forman LS, Govere S, Thulare H, Frank SC, Mhlongo B, et al. Test and Treat TB: a pilot trial of GeneXpert MTB/RIF screening on a mobile HIV testing unit in South Africa. BMC Infect Dis. 2019;19:7.
    · extracted · source: references/10665-381036.page-202.49.json
  183. Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, et al. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical Infectious Diseases. 2023;76(3):E580-E9.
    · extracted · source: references/10665-381036.page-202.50.json
  184. Auld AF, Agizew T, Pals S, Finlay A, Ndwapi N, Boyd R, et al. Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality. BMC Infect Dis. 2016;16(1):606.
    · extracted · source: references/10665-381036.page-202.51.json
  185. Hanrahan CF, Nonyane BAS, Mmolawa L, West NS, Siwelana T, Lebina L, et al. Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). PLos Med. 2019;16(4):14.
    · extracted · source: references/10665-381036.page-202.52.json
  186. Ershova JV, Volchenkov GV, Somova TR, Kuznetsova TA, Kaunetis NV, Kaminski D, et al. Impact of GeneXpert MTB/RIF R on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia. BMC Infect Dis. 2020;20(1):543.
    · extracted · source: references/10665-381036.page-202.53.json
  187. Isrctn. Xpert for Tuberculosis: Evaluating a New Diagnostic (XTEND). 2011.
    · extracted · source: references/10665-381036.page-202.54.json
  188. Peter J, Theron G, Pooran A, Pascoe M, Thomas J, Dheda KUJ. Two sputum sample acquisition methods for smear-negative or sputum-scarce persons with suspected tuberculosis in primary-care practice: A randomised controlled trial. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS. 2013;187(MeetingAbstracts).
    · extracted · source: references/10665-381036.page-202.55.json
  189. Calligaro GL, Zijenah LS, Peter JG, Theron G, Buser V, McNerney R, et al. Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infect Dis. 2017;17(4):441-50.
    · extracted · source: references/10665-381036.page-202.56.json
  190. Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden o. Lancet Respir Med. 2015;3(8):621-30.
    · extracted · source: references/10665-381036.page-202.57.json
  191. Rudolf F, Abate E, Moges B, Mendes AM, Mengistu MY, Sifna A, et al. Increasing smear positive tuberculosis detection using a clinical score - A stepped wedge multicenter trial from Africa. International Journal of Infectious Diseases. 2021;113(Supplement 1):S55-S62.
    · extracted · source: references/10665-381036.page-202.58.json
  192. Khumsri J, Hiransuthikul N, Hanvoravongchai P, Chuchottaworn C. Effectiveness of Tuberculosis Screening Technology in the Initiation of Correct Diagnosis of Pulmonary Tuberculosis at a Tertiary Care Hospital in Thailand: Comparative Analysis of Xpert MTB/RIF Versus Sputum AFB Smear. Asia Pac J Public Health. 2018;30(6):542-50.
    · extracted · source: references/10665-381036.page-202.59.json
  193. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS ONE. 2012;7(11):e48599.
    · extracted · source: references/10665-381036.page-202.60.json
  194. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187-97.
    · extracted · source: references/10665-381036.page-202.61.json
  195. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 2014;11(11):e1001760.
    · extracted · source: references/10665-381036.page-202.62.json
  196. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, et al. Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial. PLoS ONE. 2015;10(4):e0123252.
    · extracted · source: references/10665-381036.page-202.63.json
  197. Ahsberg J, Puplampu P, Kwashie A, Commey JO, Ganu VJ, Omari MA, et al. Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana. Clin Infect Dis. 2023;77(8):1185-93.
    · extracted · source: references/10665-381036.page-202.64.json
  198. Jiang Q, Ji L, Qiu Y, Su X, Guo M, Zhong S, et al. A randomised controlled trial of stepwise sputum collection to increase yields of confirmed tuberculosis. International Journal of Tuberculosis and Lung Disease. 2019;23(7):685-91.
    · extracted · source: references/10665-381036.page-202.65.json
  199. Agizew T, Chihota V, Nyirenda S, Tedla Z, Auld AF, Mathebula U, et al. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial. BMC Infect Dis. 2019;19(1):1058.
    · extracted · source: references/10665-381036.page-202.66.json
  200. Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, et al. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med. 2020;382(25):2397-410.
    · extracted · source: references/10665-381036.page-202.67.json
  201. Nct. Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts &lt;100/mm3. 2014.
    · extracted · source: references/10665-381036.page-202.68.json
  202. Ngwira LG, Corbett EL, Khundi M, Barnes GL, Nkhoma A, Murowa M, et al. Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clinical Infectious Diseases. 2019;68(7):1176-83.
    · extracted · source: references/10665-381036.page-202.69.json
  203. Santos ML, Batista JDL, Braga C, da Silva AP, Maruza M, Souza WV, et al. Effectiveness of screening for tuberculosis in HIV: a pragmatic clinical trial. Revista de Saude Publica. 2021;55:1-11.
    · extracted · source: references/10665-381036.page-202.70.json
  204. Auld AF, Agizew T, Mathoma A, Boyd R, Date A, Pals SL, et al. Effect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial. BMC Med. 2020;18(1):19.
    · extracted · source: references/10665-381036.page-202.71.json
  205. Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open forum infect. 2014;1(1):ofu038.
    · extracted · source: references/10665-381036.page-202.72.json
  206. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. The Lancet. 2018;392(10144):292-301.
    · extracted · source: references/10665-381036.page-202.73.json
  207. Van Rie A, Page-Shipp L, Mellet K, Scott L, Mkhwnazi M, Jong E, et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases. 2013;32(11):1409-15.
    · extracted · source: references/10665-381036.page-202.74.json
  208. Alvarez GG, Dyk DDV, Desjardlns M, Yasseen AS, 3rd, Aaron SD, Cameron DW, et al. The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada. Chest. 2015;148(3):767-73.
    · extracted · source: references/10665-381036.page-202.75.json
  209. Cadavid C, Realpe T, Mejía GI, Zapata E, Hernández M, Robledo J. Contribución del uso de XPERT MTB/RIF y su costo-efectividad en el diagnóstico de tuberculosis pulmonar y la resistencia a rifampicina: una comparación con métodos diagnósticos no moleculares. Infectio. 2022;26(2):121-7.
    · extracted · source: references/10665-381036.page-202.76.json
  210. Williams V, Calnan M, Edem B, Onwuchekwa C, Okoro C, Candari C, et al. GeneXpert rollout in three high-burden tuberculosis countries in Africa: A review of pulmonary tuberculosis diagnosis and outcomes from 2001 to 2019. African Journal of Laboratory Medicine. 2022;11(1) (no pagination)(a1811).
    · extracted · source: references/10665-381036.page-202.77.json
  211. Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A. The impact of Xpert( R) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015;19(4):392-8.
    · extracted · source: references/10665-381036.page-202.78.json
  212. Schmidt BM, Geldenhuys H, Tameris M, Luabeya A, Mulenga H, Bunyasi E, et al. Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African community. South African Medical Journal. 2017;107(12):1078-81.
    · extracted · source: references/10665-381036.page-202.79.json
  213. Nct. Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons. 2015.
    · extracted · source: references/10665-381036.page-202.80.json
  214. Theron G, Peter J, Meldau R, Khalfey H, Gina P, Matinyena B, et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax. 2013;68(11):1043-51.
    · extracted · source: references/10665-381036.page-202.81.json
  215. Pereira GR, Barbosa MS, Dias NJD, Almeida CPB, Silva DR. Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil. PLoS ONE. 2018;13(3):e0193988.
    · extracted · source: references/10665-381036.page-202.82.json
  216. Ramirez HL, Garcia-Clemente MM, Alvarez-Alvarez C, Palacio-Gutierrez JJ, Pando-Sandoval A, Gagatek S, et al. Impact of the Xpert( R) MTB/RIF molecular test on the late diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2014;18(4):435-7.
    · extracted · source: references/10665-381036.page-202.83.json
  217. Mwansa-Kambafwile J, Maitshotlo B, Black A. Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation. PLoS ONE. 2017;12(1):e0168659.
    · extracted · source: references/10665-381036.page-202.84.json
  218. Chaisson LH, Roemer M, Cantu D, Haller B, Millman AJ, Cattamanchi A, et al. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial. Clin Infect Dis. 2014;59(10):1353-60.
    · extracted · source: references/10665-381036.page-202.85.json
  219. Boyles TH. Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes? Int J Tuberc Lung Dis. 2017;21(3):249-50.
    · extracted · source: references/10665-381036.page-202.86.json
  220. Kim YW, Seong MW, Kim TS, Yoo CG, Han SK, Yim JJ. Evaluation of Xpert( R) MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(10):1216-21.
    · extracted · source: references/10665-381036.page-202.87.json
  221. Nikolayevskyy V, Kontsevaya I, Nikolaevskaya E, Surkova E, Samchenko S, Esipenko S. Diagnostic performance and impact of routinely implemented Xpert R MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine. Clin Microbiol Infect. 2019;25(8):1040.e1-.e6.
    · extracted · source: references/10665-381036.page-202.88.json
  222. Teixeira de Siqueira-Filha N, Militao de Albuquerque MF, Cunha Rodrigues L, Legood R, Costa Santos A. Economic burden of HIV and TB/HIV coinfection in a middle-income country: a costing analysis alongside a pragmatic clinical trial in Brazil. Sex Transm Infect. 2018;94(6):463-9.
    · extracted · source: references/10665-381036.page-202.89.json
  223. Linghua W, Lijun S, Haiyang LU, Qiang XIA. Impact of sample collecting methods and sputum features on detection rate of Mycobacterium tuberculosis by Xpert MTB/RIF in pulmonary tuberculosis patients with mechanical ventilation. Chinese Journal of Clinical Infectious Diseases. 2017(6):375-9,83.
    · extracted · source: references/10665-381036.page-202.90.json
  224. Wu Z, Rueda ZV, Li T, Zhang Z, Jiang Y, Sha W, et al. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China. BMC Infectious Diseases. 2020;20(1) (no pagination)(153).
    · extracted · source: references/10665-381036.page-202.91.json
  225. Padayatchi N, Naidu N, Yende-Zuma N, O'Donnell MR, Naidoo K, Augustine S, et al. Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis. Jaids. 2016;73(1):e1-e7.
    · extracted · source: references/10665-381036.page-202.92.json
  226. Kritski A, Oliveira MM, Almeida IN, Ramalho D, Andrade MKN, Carvalho M, et al. Clinical Impact of the Line Probe Assay and Xpert R MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial. Rev Soc Bras Med Trop. 2022;55:e0191.
    · extracted · source: references/10665-381036.page-202.93.json
  227. Lee JH, Garg T, Lee J, McGrath S, Rosman L, Schumacher SG, et al. Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases. 2022;22(1) (no pagination)(940).
    · extracted · source: references/10665-381036.page-202.94.json
  228. Fielding KL, McCarthy KM, Cox H, Erasmus L, Ginindza S, Vassall A, et al. Xpert as the first-line TB test in South Africa: Yield, initial loss to follow-up, proportion treated. Topics in Antiviral Medicine. 2014;22(E-1):48-9.
    · extracted · source: references/10665-381036.page-202.95.json
  229. Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health. 2019;7(2):e191-e9.
    · extracted · source: references/10665-381036.page-202.96.json
  230. Santos AP, Silva DR, Delazare G, Rodrigues JG, de Aguiar M, Romano FM, et al. Clinical impact of Xpert R MTB/RIF Ultra for pulmonary TB diagnosis under routine conditions in a reference center in Brazil. Pulmonology. 2023;30:30.
    · extracted · source: references/10665-381036.page-202.97.json
  231. Lessells RJ. Impact of the xpert mtb/rif tuberculosis diagnostic system in individuals at high risk of mortality in rural South Africa. England: University of London, London School of Hygiene and Tropical Medicine (United Kingdom); 2015.
    · extracted · source: references/10665-381036.page-202.98.json
  232. Bonnet M. Xpert MTB/RIF Ultra: what is the real impact? Lancet Respir Med. 2020;8(4):325-6.
    · extracted · source: references/10665-381036.page-202.99.json
  233. Nathavitharana RR, Lederer P, Chaplin M, Bjerrum S, Steingart KR, Shah M. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021;8:CD014641.
    · extracted · source: references/10665-381036.page-202.100.json
  234. Ochodo EA, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, et al. Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Res. 2019;4:173.
    · extracted · source: references/10665-381036.page-202.101.json
  235. Danfack 2024a1 206/928 (22%) Multiple extrapulmonary specimens (lymph node aspirate, lymph node tissue, lymph node pus, CSF, pleural fluid, pleural tissue, pleural pus, ascitic fluid, synovial fluid, urine) 48/1289 (4%) Danfack 2024b 100% Expectorated sputum, BAL Gelaw 2017 23/78 (29%)
    · extracted · source: references/10665-381036.page-214.5.json
  236. Getahun 20172 57/190 (30%) 0 (0%) Gray 2016 India, Uganda, Peru 266/440 (60%) 250/1777 (14%)
    · extracted · source: references/10665-381036.page-214.6.json
  237. Pham 20183 Peru, South Africa, Brazil, and Vietnam 96/964 (10%) 216/964 (22%) Promsena 20221 Thailand Ogawa Multiple respiratory specimens (BAL, gastric aspirate, tracheal aspirate) and lymph node 4/16 (25%) Reddy 2017 52/402 (7%)
    · extracted · source: references/10665-381036.page-215.3.json
  238. Singh 20211 Pleural fluid, ascitic fluid, CSF, lymph node Spooner 2022 100% Expectorated and induced sputum 30/593 (5%)
    · extracted · source: references/10665-381036.page-215.4.json
  239. Yadav 2021 Multiple respiratory specimens (expectorated sputum BAL, gastric aspirate, gastric lavage) 1Singh 2021 and Danfack 2024a assessed extrapulmonary TB, Promsena 2022 assessed both pulmonary and extrapulmonary TB. Danfack 2024a and Danfack 2024b are unpublished data received from the study authors separately for pulmonary TB and extrapulmonary TB, unclear if from the same study. 2Included only smear negative patients and so only included in the subgroup analysis involving smear negative patients. 3Specimen level analysis but due to a small difference between the number of patients and the specimen level 2x2 data, we included the study.
    · extracted · source: references/10665-381036.page-215.8.json
  240. CSF = cerebrospinal fluid; BAL - bronchoalveolar lavage; LJ = Löwenstein-Jensen medium; MGIT = Mycobacteria Growth Indicator Tube (liquid culture); PLHIV = people living with HIV.
    · extracted · source: references/10665-381036.page-215.9.json
  241. Included studies Bojang AL, Mendy FS, Tientcheu LD, Otu J, Antonio M, Kampmann B, et al. Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia. Journal of Infection [Internet]. 2016 Mar 1 [cited 2020 Sep 30];72(3):332–7.
    · extracted · source: references/10665-381036.page-228.1.json
  242. Cheng S, Pheng SH, Heng S, Marks GB, Bañuls AL, Mao TE, et al. Evaluation of Loopamp Assay for the Diagnosis of Pulmonary Tuberculosis in Cambodia. BioMed Research International [Internet]. 2020 Jun 1 [cited 2022 Dec 8];2020:6828043.
    · extracted · source: references/10665-381036.page-228.2.json
  243. Donfack VD, Ngando L, Pefura EY, Che D, Ateba G, Bigna JR, et al. Comparative study of LoopampTM Mycobacterium tuberculosis Complex Kit for Rapid Detection of Mycobacterium tuberculosis complex in cameroon. Biomedical and Biotechnology Research Journal (BBRJ). 2018;2(1):46.
    · extracted · source: references/10665-381036.page-228.3.json
  244. Donfack VD, Grand L, Ongboulal SM, Nguimfack S, SHILE B, Assolo YP, et al. Effectiveness of TB-LAMP in diagnosis of tuberculosis among HIV-infected persons in Cameroon. International Research Journal of Public and Environmental Health. 2023 Jun 15;10(2).
    · extracted · source: references/10665-381036.page-228.4.json
  245. Donfack VD. Performance Evaluation of TB-LAMP among TB patients with EPTB in Cameroon. 2024a Donfack VD. Performance Evaluation of TB-LAMP among TB patients with HIV in Cameroon. 2024b Gelaw B, Shiferaw Y, Alemayehu M, Bashaw AA. Comparison of loop-mediated isothermal amplification assay and smear microscopy with culture for the diagnostic accuracy of tuberculosis. BMC Infectious Diseases. 2017 Jan 17;17(1).
    · extracted · source: references/10665-381036.page-228.5.json
  246. Getahun M, Dagne Z, Yaregal Z, Mariam AH, Moga S, Meaza A, et al. Conventional and Molecular Methods for the Diagnosis of Smear Negative Pulmonary TB and Concordance of Empirical TB Diagnosis with Culture Assay. Ethiopian Journal of Public Health and Nutrition [Internet]. 2017 [cited 2024 Mar 13];1(2):99–104.
    · extracted · source: references/10665-381036.page-228.6.json
  247. Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, et al. Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study. Carroll KC, editor. Journal of Clinical Microbiology. 2016 Aug;54(8):1984–91.
    · extracted · source: references/10665-381036.page-228.7.json
  248. Kaku T, Minamoto F, D’Meza R, Morose W, Boncy J, Bijou J, et al. Accuracy of LAMP-TB Method for Diagnosing Tuberculosis in Haiti. Japanese Journal of Infectious Diseases. 2016 Jan 1;69(6):488–92.
    · extracted · source: references/10665-381036.page-228.8.json
  249. Kim CK, Cho EA, Shin DM, Choi SW, Shin SY. Comparative Evaluation of the Loop-Mediated Isothermal Amplification Assay for Detecting Pulmonary Tuberculosis. Annals of laboratory medicine. 2018 Mar 28;38(2):119–24.
    · extracted · source: references/10665-381036.page-228.9.json
  250. Mitarai S, Okumura M, Toyota E, Yoshiyama T, Aono A, Sejimo A, et al. Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2011 Sep 1;15(9):1211–7.
    · extracted · source: references/10665-381036.page-228.10.json
  251. N’guessan K, Adegbele J, Coulibaly I, Kouame-N’takpé N, Seck-Angu H, Guei A, et al. Clinical Performances of Pure TB-Lamp Kit for M. tuberculosis Complex Detection in Sputum Samples. Journal of tuberculosis research. 2017 Jan 1;05(02):129–38.
    · extracted · source: references/10665-381036.page-228.11.json
  252. Nakiyingi L, Nakanwagi P, Briggs J, Agaba T, Mubiru F, Mugenyi M, et al. Performance of loop-mediated isothermal amplification assay in the diagnosis of pulmonary tuberculosis in a high prevalence TB/HIV rural setting in Uganda. BMC Infectious Diseases. 2018 Feb 21;18(1).
    · extracted · source: references/10665-381036.page-228.12.json
  253. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, et al. The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. Fernandez-Reyes D, editor. PLOS ONE. 2016 May 12;11(5):e0155101.
    · extracted · source: references/10665-381036.page-228.13.json
  254. Odume B, Nwokoye N, Spruijt I, Slyzkyi A, Dim C, Chukwuog O, et al. Diagnostic Accuracy of TB-LAMP for Diagnosis of Pulmonary Tuberculosis among Adult Presumptive TB in Nigeria. Greener Journal of Medical Sciences. 2021;11(2):122–9.
    · extracted · source: references/10665-381036.page-228.14.json
  255. Ou X, Li Q, Xia H, Pang Y, Wang S, Zhao B, et al. Diagnostic Accuracy of the PURE-LAMP Test for Pulmonary Tuberculosis at the County-Level Laboratory in China. Cattamanchi A, editor. PLoS ONE. 2014 May 1;9(5):e94544.
    · extracted · source: references/10665-381036.page-228.15.json
  256. Ou X, Wang S, Dong H, Pang Y, Li Q, Xia H, et al. Multicenter evaluation of a real-time loop-mediated isothermal amplification (RealAmp) test for rapid diagnosis of Mycobacterium tuberculosis. Journal of Microbiological Methods. 2016 Oct 1;129:39–43.
    · extracted · source: references/10665-381036.page-228.16.json
  257. Ou XC, Li H, Liu DX, Xia H, Ma XG, Wang SH, et al. Comparison of Xpert MTB/RIF, RealAmp, and CPA Tests in Detecting Mycobacterium tuberculosis. PubMed. 2019 Mar 1;32(3):215–9.
    · extracted · source: references/10665-381036.page-228.17.json
  258. Pham TH, Peter J, Mello FCQ, Parraga T, Lan NTN, Nabeta P, et al. Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. International Journal of Infectious Diseases. 2018 Mar;68:44–9.
    · extracted · source: references/10665-381036.page-228.18.json
  259. Promsena P, Jantarabenjakul W, Suntarattiwong P, Sudjaritruk T, Anugulruengkitt S, Rotcheewaphan S, et al. Diagnostic Accuracy of Loop-Mediated Isothermal Amplification (TB-LAMP) for Tuberculosis in Children. Journal of the Pediatric Infectious Diseases Society. 2021 Oct 13;11(1):9–15.
    · extracted · source: references/10665-381036.page-228.19.json
  260. Reddy S, Ntoyanto S, Sakadavan Y, Reddy T, Mahomed S, Dlamini M, et al. Detecting Mycobacterium tuberculosis using the loop-mediated isothermal amplification test in South Africa. The International Journal of Tuberculosis and Lung Disease. 2017 Oct 1;21(10):1154–60.
    · extracted · source: references/10665-381036.page-228.20.json
  261. Singh P, Kanade S, Nataraj G. Performance of loop-mediated isothermal amplification assay for diagnosis of extrapulmonary tuberculosis and antituberculosis treatment initiation. International Journal of Mycobacteriology. 2021;10(4):373.
    · extracted · source: references/10665-381036.page-228.21.json
  262. Spooner E, Reddy S, Ntoyanto S, Sakadavan Y, Reddy T, Mahomed S, et al. TB testing in HIV-positive patients prior to antiretroviral treatment. The International Journal of Tuberculosis and Lung Disease. 2022 Mar 1;26(3):224–31.
    · extracted · source: references/10665-381036.page-228.22.json
  263. Wahid M, Sjahrurachman A, Sitorus A, Burhan E. The Role of TB-LAMP Method in Detecting Mycobacterium tuberculosis from Sputum of Patients Suspected of Having Pulmonary Tuberculosis. 352 ORIGINAL ARTICLE Acta Med Indones -Indones J Intern Med •. 2020;52.
    · extracted · source: references/10665-381036.page-228.23.json
  264. Wang Z, Sun H, Ren Z, Xue B, Lu J, Zhang H. Feasibility and Performance of Loop-Mediated Isothermal Amplification Assay in the Diagnosis of Pulmonary Tuberculosis in Decentralized Settings in Eastern China. BioMed Research International. 2019 Jan 22;2019:1–4.
    · extracted · source: references/10665-381036.page-228.24.json
  265. Yadav R, Sharma N, Khaneja R, Agarwal P, Kanga A, Behera D, et al. Evaluation of the TB-LAMP assay for the rapid diagnosis of pulmonary tuberculosis in Northern India. The International Journal of Tuberculosis and Lung Disease. 2017 Oct 1;21(10):1150–3.
    · extracted · source: references/10665-381036.page-228.25.json
  266. Yadav R, Daroch P, Gupta P, Vaidya P, Mathew JL, Singh M, et al. Evaluation of TB-LAMP assay for detection of Mycobacterium tuberculosis in children. Infectious Diseases. 2021 Aug 17;53(12):942–6.
    · extracted · source: references/10665-381036.page-228.26.json
  267. Xin-Xin R, Dan C, Lu YH, Feng XL. Value of rifampicin-resistant real-time fluorescence quantitative nucleic acid amplification detection technology in the fast diagnosis of pulmonary tuberculosis. China Tropical Medicine. 2023;23(3).
    · extracted · source: references/10665-381036.page-228.27.json
  268. Journal of Clinical Epidemiology. 2020 Jun;122:142–52.
    · extracted · source: references/10665-381036.page-228.29.json
  269. World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance [Internet]. iris.who.int. Geneva: World Health Organization; 2016 [cited 2024 Mar 13]. Available from: https://iris.who.int/handle/10665/249154World Health Organization. Global tuberculosis report 2023 [Internet]. Geneva: World Health Organization; 2023 [cited 2024 Mar 13]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reportsZifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews. 2021 Feb 22;2021(5).
    · extracted · link · source: references/10665-381036.page-228.30.json · held: library/10665-249154
  270. Appendix 1. Detailed search strategies Ovid MEDLINE(R) ALL <1946 to September 29, 2023>
    · extracted · source: references/10665-381036.page-228.31.json
  271. Tuberculosis, Pulmonary/Extensively Drug-Resistant Tuberculosis/Tuberculosis, Multidrug-Resistant/exp Tuberculosis, Extrapulmonary/5 and 6 7 or 8 1 or 2 or 3 or 4 or 9 12 or 13 or 14 10 and 15 11 or 16 Embase 1947-Present, updated daily
    · extracted · source: references/10665-381036.page-228.32.json
  272. Lung tuberculosis/extensively drug resistant tuberculosis/drug resistant tuberculosis/extrapulmonary tuberculosis/5 and 6 7 or 8 1 or 2 or 3 or 4 or 9 12 or 13 or 14 10 and 15 11 or 16 Web of Science Search Strategy (Science Citation index-Expanded and Biosis previews) #1 Search: tuberculosis or TB (Topic) #2 Search: (extrapulmonary or lymph node* or mening* or pulmonary or lung ) (Topic) #3 Search: multidrug resistant tuberculosis or extensively drug resistant tuberculosis (Topic) #4 Search: MDR-TB or XDR-TB (Topic) #5 Search: #1 AND #2 #6 Search: #3 OR #4 OR #5 #7 Search: Loop-Mediated Isothermal Amplification (Topic)
    · extracted · source: references/10665-381036.page-228.33.json
  273. Included studies Bojang AL, Mendy FS, Tientcheu LD, Otu J, Antonio M, Kampmann B, et al. Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia. Journal of Infection. 2016 Mar;72(3):332-7. doi: 10.1016/j.jinf.2015.11.011. Epub 2015 Dec 24. PMID: 26724771 Donfack VD et al. Performance Evaluation of TB-LAMP in children. 2024 (Unpublished)
    · extracted · doi:10.1016/j.jinf.2015.11.011 · source: references/10665-381036.page-250.1.json
  274. Promsena P, Jantarabenjakul W, Suntarattiwong P, Sudjaritruk T, Anugulruengkitt S, Rotcheewaphan S, et al. Diagnostic accuracy of loop-mediated isothermal amplification (TB-LAMP) for tuberculosis in children. 2022. Journal of the Pediatric Infectious Diseases Society;11(1):9-15. doi: 10.1093/jpids/piab097. PMID: 34643215.
    · extracted · doi:10.1093/jpids/piab097 · source: references/10665-381036.page-250.2.json
  275. Yadav R, Daroch P, Gupta P, Vaidya P, Mathew JL, Singh M, et al. Evaluation of TB-LAMP assay for detection of Mycobacterium tuberculosis in children. 2021. Infectious Diseases;53(12):942-946. doi: 10.1080/23744235.2021.1963467. Epub 2021 Aug 17. PMID: 34403308.
    · extracted · doi:10.1080/23744235.2021.1963467 · source: references/10665-381036.page-250.3.json
  276. Additional references Lighter J, Rigaud M. Diagnosing childhood tuberculosis: traditional and innovative modalities. Current Problems in Pediatric and Adolescent Health Care 2009;39(3):61-88. [PubMed: 19215860; DOI: 10.1016/j.cppeds.2008.12.003]
    · extracted · doi:10.1016/j.cppeds.2008.12.003 · source: references/10665-381036.page-250.4.json
  277. Marais BJ. Childhood tuberculosis: epidemiology and natural history of disease. Indian Journal of Pediatrics 2011;78(3):321-7. [PubMed: 21213073; DOI: 10.1007/s12098-010-0353-1]
    · extracted · doi:10.1007/s12098-010-0353-1 · source: references/10665-381036.page-250.5.json
  278. Piccini P, Chiappini E, Tortoli E, DeMartino M, Galli L. Clinical peculiarities of tuberculosis. BMC Infectious Diseases 2014;14(Suppl 1):1-12. [PubMed: 24564419; DOI: 10.1186/1471-2334-14-s1-s4] 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology 2020a;122:129-41. 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables.
    · extracted · doi:10.1186/1471-2334-14-s1-s4 · source: references/10665-381036.page-250.6.json
  279. Journal of Clinical Epidemiology 2020b;122:142-52. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis 2003;83(1-3):208-12.
    · extracted · source: references/10665-381036.page-250.7.json
  280. [PubMed: 12758213; DOI: 10.1016/s1472-9792(02)00088-4]
    · extracted · doi:10.1016/s1472-9792(02)00088-4 · source: references/10665-381036.page-250.8.json
  281. World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. 2016. apps.who.int/iris/handle/10665/249154 (accessed 08 December 2023)
    · extracted · source: references/10665-381036.page-250.9.json
  282. World Health Organization. Global TB report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports (accessed 08 December 2023)
    · extracted · link · source: references/10665-381036.page-250.10.json
  283. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005;365(9454):130-4. [PubMed: 15639294; DOI: 10.1016/s0140-6736(05)17702-2]
    · extracted · doi:10.1016/s0140-6736(05)17702-2 · source: references/10665-381036.page-250.11.json
  284. Page 246 of 1168 Appendix 1. Detailed search strategies Detailed search strategies Ovid MEDLINE(R) ALL <1946 to September 29, 2023>
    · extracted · source: references/10665-381036.page-250.12.json
  285. Tuberculosis, Pulmonary/Extensively Drug-Resistant Tuberculosis/Tuberculosis, Multidrug-Resistant/exp Tuberculosis, Extrapulmonary/5 and 6 7 or 8 1 or 2 or 3 or 4 or 9 12 or 13 or 14 10 and 15 11 or 16 Embase 1947-Present, updated daily
    · extracted · source: references/10665-381036.page-250.13.json
  286. Lung tuberculosis/extensively drug resistant tuberculosis/drug resistant tuberculosis/extrapulmonary tuberculosis/5 and 6 7 or 8 1 or 2 or 3 or 4 or 9 12 or 13 or 14 10 and 15 11 or 16 Web of Science Search Strategy (Science Citation index-Expanded and Biosis previews) #1 Search: tuberculosis or TB (Topic) #2 Search: (extrapulmonary or lymph node* or mening* or pulmonary or lung ) (Topic) #3 Search: multidrug resistant tuberculosis or extensively drug resistant tuberculosis (Topic) #4 Search: MDR-TB or XDR-TB (Topic) #5 Search: #1 AND #2 #6 Search: #3 OR #4 OR #5 #7 Search: Loop-Mediated Isothermal Amplification (Topic)
    · extracted · source: references/10665-381036.page-250.14.json
  287. Abbott. "Determine TB LAM Package Insert." Ainan, S., F. F. Furia, F. Mhimbira, N. P. Mnyambwa, N. Mgina, et al. 2021. "Xpert R MTB/RIF assay testing on stool for the diagnosis of paediatric pulmonary TB in Tanzania." Public Health in Action 11 (2): 75-79.
    · extracted · source: references/10665-381036.page-318.1.json
  288. Babo, Y., B. Seremolo, M. Bogale, A. Bedru, Y. Wabe, et al. 2023. "Comparison of Xpert MTB/RIF Ultra Results of Stool and Sputum in Children with Presumptive Tuberculosis in Southern Ethiopia." Tropical Medicine & Infectious Disease 8 (7): 30.
    · extracted · source: references/10665-381036.page-318.2.json
  289. Banada, P. P., U. Naidoo, S. Deshpande, F. Karim, J. L. Flynn, et al. 2016. "A Novel Sample Processing Method for Rapid Detection of Tuberculosis in the Stool of Pediatric Patients Using the Xpert MTB/RIF Assay." PLoS One 11 (3): e0151980.
    · extracted · source: references/10665-381036.page-318.3.json
  290. Beynon, R., M. M. Leeflang, S. McDonald, A. Eisinga, R. L. Mitchell, et al. 2013. "Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE." Cochrane Database Syst Rev 2013 (9): Mr000022.
    · extracted · source: references/10665-381036.page-318.4.json
  291. Bioneer. "IRON-qPCR. https://eng.bioneer.com/20-a-2600.html. Last accessed 17 Apr 2024." Biosensor, SD. "STANDARD M10. https://www.sdbiosensor.com/product/product_view?product_no=23007. Last accessed 17 Apr 2024.".
    · extracted · link · source: references/10665-381036.page-318.5.json
  292. Bjerrum, Stephanie, Ian Schiller, Nandini Dendukuri, Michael Eisenhut, Mikashmi Kohli, et al. 2019a. "Lateral flow urine lipoarabinomannan assay ( LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update ( 2019): Web Annex A. LF-LAM for detecting active tuberculosis in people living with HIV: an updated systematic review." Bjerrum, Stephanie, Ian Schiller, Nandini Dendukuri, Mikashmi Kohli, Ruvandhi R Nathavitharana, et al. 2019b. "Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV." Cochrane Database of Systematic Reviews (10).
    · extracted · source: references/10665-381036.page-318.6.json
  293. Briken, Volker, Steven A Porcelli, Gurdyal S Besra, and Laurent Kremer. 2004. "Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response." Molecular microbiology 53 (2): 391-403.
    · extracted · source: references/10665-381036.page-318.7.json
  294. Broger, Tobias, Lisa Koeppel, Helena Huerga, Poppy Miller, Ankur Gupta-Wright, et al. 2023.
    · extracted · source: references/10665-381036.page-318.8.json
  295. "Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data." The Lancet Global Health 11 (6): e903-e916. Broger, Tobias, Bianca Sossen, Elloise du Toit, Andrew D Kerkhoff, Charlotte Schutz, et al. 2019.
    · extracted · source: references/10665-381036.page-318.9.json
  296. "Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study." The Lancet Infectious Diseases 19 (8): 852-861. Chabala, Chishala, Clementine Roucher, Minh Huyen Ton Nu Nguyet, Esther Babirekkere, Muleya Inambao, et al. 2024. Development of Tuberculosis Treatment Decision Algorithms in Children Below 5 Years Hospitalized with Severe Acute Malnutrition: A Diagnostic Cohort Study. Available at SSRN: https://ssrn.com/abstract=4663334 or http://dx.doi.org/10.2139/ssrn.4663334.
    · extracted · link · doi:10.2139/ssrn.4663334 · source: references/10665-381036.page-318.10.json
  297. Chipinduro, M., K. Mateveke, B. Makamure, R. A. Ferrand, and E. Gomo. 2017. "Stool XpertW MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis at primary clinics in Zimbabwe." International Journal of Tuberculosis and Lung Disease 21(2): 161-166.
    · extracted · source: references/10665-381036.page-318.11.json
  298. Chu, H., and S. R. Cole. 2006. "Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach." J Clin Epidemiol 59 (12): 1331-2; author reply 1332-3.
    · extracted · source: references/10665-381036.page-318.12.json
  299. Review Manager (RevMan). Version 5.4.1. Cruz, A. T., P. A. Revell, and J. R. Starke. 2013. "Gastric Aspirate Yield For Children With Suspected Pulmonary Tuberculosis." J Pediatric Infect Dis Soc 2 (2): 171-4.
    · extracted · source: references/10665-381036.page-318.13.json
  300. de Haas, P., B. Yenew, E. Mengesha, A. Slyzkyi, Z. Gashu, et al. 2021. "The Simple One-Step (SOS)
    · extracted · source: references/10665-381036.page-318.14.json
  301. Stool Processing Method for Use with the Xpert MTB/RIF Assay for a Child-Friendly Diagnosis of Tuberculosis Closer to the Point of Care." J Clin Microbiol 59 (8): e0040621. DiNardo, A. R., A. Detjen, P. Ustero, K. Ngo, J. Bacha, et al. 2016. "Culture is an imperfect and heterogeneous reference standard in pediatric tuberculosis." Tuberculosis (Edinb) 101s: S105-s108.
    · extracted · source: references/10665-381036.page-318.15.json
  302. Donkeng, V. 2022. "Performance Evaluation of TB-LAMP in children. Centre Pasteur du Cameroun: Yaoundé, Cameroun, 2022.".
    · extracted · source: references/10665-381036.page-318.16.json
  303. Du Toit, G, G Swingler, and K Iloni. 2002. "Observer variation in detecting lymphadenopathy on chest radiography." The International Journal of Tuberculosis and Lung Disease 6 (9): 814-817.
    · extracted · source: references/10665-381036.page-318.17.json
  304. Edwards, DJ, F Kitetele, and A Van Rie. 2007. "Agreement between clinical scoring systems used for the diagnosis of pediatric tuberculosis in the HIV era." The International Journal of Tuberculosis and Lung Disease 11 (3): 263-269.
    · extracted · source: references/10665-381036.page-318.18.json
  305. Graham, S. M., L. E. Cuevas, P. Jean-Philippe, R. Browning, M. Casenghi, et al. 2015. "Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update." Clin Infect Dis 61Suppl 3: S179-87.
    · extracted · source: references/10665-381036.page-318.19.json
  306. Gupta-Wright, Ankur, Elizabeth L. Corbett, Joep J. van Oosterhout, Douglas Wilson, Daniel Grint, et al. 2018. "Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial." The Lancet 392 (10144): 292-301.
    · extracted · source: references/10665-381036.page-318.20.json
  307. Guyatt, G., A. D. Oxman, E. A. Akl, R. Kunz, G. Vist, et al. 2011. "GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables." J Clin Epidemiol 64 (4): 383-94.
    · extracted · source: references/10665-381036.page-318.21.json
  308. Hanrahan, C. F., H. Dansey, L. Mutunga, H. France, S. V. Omar, et al. 2018. "Diagnostic strategies for childhood tuberculosis in the context of primary care in a high-burden setting: the value of alternative sampling methods." Paediatr Int Child Health: 1-7.
    · extracted · source: references/10665-381036.page-318.22.json
  309. Hasan, Z., S. Shakoor, F. Arif, A. Mehnaz, A. Akber, et al. 2017. "Evaluation of Xpert MTB/RIF testing for rapid diagnosis of childhood pulmonary tuberculosis in children by Xpert MTB/RIF testing of stool samples in a low resource setting." BMC Research Notes 10 (1): 473.
    · extracted · source: references/10665-381036.page-318.23.json
  310. Huerga, H., G. Ferlazzo, P. Bevilacqua, B. Kirubi, E. Ardizzoni, et al. 2017. "Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for Hospitalized and Ambulatory HIV-Positive Patients in Kenya." PLoS One 12 (1): e0170976.
    · extracted · source: references/10665-381036.page-318.24.json
  311. Inbaraj, L. R., J. Daniel, M. K. Sathya Narayanan, V. A. Srinivasalu, A. Bhaskar, et al. 2023. "TB‐LAMP (loop‐mediated isothermal amplification) for diagnosing pulmonary tuberculosis in children." Cochrane Database of Systematic Reviews (9).
    · extracted · source: references/10665-381036.page-318.25.json
  312. Jaganath, D. 2024. Stool Processing Kit (SPK) Evaluation for Paediatric TB. NCT04899076.
    · extracted · source: references/10665-381036.page-318.26.json
  313. Kabir, S., S. M. M. Rahman, S. Ahmed, M. S. Islam, R. S. Banu, et al. 2021. "Xpert Ultra Assay on Stool to Diagnose Pulmonary Tuberculosis in Children." Clinical Infectious Diseases 73 (2): 226-234.
    · extracted · source: references/10665-381036.page-318.27.json
  314. Kay, A. W., L. González Fernández, Y. Takwoingi, M. Eisenhut, A. K. Detjen, et al. 2020. "Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children." Cochrane Database Syst Rev 8 (8): Cd013359.
    · extracted · source: references/10665-381036.page-318.28.json
  315. Kay, A. W., H. Rabie, E. Maleche-Obimbo, M. P. Sekadde, M. F. Cotton, et al. 2021. "HIV-Associated Tuberculosis in Children and Adolescents: Evolving Epidemiology, Screening, Prevention and Management Strategies." Pathogens 11 (1).
    · extracted · source: references/10665-381036.page-318.29.json
  316. Kay, A.W., Tara Ness, Sabine E Verkuijl, Kerri Viney, Annemieke Brands, et al. 2022. "Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children." Cochrane Database of Systematic Reviews (9).
    · extracted · source: references/10665-381036.page-318.30.json
  317. Kohli, M., I. Schiller, N. Dendukuri, M. Yao, K. Dheda, et al. 2021. "Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults." Cochrane Database Syst Rev 1 (1): Cd012768.
    · extracted · source: references/10665-381036.page-318.31.json
  318. Kroidl, I., P. Clowes, K. Reither, B. Mtafya, G. Rojas-Ponce, et al. 2015. "Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania." Eur Respir J.
    · extracted · source: references/10665-381036.page-318.32.json
  319. Kunkel, Amber, Pia Abel Zur Wiesch, Ruvandhi R Nathavitharana, Florian M Marx, Helen E Jenkins, et al. 2016. "Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis." BMC infectious diseases 16 (1): 1-9.
    · extracted · source: references/10665-381036.page-318.33.json
  320. LaCourse, S. M., P. B. Pavlinac, L. M. Cranmer, I. N. Njuguna, C. Mugo, et al. 2018. "Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV-infected children." AIDS 32 (1): 69-78.
    · extracted · source: references/10665-381036.page-318.34.json
  321. Lawn, S. D., A. D. Kerkhoff, R. Burton, C. Schutz, A. Boulle, et al. 2017. "Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort." BMC Med 15.
    · extracted · source: references/10665-381036.page-318.35.json
  322. Lawn, S.D., K. Dheda, A. D. Kerkhoff, J. G. Peter, S. Dorman, et al. 2013. "Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies." BMC Infect Dis 13: 407.
    · extracted · source: references/10665-381036.page-318.36.json
  323. Lewinsohn, David M., Michael K. Leonard, Philip A. LoBue, David L. Cohn, Charles L. Daley, et al. 2016. "Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children." Clinical Infectious Diseases 64 (2): e1-e33.
    · extracted · source: references/10665-381036.page-318.37.json
  324. Lounnas, M., A. Diack, M. P. Nicol, S. Eyangoh, E. Wobudeya, et al. 2020. "Laboratory development of a simple stool sample processing method diagnosis of pediatric tuberculosis using Xpert Ultra." Tuberculosis (Edinb) 125: 102002.
    · extracted · source: references/10665-381036.page-318.38.json
  325. MacLean, E., G. Sulis, C. M. Denkinger, J. C. Johnston, M. Pai, et al. 2019. "Diagnostic Accuracy of Stool Xpert MTB/RIF for Detection of Pulmonary Tuberculosis in Children: a Systematic Review and Meta-analysis." J Clin Microbiol 57 (6).
    · extracted · source: references/10665-381036.page-318.39.json
  326. Marais, B. J., R. P. Gie, A. C. Hesseling, H. S. Schaaf, C. Lombard, et al. 2006. "A refined symptom-based approach to diagnose pulmonary tuberculosis in children." Pediatrics 118 (5): e1350-9.
    · extracted · source: references/10665-381036.page-318.40.json
  327. Mathabire Rucker, S. C., L. Cossa, R. E. Harrison, J. Mpunga, S. Lobo, et al. 2019. "Feasibility of using Determine TB-LAM to diagnose tuberculosis in HIV-positive patients in programmatic conditions: a multisite study." Glob Health Action 12 (1): 1672366.
    · extracted · source: references/10665-381036.page-318.41.json
  328. Minion, J., E. Leung, E. Talbot, K. Dheda, M. Pai, et al. 2011. "Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis." Eur Respir J 38 (6): 1398-405.
    · extracted · source: references/10665-381036.page-318.42.json
  329. Mwaura, M., and N. Engel. 2021. "Constructing confidence: User perspectives on AlereLAM testing for tuberculosis." Int J Infect Dis 112: 237-242.
    · extracted · source: references/10665-381036.page-318.43.json
  330. Nabeta, Pamela. 2021. "Optimization of stool processing for Ultra testing: pooled data from two head to head studies comparing stool processing methods." 52nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).
    · extracted · source: references/10665-381036.page-318.44.json
  331. Nel, J. S., C. K. Lippincott, R. Berhanu, D. C. Spencer, I. M. Sanne, et al. 2017. "Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review." Clin Infect Dis 65 (7): 1226-1228.
    · extracted · source: references/10665-381036.page-318.45.json
  332. Nicol, M. P., K. Spiers, L. Workman, W. Isaacs, J. Munro, et al. 2013. "Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children." Clin Infect Dis 57 (3): e18-21.
    · extracted · source: references/10665-381036.page-318.46.json
  333. Nicol, M. P., L. Workman, W. Isaacs, J. Munro, F. Black, et al. 2011. "Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study." Lancet Infect Dis.
    · extracted · source: references/10665-381036.page-318.47.json
  334. Nicol, M.P., Veronica Allen, Lesley Workman, Washiefa Isaacs, Jacinta Munro, et al. 2014. "Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study." The lancet global health 2 (5): e278-e284.
    · extracted · source: references/10665-381036.page-318.48.json
  335. Nicol, Mark P, and Heather J Zar. 2020. "Advances in the diagnosis of pulmonary tuberculosis in children." Paediatric Respiratory Reviews 36: 52-56.
    · extracted · source: references/10665-381036.page-318.49.json
  336. Olbrich, L. 2024. "Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease (RaPaed-TB).
    · extracted · source: references/10665-381036.page-318.50.json
  337. NCT03734172." Orikiriza, P., J. Smith, B. Ssekyanzi, D. Nyehangane, I. Mugisha Taremwa, et al. 2021. "Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children." European Respiratory Journal 59 (1): 01.
    · extracted · source: references/10665-381036.page-318.51.json
  338. Penn-Nicholson, A., S. N. Gomathi, C. Ugarte-Gil, A. Meaza, E. Lavu, et al. 2021. "A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays." Eur Respir J 58 (5).
    · extracted · source: references/10665-381036.page-318.52.json
  339. Peter, Jonny G, Lynn S Zijenah, Duncan Chanda, Petra Clowes, Maia Lesosky, et al. 2016. "Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial." The Lancet 387 (10024): 1187-1197.
    · extracted · source: references/10665-381036.page-318.53.json
  340. Qvist, T., I. S. Johansen, T. Pressler, N. Høiby, A. B. Andersen, et al. 2014. "Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria--experiences from the Danish Cystic Fibrosis cohort study." BMC Infect Dis 14: 655.
    · extracted · source: references/10665-381036.page-318.54.json
  341. Reitsma, J. B., A. S. Glas, A. W. Rutjes, R. J. Scholten, P. M. Bossuyt, et al. 2005. "Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews." J Clin Epidemiol 58 (10): 982-90.
    · extracted · source: references/10665-381036.page-318.55.json
  342. Sabi, Issa, Andrea Rachow, Daniel Mapamba, Petra Clowes, Nyanda E Ntinginya, et al. 2018. "Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study." Journal of Infection 77 (4): 321-327.
    · extracted · source: references/10665-381036.page-318.56.json
  343. Seid, G., A. Alemu, T. Tsedalu, and B. Dagne. 2022. "Value of urine-based lipoarabinomannan (LAM) antigen tests for diagnosing tuberculosis in children: systematic review and meta-analysis." IJID Reg 4: 97-104.
    · extracted · source: references/10665-381036.page-318.57.json
  344. Shah, M., C. Hanrahan, Z. Y. Wang, N. Dendukuri, S. D. Lawn, et al. 2016a. "Lateral flow urine Database of Systematic Reviews (5): CD011420. Shah, M., C. Hanrahan, Z. Y. Wang, N. Dendukuri, S. D. Lawn, et al. 2016b. "Lateral flow urine Database Syst Rev 2016 (5): Cd011420.
    · extracted · source: references/10665-381036.page-318.58.json
  345. Shapiro, A. E., J. M. Ross, M. Yao, I. Schiller, M. Kohli, et al. 2021. "Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms." Cochrane Database Syst Rev 3 (3): Cd013694.
    · extracted · source: references/10665-381036.page-318.59.json
  346. Shingadia, Delane, and Vas Novelli. 2003. "Diagnosis and treatment of tuberculosis in children." The Lancet infectious diseases 3 (10): 624-632.
    · extracted · source: references/10665-381036.page-318.60.json
  347. Singh, Urvashi B., Manjula Singh, Sangeeta Sharma, Neeraj Mahajan, Kiran Bala, et al. 2023.
    · extracted · source: references/10665-381036.page-318.61.json
  348. "Expedited diagnosis of pediatric tuberculosis using Truenat MTB-Rif Dx and GeneXpert MTB/RIF." Scientific Reports 13 (1): 6976. Song, Rinn, Eleanor S Click, Kimberly D McCarthy, Charles M Heilig, Walter Mchembere, et al. 2021.
    · extracted · source: references/10665-381036.page-318.62.json
  349. "Sensitive and feasible specimen collection and testing strategies for diagnosing tuberculosis in young children." JAMA pediatrics 175 (5): e206069-e206069. Sterne, J. A. C., J. Savović, M. J. Page, R. G. Elbers, N. S. Blencowe, et al. 2019. "RoB 2: a revised tool for assessing risk of bias in randomised trials." Bmj 366: l4898.
    · extracted · source: references/10665-381036.page-318.63.json
  350. Swingler, GH, G Du Toit, S Andronikou, L Van der Merwe, and HJ Zar. 2005. "Diagnostic accuracy of chest radiography in detecting mediastinal lymphadenopathy in suspected pulmonary tuberculosis." Archives of disease in childhood 90 (11): 1153-1156.
    · extracted · source: references/10665-381036.page-318.64.json
  351. Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, et al. 2022. "Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, et al. Chapter 10: Undertaking meta-analysis. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editors(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Vol. 2nd. London: Cochrane, 2022.".
    · extracted · source: references/10665-381036.page-318.65.json
  352. Thit, Swe Swe, Ne Myo Aung, Zaw Win Htet, Mark A. Boyd, Htin Aung Saw, et al. 2017. "The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study." BMC Medicine 15 (1): 145.
    · extracted · source: references/10665-381036.page-318.66.json
  353. Thomas, T. A. 2019. "Tuberculosis in Children." Thorac Surg Clin 29 (1): 109-121.
    · extracted · source: references/10665-381036.page-318.67.json
  354. Covidence systematic review software., , Melbourne, Australia. Available at www.covidence.org.
    · extracted · link · source: references/10665-381036.page-318.68.json
  355. Walters, E., L. Scott, P. Nabeta, A. M. Demers, G. Reubenson, et al. 2018. "Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method." J Clin Microbiol 56 (9).
    · extracted · source: references/10665-381036.page-318.69.json
  356. Whiting, P. F., A. W. Rutjes, M. E. Westwood, S. Mallett, J. J. Deeks, et al. 2011. "QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies." Ann Intern Med 155 (8): 529-36.
    · extracted · source: references/10665-381036.page-318.70.json
  357. Wobudeya, E. 2024. "TB-Speed Decentralisation Study. NCT04038632." Wobudeya, E., M. Bonnet, E. G. Walters, P. Nabeta, R. Song, et al. 2022. "Diagnostic Advances in Childhood Tuberculosis-Improving Specimen Collection and Yield of Microbiological Diagnosis for Intrathoracic Tuberculosis." Pathogens 11 (4).
    · extracted · source: references/10665-381036.page-318.71.json
  358. World Bank. 2022. "The World by Income and Region. Available at: https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html. Last accessed 17 Apr 2024.".
    · extracted · link · source: references/10665-381036.page-318.72.json
  359. World Health Organization. 2013. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB.
    · extracted · source: references/10665-381036.page-318.73.json
  360. World Health Organization. World Health Organization. 2017. WHO Meeting Report of a Technical Expert Consultation: Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Available at: https://www.who.int/tb/publications/2017/XpertUltra/en/.
    · extracted · link · source: references/10665-381036.page-318.74.json
  361. World Health Organization. 2018. "Roadmap towards ending TB in children and adolescents." World Health Organization. 2019. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update (2019): evidence to decision tables. World Health Organization.
    · extracted · source: references/10665-381036.page-318.75.json
  362. World Health Organization. 2021. WHO consolidated guidelines on tuberculosis. Module 2: screening-systematic screening for tuberculosis disease. World Health Organization.
    · extracted · source: references/10665-381036.page-318.76.json
  363. World Health Organization. 2022a. "Global Tuberculosis Report 2022. Geneva: WHO, 2022.".
    · extracted · source: references/10665-381036.page-318.77.json
  364. World Health Organization. 2022b. "WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents." In WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization 2022.
    · extracted · source: references/10665-381036.page-318.78.json
  365. World Health Organization. 2023. "Roadmap towards ending TB in children and adolescents, third edition. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.".
    · extracted · source: references/10665-381036.page-318.79.json
  366. World Health Organization. 2024. "WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.".
    · extracted · source: references/10665-381036.page-318.80.json
  367. World Health Organization. 2021. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update., , ed World Health Organization.
    · extracted · source: references/10665-381036.page-318.81.json
  368. Geneva (accessed 3 January 2023).
    · extracted · source: references/10665-381036.page-318.82.json
  369. Yang, B., S. Mallett, Y. Takwoingi, C. F. Davenport, C. J. Hyde, et al. 2021a. "QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies." Ann Intern Med 174 (11): 1592-1599. Yang, B., R. A. Mustafa, P. M. Bossuyt, J. Brozek, M. Hultcrantz, et al. 2021b. "GRADE Guidance: 31. Assessing the certainty across a body of evidence for comparative test accuracy." J Clin Epidemiol 136: 146-156. Zar, Heather J, Lesley Workman, Washiefa Isaacs, Jacinta Munro, Faye Black, et al. 2012. "Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens." Clinical infectious diseases 55 (8): 1088-1095.
    · extracted · source: references/10665-381036.page-318.83.json
  370. Zar, Heather J, Lesley J Workman, Margaretha Prins, Linda J Bateman, Slindile P Mbhele, et al. 2019.
    · extracted · source: references/10665-381036.page-318.84.json
  371. "Tuberculosis diagnosis in children using Xpert Ultra on different respiratory specimens." American journal of respiratory and critical care medicine 200 (12): 1531-1538. Zifodya, J. S., J. S. Kreniske, I. Schiller, M. Kohli, N. Dendukuri, et al. 2021. "Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis." Cochrane Database Syst Rev 2: Cd009593.
    · extracted · source: references/10665-381036.page-318.85.json
  372. Web Annex B.8. Parallel use of low-complexity automated nucleic acid amplification tests and lateral flow urine lipoarabinomannan assay to detect tuberculosis disease in adults and adolescents with HIV: a systematic review Stephanie Bjerrum*, Bada Yang, Johanna Åhsberg, Laura Olbrich, Mathias Weis Damkjær, Ruvandhi Nathavitharana, Tobias Broger, Ioana Diana Olaru, Brittney Sweetser, Hayley Poore, Alia Razid, Alexander Kay, Claudia M. Denkinger, Ian Schiller, Nandini Dendukuri, Devan Jaganath, Andreas Lundh, Maunank Shah Stephanie Bjerrum, Department of Clinical Research, Research Unit of Infectious Diseases, University of Southern Denmark; Department of infectious Diseases, Copenhagen University Hospital, Rigshospitalet.
    · extracted · source: references/10665-381036.page-318.86.json
  373. Abbott. 2022. "Determine TB LAM Package Insert., ." https://www.globalpointofcare.abbott/en/product-details/determine-tb-lam.html.
    · extracted · link · source: references/10665-381036.page-372.1.json
  374. Åhsberg, J., P. Puplampu, A. Kwashie, J. O. Commey, V. J. Ganu, et al. 2023. "Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana." Clinical Infectious Diseases 77 (8): 1185-1193.
    · extracted · source: references/10665-381036.page-372.2.json
  375. Barr, D. A., J. M. Lewis, N. Feasey, C. Schutz, A. D. Kerkhoff, et al. 2020. "Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data." The Lancet Infectious Diseases 20 (6): 742-752.
    · extracted · source: references/10665-381036.page-372.3.json
  376. Benjamin, A., S. C. Cavalcante, L. F. Jamal, D. Arakaki-Sanchez, J. N. de Lima, et al. 2019. "Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units." PLoS ONE [Electronic Resource] 14 (9): e0221038.
    · extracted · source: references/10665-381036.page-372.4.json
  377. Beynon, R., M. M. Leeflang, S. McDonald, A. Eisinga, R. L. Mitchell, et al. 2013. "Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE." Cochrane Database Syst Rev 2013 (9): MR000022.
    · extracted · source: references/10665-381036.page-372.5.json
  378. BIONEER. 2022. "IRON-qPCR." https://eng.bioneer.com/20-a-2600.html.
    · extracted · link · source: references/10665-381036.page-372.6.json
  379. Bjerrum, S., T. Broger, R. Szekely, S. Mitarai, J. A. Opintan, et al. 2020. "Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus." Open Forum Infect Dis 7 (1): ofz530.
    · extracted · source: references/10665-381036.page-372.7.json
  380. Bjerrum, S., E. Kenu, M. Lartey, M. J. Newman, K. K. Addo, et al. 2015. "Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana-findings from the DETECT HIV-TB study." BMC Infectious Diseases 15: 407.
    · extracted · source: references/10665-381036.page-372.8.json
  381. Bjerrum, S., I. Schiller, N. Dendukuri, M. Kohli, R. R. Nathavitharana, et al. 2019a. "Lateral flow urine Database Syst Rev 10 (10): CD011420. Bjerrum, S., I. Schiller, N. Dendukuri, M. Kohli, R. R. Nathavitharana, et al. 2019b. "Lateral flow urine Database of Systematic Reviews 10: CD011420. Bjerrum, S., I. Schiller, N. Dendukuri, M. Kohli, R. R. Nathavitharana, et al. 2019c. "Lateral flow urine Database Syst Rev 10: CD011420. Boloko, L., C. Schutz, N. Sibiya, A. Balfour, A. Ward, et al. 2022. "Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study." The Lancet. Microbe 3 (7): e521-e532.
    · extracted · source: references/10665-381036.page-372.9.json
  382. Bonnet, M., D. Gabillard, S. Domoua, C. Muzoora, E. Messou, et al. 2023. "High Performance of Systematic Combined Urine Liboarabinomannan Test and Sputum Xpert MTB/RIF for Tuberculosis Screening in Severely Immunosuppressed Ambulatory Adults With Human Immunodeficiency Virus." Clinical Infectious Diseases 77(1): 112-119.
    · extracted · source: references/10665-381036.page-372.10.json
  383. Briken, V., S. A. Porcelli, G. S. Besra, and L. Kremer. 2004. "Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response." Mol Microbiol 53 (2): 391-403.
    · extracted · source: references/10665-381036.page-372.11.json
  384. Broger, T., L. Koeppel, H. Huerga, P. Miller, A. Gupta-Wright, et al. 2023a. "Diagnostic yield of urine and meta-analysis of individual participant data." The Lancet Global Health 11 (6): e903-e916. Broger, T., L. Koeppel, H. Huerga, P. Miller, A. Gupta-Wright, et al. 2023b. "Diagnostic yield of urine and meta-analysis of individual participant data." Lancet Glob Health 11 (6): e903-e916. Broger, T., M. P. Nicol, G. B. Sigal, E. Gotuzzo, A. J. Zimmer, et al. 2020. "Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients." Journal of Clinical Investigation 130 (11): 5756-5764.
    · extracted · source: references/10665-381036.page-372.12.json
  385. Broger, T., B. Sossen, E. du Toit, A. D. Kerkhoff, C. Schutz, et al. 2019. "Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study." Lancet Infect Dis.
    · extracted · source: references/10665-381036.page-372.13.json
  386. Broger-Cohort4, T., M. P. Nicol, R. Szekely, S. Bjerrum, B. Sossen, et al. 2020. "Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data." PLoS Medicine / Public Library of Science 17 (5): e1003113.
    · extracted · source: references/10665-381036.page-372.14.json
  387. Bulterys, M. A., B. Wagner, M. Redard-Jacot, A. Suresh, N. R. Pollock, et al. 2019. "Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update." J Clin Med 9 (1).
    · extracted · source: references/10665-381036.page-372.15.json
  388. Calligaro, G. L., L. S. Zijenah, J. G. Peter, G. Theron, V. Buser, et al. 2017. "Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial." The Lancet Infectious Diseases 17 (4): 441-450.
    · extracted · source: references/10665-381036.page-372.16.json
  389. Cepheid. 2023a. "Xpert MTB/RIF ". Accessed November 12 https://www.cepheid.com/en-US/tests/tb-emerging-infectious-diseases/xpert-mtb-rif.html.
    · extracted · link · source: references/10665-381036.page-372.17.json
  390. Cepheid. 2023b. "Xpert MTB/RIF Ultra." Accessed November 12. https://www.cepheid.com/en-GB/tests/tb-emerging-infectious-diseases/xpert-mtb-rif-ultra.html.
    · extracted · link · source: references/10665-381036.page-372.18.json
  391. Chu, H., and S. R. Cole. 2006. "Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach." J Clin Epidemiol 59 (12): 1331-2; author reply 1332-3.
    · extracted · source: references/10665-381036.page-372.19.json
  392. Cochrane Library Content. "Cochrane Conflict of Interest Policy for Cochrane Library Content Effective date Oct 14th 2020 Next review date Date TBA Trusted evidence. Informed decisions. Better health. ." Cochrane Library Content. Accessed 01.04.2024. https://training.cochrane.org/online-learning/coi-policy/coi-policy-cochrane-library.
    · extracted · link · source: references/10665-381036.page-372.20.json
  393. Cox, J. A., R. L. Lukande, S. Kalungi, E. Van Marck, K. Van de Vijver, et al. 2015. "Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults." PLoS One 10 (4): e0123323. de Vasconcellos, K., P. Ramjathan, and D. Singh. 2021. "The utility of point-of-care urinary lipoarabinomannan testing for the diagnosis of tuberculosis in critically ill patients: a prospective observational study." BMC Infectious Diseases 21 (1): 281.
    · extracted · source: references/10665-381036.page-372.21.json
  394. Dhana, A., Y. Hamada, A. P. Kengne, A. D. Kerkhoff, M. X. Rangaka, et al. 2022a. "Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis." Lancet HIV. Dhana, A., Y. Hamada, A. P. Kengne, A. D. Kerkhoff, M. X. Rangaka, et al. 2022b. "Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis." Lancet Infect Dis 22 (4): 507-518. Diagnostics, Molbio. 2023a. "Truenat MTB ". Accessed 9 November. https://www.molbiodiagnostics.com/product_details.php?id=1.
    · extracted · link · source: references/10665-381036.page-372.22.json
  395. Diagnostics, Molbio. 2023b. "Truenat MTB Plus." Accessed November 9. https://www.molbiodiagnostics.com/product_details.php?id=49.
    · extracted · link · source: references/10665-381036.page-372.23.json
  396. Garcia, J. I., J. Melendez, R. Alvarez, C. Mejia-Chew, H. V. Kelley, et al. 2020. "Accuracy of the tuberculosis point-of-care Alere determine lipoarabinomannan antigen diagnostic test using alpha-mannosidase treated and untreated urine in a cohort of people living with HIV in Guatemala." AIDS Research & Therapy [Electronic Resource] 17 (1): 62.
    · extracted · source: references/10665-381036.page-372.24.json
  397. Gils, T., M. Kamele, T. Madonsela, S. Bosman, T. Ngubane, et al. 2023. "Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluation." PLoS One 18 (12): e0296197.
    · extracted · source: references/10665-381036.page-372.25.json
  398. Grant, A. D., S. Charalambous, M. Tlali, A. S. Karat, S. E. Dorman, et al. 2020. "Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial." Lancet HIV 7 (1): e27-e37.
    · extracted · source: references/10665-381036.page-372.26.json
  399. Gupta-Wright, A., E. L. Corbett, J. J. van Oosterhout, D. Wilson, D. Grint, et al. 2018. "Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial." Lancet 392 (10144): 292-301.
    · extracted · source: references/10665-381036.page-372.27.json
  400. Hanrahan, C. F., G. Theron, J. Bassett, K. Dheda, L. Scott, et al. 2014. "Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression." Am J Respir Crit Care Med 189 (11): 1426-34.
    · extracted · source: references/10665-381036.page-372.28.json
  401. Higgins, Julian P T, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, et al. 2011. "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials." BMJ 343: d5928.
    · extracted · source: references/10665-381036.page-372.29.json
  402. Horne, D. J., M. Kohli, J. S. Zifodya, I. Schiller, N. Dendukuri, et al. 2019. "Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults." Cochrane Database Syst Rev 6 (6): CD009593.
    · extracted · source: references/10665-381036.page-372.30.json
  403. Huerga, H., S. C. Mathabire Rucker, M. Bastard, J. Mpunga, I. Amoros Quiles, et al. 2021. "Urine Lipoarabinomannan Testing for All HIV Patients Hospitalized in Medical Wards Identifies a Large Proportion of Patients With Tuberculosis at Risk of Death." Open Forum Infectious Diseases 8 (2): ofaa639.
    · extracted · source: references/10665-381036.page-372.32.json
  404. Huerga, H., S. C. Mathabire Rucker, L. Cossa, M. Bastard, I. Amoros, et al. 2019. "Diagnostic value of the urine lipoarabinomannan assay in HIV-positive, ambulatory patients with CD4 below 200 cells/mul in 2 low-resource settings: A prospective observational study." PLoS Medicine / Public Library of Science 16 (4): e1002792.
    · extracted · source: references/10665-381036.page-372.33.json
  405. Huerga, H., S. C. M. Rucker, M. Bastard, A. Dimba, C. Kamba, et al. 2020. "Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi." Journal of Acquired Immune Deficiency Syndromes: JAIDS 83 (1): 24-30.
    · extracted · source: references/10665-381036.page-372.34.json
  406. Inbaraj, L. R., J. Daniel, P. Rajendran, A. Bhaskar, V. A. Srinivasalu, et al. 2023a. "Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults." Cochrane Database of Systematic Reviews (1). Inbaraj, L. R., J. Daniel, M. K. Sathya Narayanan, V. A. Srinivasalu, A. Bhaskar, et al. 2023b. "TB‐LAMP (loop‐mediated isothermal amplification) for diagnosing pulmonary tuberculosis in children." Cochrane Database of Systematic Reviews (9). Kasaro, M. P., O. N. Chilyabanyama, N. S. Shah, B. Muluka, N. Kapata, et al. 2020. "Performance of xpert mtb/rif and determineTM tb-lam ag in hiv-infected adults in peri-urban sites in Zambia." Public Health Action 10(4): 134-140.
    · extracted · source: references/10665-381036.page-372.35.json
  407. Kebede, W., G. Abebe, E. K. Gudina, and A. Van Rie. 2021. "The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study." Scientific Reports 11 (1): 24428.
    · extracted · source: references/10665-381036.page-372.36.json
  408. Kerkhoff, A. D., D. A. Barr, C. Schutz, R. Burton, M. P. Nicol, et al. 2017. "Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays." Sci Rep 7 (1): 10931.
    · extracted · source: references/10665-381036.page-372.37.json
  409. Kerkhoff, A. D., B. Sossen, C. Schutz, E. I. Reipold, A. Trollip, et al. 2020. "Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV." European Respiratory Journal 55 (2).
    · extracted · source: references/10665-381036.page-372.38.json
  410. Kohli, M., I. Schiller, N. Dendukuri, M. Yao, K. Dheda, et al. 2021a. "Xpert MTB/RIF Ultra and Xpert Database Syst Rev 1: CD012768. Kohli, M., I. Schiller, N. Dendukuri, M. Yao, K. Dheda, et al. 2021b. "Xpert MTB/RIF Ultra and Xpert Database Syst Rev 1 (1): CD012768. Lawn, S. D., A. D. Kerkhoff, R. Burton, C. Schutz, A. Boulle, et al. 2017a. "Diagnostic accuracy, prospective cohort." BMC Med 15 (1): 67. Lawn, S. D., A. D. Kerkhoff, R. Burton, C. Schutz, A. Boulle, et al. 2017b. "Diagnostic accuracy, prospective cohort." BMC Medicine 15 (1): 67. Liu, D., L. Gu, R. Zhang, L. Liu, Y. Shen, et al. 2022. "Utility of urine lipoarabinomannan (LAM) in diagnosing mycobacteria infection among hospitalized HIV-positive patients." Int J Infect Dis 118: 65-70.
    · extracted · source: references/10665-381036.page-372.39.json
  411. Nakiyingi, L., V. M. Moodley, Y. C. Manabe, M. P. Nicol, M. Holshouser, et al. 2014. "Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults." Journal of Acquired Immune Deficiency Syndromes: JAIDS 66 (3): 270-9.
    · extracted · source: references/10665-381036.page-372.40.json
  412. Nathavitharana, R. R., P. Lederer, M. Chaplin, S. Bjerrum, K. R. Steingart, and M. Shah. 2021. "Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV." Cochrane Database of Systematic Reviews 8: CD014641.
    · extracted · source: references/10665-381036.page-372.41.json
  413. Olbrich, L., A. W. Kay, S. Bjerrum, B. Yang, J. Åhsberg, et al. 2024. "Parallel use of low‐complexity automated nucleic acid amplification tests on respiratory samples and stool with or without lateral flow lipoarabinomannan assays to detect pulmonary tuberculosis disease in children." Cochrane Database of Systematic Reviews (5).
    · extracted · source: references/10665-381036.page-372.42.json
  414. Olbrich, L., M. Nliwasa, I. Sabi, N. E. Ntinginya, C. Khosa, et al. 2023. "Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis." Pediatr Infect Dis J 42 (5): 353-360.
    · extracted · source: references/10665-381036.page-372.43.json
  415. Organization, World Health. 2023. Global tuberculosis report 2023. World Health Organization (WHO)
    · extracted · source: references/10665-381036.page-372.44.json
  416. (Geneva). Page, M. J., J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, et al. 2021. "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews." BMJ 372: n71.
    · extracted · source: references/10665-381036.page-372.45.json
  417. Pai, M., M. A. Behr, D. Dowdy, K. Dheda, M. Divangahi, et al. 2016. "Tuberculosis." Nat Rev Dis Primers 2: 16076.
    · extracted · source: references/10665-381036.page-372.46.json
  418. Penn-Nicholson, A., S. N. Gomathi, C. Ugarte-Gil, A. Meaza, E. Lavu, et al. 2021. "A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays." Eur Respir J 58 (5).
    · extracted · source: references/10665-381036.page-372.47.json
  419. Peter, J. G., L. S. Zijenah, D. Chanda, P. Clowes, M. Lesosky, et al. 2016. "Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial." Lancet 387 (10024): 1187-97.
    · extracted · source: references/10665-381036.page-372.48.json
  420. Peter, J., G. Theron, D. Chanda, P. Clowes, A. Rachow, et al. 2015a. "Test characteristics and potential and able to self-expectorate sputum for diagnostic testing." BMC Infectious Diseases 15: 262. Peter, J., G. Theron, D. Chanda, P. Clowes, A. Rachow, et al. 2015b. "Test characteristics and potential and able to self-expectorate sputum for diagnostic testing." BMC Infect Dis 15: 262. Reeve, B. W., G. Ndlangalavu, H. Mishra, Z. Palmer, H. Tshivhula, et al. 2023. "Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected
    · extracted · source: references/10665-381036.page-372.49.json
  421. antiretroviral therapy initiators: a prospective diagnostic accuracy study." MedRxiv : the Preprint Server for Health Sciences 05: 05. Reitsma, J. B., A. S. Glas, A. W. Rutjes, R. J. Scholten, P. M. Bossuyt, and A. H. Zwinderman. 2005.
    · extracted · source: references/10665-381036.page-372.50.json
  422. "Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews." J Clin Epidemiol 58 (10): 982-90. SD BIOSENSOR. 2021. "STANDARD M M10 MDR-TB." https://www.sdbiosensor.com/product/product_view?product_no=23007.
    · extracted · link · source: references/10665-381036.page-372.51.json
  423. Shah, M., C. Hanrahan, Z. Y. Wang, N. Dendukuri, S. D. Lawn, et al. 2016a. "Lateral flow urine Database Syst Rev 2016 (5): CD011420.
    · extracted · source: references/10665-381036.page-372.52.json
  424. Shah, M., C. Hanrahan, Z. Y. Wang, N. Dendukuri, S. D. Lawn, et al. 2016b. "Lateral flow urine Database of Systematic Reviews (5): CD011420. Shah, M., N. A. Martinson, R. E. Chaisson, D. J. Martin, E. Variava, and S. E. Dorman. 2010. "Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis." Journal of Clinical Microbiology 48 (8): 2972-4.
    · extracted · source: references/10665-381036.page-372.53.json
  425. Shah, M., W. Ssengooba, D. Armstrong, L. Nakiyingi, M. Holshouser, et al. 2014. "Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals." AIDS 28 (9): 1307-14.
    · extracted · source: references/10665-381036.page-372.54.json
  426. Shapiro, A. E., A. M. Olson, L. Kidoguchi, X. Niu, Z. Ngcobo, et al. 2022. "Complementary Nonsputum Diagnostic Testing for Tuberculosis in People with HIV Using Oral Swab PCR and Urine Lipoarabinomannan Detection." Journal of Clinical Microbiology 60 (8): e0043122.
    · extracted · source: references/10665-381036.page-372.55.json
  427. Shapiro, A. E., J. M. Ross, M. Yao, I. Schiller, M. Kohli, et al. 2021. "Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms." Cochrane Database Syst Rev 3 (3): CD013694.
    · extracted · source: references/10665-381036.page-372.56.json
  428. Shivakoti, R., D. Sharma, G. Mamoon, and K. Pham. 2017. "Association of HIV infection with extrapulmonary tuberculosis: a systematic review." Infection 45 (1): 11-21.
    · extracted · source: references/10665-381036.page-372.57.json
  429. Snow, K. J., A. T. Cruz, J. A. Seddon, R. A. Ferrand, S. S. Chiang, et al. 2020. "Adolescent tuberculosis." Lancet Child Adolesc Health 4 (1): 68-79.
    · extracted · source: references/10665-381036.page-372.58.json
  430. Spooner, E., S. Reddy, S. Ntoyanto, Y. Sakadavan, T. Reddy, et al. 2022. "TB testing in HIV-positive patients prior to antiretroviral treatment." International Journal of Tuberculosis & Lung Disease 26 (3): 224-231.
    · extracted · source: references/10665-381036.page-372.59.json
  431. Stead, D. F., S. Wasserman, E. Steenkamp, A. G. Parrish, and G. Meintjes. 2023. "Performance of Urine Xpert Ultra Vs Alere Lam for Diagnosing Tb in Hiv in-Patients." Topics in Antiviral Medicine 31(2): 303-304.
    · extracted · source: references/10665-381036.page-372.60.json
  432. Swanepoel, J., K. Zimri, M. M. van der Zalm, G. Hoddinott, M. Palmer, et al. 2022. "Understanding the biology, morbidity and social contexts of adolescent tuberculosis: a prospective observational cohort study protocol (Teen TB)." BMJ Open 12 (12): e062979.
    · extracted · source: references/10665-381036.page-372.61.json
  433. Szekely, R., B. Sossen, M. Mukoka, M. Muyoyeta, E. Nakabugo, et al. 2022. "Multicentre accuracy trial of FUJIFILM SILVAMP TB LAM test in people with HIV reveals lot variability." medRxiv. 09.
    · extracted · source: references/10665-381036.page-372.62.json
  434. Székely, Rita, Bianca Sossen, Madalo Mukoka, Monde Muyoyeta, Elizabeth Nakabugo, et al. 2022.
    · extracted · source: references/10665-381036.page-372.63.json
  435. "Multicentre accuracy trial of FUJIFILM SILVAMP TB LAM test in people with HIV reveals lot variability." medRxiv: 2022.09.07.22278961.
    · extracted · source: references/10665-381036.page-372.64.json
  436. Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, et al. 2022. "Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, et al. Chapter 10: Undertaking meta-analysis. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editors(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Vol. 2nd. London: Cochrane, 2022.".
    · extracted · source: references/10665-381036.page-372.65.json
  437. Review Manager Web (RevMan Web). , Available at revman.cochrane.org. Thit, S. S., N. M. Aung, Z. W. Htet, M. A. Boyd, H. A. Saw, et al. 2017. "The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study." BMC Medicine 15 (1): 145.
    · extracted · source: references/10665-381036.page-372.66.json
  438. Van Hoving, D. J., S. Lahri, H. J. Lategan, M. P. Nicol, G. Maartens, and G. Meintjes. 2019. "Brief Report: Real-World Performance and Interobserver Agreement of Urine Lipoarabinomannan in Diagnosing HIV-Associated Tuberculosis in an Emergency Center." Journal of Acquired Immune Deficiency Syndromes: JAIDS 81 (1): e10-e14.
    · extracted · source: references/10665-381036.page-372.67.json
  439. Covidence systematic review software., , Melbourne, Australia. Available at www.covidence.org.
    · extracted · link · source: references/10665-381036.page-372.68.json
  440. Whiting, P. F., A. W. Rutjes, M. E. Westwood, S. Mallett, J. J. Deeks, et al. 2011. "QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies." Ann Intern Med 155 (8): 529-36.
    · extracted · source: references/10665-381036.page-372.69.json
  441. WHO. 2014. Meeting report: High-priority target product profi les for new tuberculosis diagnostics: report of a consensus meeting. World Health Organization (Geneva, https://www.who.int/publications/i/item/WHO-HTM-TB-2014.18).
    · extracted · link · source: references/10665-381036.page-372.70.json
  442. WHO. 22 March 2021. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. . World Health Organization (Geneva, https://www.who.int/publications/i/item/9789240022676).
    · extracted · link · source: references/10665-381036.page-372.71.json
  443. World Health Organization. 2017. WHO Meeting Report of a Technical Expert Consultation: Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. (Geneva, (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.).
    · extracted · source: references/10665-381036.page-372.72.json
  444. World Health Organization. 2019. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update 2019. Licence: CC BY-NC-SA 3.0 IGO.,. (Geneva, https://apps.who.int/iris/handle/10665/329479).
    · extracted · link · source: references/10665-381036.page-372.73.json
  445. World Health Organization. 2021a. WHO consolidated guidelines on tuberculosis - Module 3: Diagnosis -Rapid diagnostics for tuberculosis detection. (Geneva, https://www.who.int/publications/i/item/9789240029415).
    · extracted · link · source: references/10665-381036.page-372.74.json
  446. World Health Organization. 2021b. WHO global lists of high burden countries for TB, multidrug/rifampicin-resistant TB (MDR/RR-TB) and TB/HIV, 2021–2025. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.,.
    · extracted · source: references/10665-381036.page-372.75.json
  447. World Health Organization. 2021c. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update., , ed World Health Organization.
    · extracted · source: references/10665-381036.page-372.76.json
  448. Geneva (accessed 3 January 2023).
    · extracted · source: references/10665-381036.page-372.77.json
  449. Yang, B., S. Mallett, Y. Takwoingi, C. F. Davenport, C. J. Hyde, et al. 2021a. "QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies." Ann Intern Med 174 (11): 1592-1599. Yang, B., R. A. Mustafa, P. M. Bossuyt, J. Brozek, M. Hultcrantz, et al. 2021b. "GRADE Guidance: 31. Assessing the certainty across a body of evidence for comparative test accuracy." J Clin Epidemiol 136: 146-156. Yoon, C., F. C. Semitala, L. Asege, J. Katende, S. Mwebe, et al. 2019. "Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV." American Journal of Respiratory & Critical Care Medicine 199 (5): 643-650.
    · extracted · source: references/10665-381036.page-372.78.json
  450. Zifodya, J. S., J. S. Kreniske, I. Schiller, M. Kohli, N. Dendukuri, et al. 2021. "Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis." Cochrane Database Syst Rev 2: CD009593.
    · extracted · source: references/10665-381036.page-372.79.json
  451. World Health Organization. Global Tuberculosis Report 2023. Geneva ; 2023.
    · extracted · source: references/10665-381036.page-434.1.json
  452. Nguyen TNA, Anton-Le Berre V, Bañuls AL, Nguyen TVA. Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review. Front Microbiol. 2019 Apr 16;10.
    · extracted · source: references/10665-381036.page-434.2.json
  453. World Health Organization. Module 3: Diagnosis WHO operational handbook on tuberculosis - rapid diagnostics for tuberculosis detection . Geneva; 2021.
    · extracted · source: references/10665-381036.page-434.3.json
  454. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? European Respiratory Journal. 2015 Jan;45(1):150–60.
    · extracted · source: references/10665-381036.page-434.4.json
  455. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method. J Clin Microbiol. 2007 Aug;45(8):2662–8.
    · extracted · source: references/10665-381036.page-434.5.json
  456. Yusoof KA, García JI, Schami A, Garcia-Vilanova A, Kelley H V., Wang SH, et al. Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review. Front Immunol. 2022 Jul 7;13.
    · extracted · source: references/10665-381036.page-434.6.json
  457. Gilpin C, Korobitsyn A, Weyer K. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther Adv Infect Dis. 2016 Dec 15;3(6):145–51.
    · extracted · source: references/10665-381036.page-434.7.json
  458. Amini S, Hoffner S, Allahyar Torkaman MR, Hamzehloo G, Nasiri MJ, Salehi M, et al. Direct drug susceptibility testing of Mycobacterium tuberculosis using the proportional method: A multicenter study. J Glob Antimicrob Resist. 2019 Jun;17:242–4.
    · extracted · source: references/10665-381036.page-434.8.json
  459. Nathavitharana RR, Lederer P, Tierney DB, Nardell E. Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2019 Apr 1;23(4):396–404.
    · extracted · source: references/10665-381036.page-434.9.json
  460. García JI, Allué-Guardia A, Tampi RP, Restrepo BI, Torrelles JB. New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy. Curr Epidemiol Rep. 2021 Apr 7;8(2):33–45.
    · extracted · source: references/10665-381036.page-434.10.json
  461. World Health Organization. Update on the use of nucleic acid amplification tests to detect TB and drug resistant TB: rapid communication. Geneva ; 2021.
    · extracted · source: references/10665-381036.page-434.11.json
  462. Nandlal L, Perumal R, Naidoo K. Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis. Infect Drug Resist. 2022 Aug;Volume 15:4971–84.
    · extracted · source: references/10665-381036.page-434.12.json
  463. World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis - policy guidance. Geneva ; 2016.
    · extracted · source: references/10665-381036.page-434.13.json
  464. Hao X, Lou H, Bai J, Ding Y, Yang J, Pan W. Cost-effectiveness analysis of Xpert in detecting Mycobacterium tuberculosis: A systematic review. International Journal of Infectious Diseases. 2020 Jun;95:98–105.
    · extracted · source: references/10665-381036.page-434.14.json
  465. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct 2;169(7):467–73.
    · extracted · source: references/10665-381036.page-434.15.json
  466. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71.
    · extracted · source: references/10665-381036.page-434.16.json
  467. The United Nations. The United Nations . 2024. United Nations Treasury - The United Nations Operational Rates of Exchange .
    · extracted · source: references/10665-381036.page-434.17.json
  468. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013 Mar 25;346.
    · extracted · source: references/10665-381036.page-434.18.json
  469. ClinicoEconomics and Outcomes Research. 2022;14:61–73.
    · extracted · source: references/10665-381036.page-434.19.json
  470. una comparación con métodos diagnósticos no moleculares Contribution of the use of xpert MTB/RIF and its cost-effectiveness in the diagnosis of pulmonary tuberculosis and resistance to rifampicin: a comparison with non molecular diagnostic methods. Infect. 2022;26(2):121–7.
    · extracted · source: references/10665-381036.page-434.20.json
  471. LAM Ag. J Clin Microbiol. 2020 Sep 22;58(10).
    · extracted · source: references/10665-381036.page-434.21.json
  472. Da Silva SCA, Vater MC, Ramalho DMDP, De Almeida IN, De Miranda SS, Kritski A. Cost-effectiveness of xpert®MTB/RIF in the diagnosis of tuberculosis: Pragmatic study. Rev Soc Bras Med Trop. 2021;54:1–8.
    · extracted · source: references/10665-381036.page-434.22.json
  473. diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia. PLoS One. 2021 Oct 1;16(10 October).
    · extracted · source: references/10665-381036.page-434.24.json
  474. MTB/RIF for Multi-Outcomes of Presumptive Pulmonary Tuberculosis Patients in Thailand. Value Health Reg Issues. 2020 May 1;21:264–71.
    · extracted · source: references/10665-381036.page-434.25.json
  475. Mycobacterium tuberculosis Sepsis in Uganda. Int J Environ Res Public Health. 2023 Mar 1;20(6).
    · extracted · source: references/10665-381036.page-434.26.json
  476. Sedrak AS, Salem AA, Amin TT, Amin W. Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt [Internet]. Vol. 88, The Egyptian Journal of Hospital Medicine. 2022. Available from: https://ejhm.journals.ekb.eg/
    · extracted · link · source: references/10665-381036.page-434.27.json
  477. pulmonary tuberculosis among hospitalized patients in a low-burden setting: Cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy. Infect Control Hosp Epidemiol. 2022 Jul
    · extracted · source: references/10665-381036.page-434.28.json
  478. una comparación con métodos diagnósticos no moleculares. Infectio. 2021 Oct 15;121–7.
    · extracted · source: references/10665-381036.page-434.29.json
  479. LAM Ag. J Clin Microbiol. 2020 Sep 22;58(10).
    · extracted · source: references/10665-381036.page-434.30.json
  480. pulmonary tuberculosis among hospitalized patients in a low-burden setting: cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy. Infect Control Hosp Epidemiol. 2022 Jul
    · extracted · source: references/10665-381036.page-434.31.json
  481. analysis. PLoS One. 2023 Jul 1;18(7 July).
    · extracted · source: references/10665-381036.page-434.32.json
  482. Lancet Glob Health. 2023 Feb 1;11(2):e278–86.
    · extracted · source: references/10665-381036.page-434.35.json
  483. modelling [Internet]. Vol. 76, Thorax. 2021. Available from: http://group.bmj.com/products/journals/instructions-for-
    · extracted · link · source: references/10665-381036.page-434.36.json
  484. Mafirakureva N, Klinkenberg E, Spruijt I, Levy J, Shaweno D, De Haas P, et al. Xpert Ultra stool testing to BMJ Open. 2022 Jul 1;12(7).
    · extracted · source: references/10665-381036.page-434.37.json
  485. Fantom N, Serajuddin U. The World Bank’s Classification of Countries by Income [Internet]. 2016. Available from: http://econ.worldbank.org.
    · extracted · link · source: references/10665-381036.page-434.38.json
  486. Mafirakureva N, Klinkenberg E, Spruijt I, Levy J, Shaweno D, de Haas P, et al. Xpert Ultra stool testing to BMJ Open. 2022 Jul 1;12(7):e058388.
    · extracted · source: references/10665-381036.page-434.39.json
  487. for diagnosis of pediatric tuberculosis under national tuberculosis elimination program. Vol. 48, Indian Journal of Community Medicine. Wolters Kluwer Medknow Publications; 2023. p. 24–30.
    · extracted · source: references/10665-381036.page-434.40.json
  488. ClinicoEconomics and Outcomes Research. 2022 Feb;Volume 14:61–73.
    · extracted · source: references/10665-381036.page-434.41.json
  489. BMJ Open. 2022 Aug 23;12(8):e059823.
    · extracted · source: references/10665-381036.page-434.42.json
  490. Silva SCA da, Vater MC, Ramalho DM de P, Almeida IN de, Miranda SS de, Kritski A. Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study. Rev Soc Bras Med Trop. 2021;54.
    · extracted · source: references/10665-381036.page-434.43.json
  491. diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia. PLoS One. 2021 Oct 25;16(10):e0259056.
    · extracted · source: references/10665-381036.page-434.44.json
  492. Mycobacterium tuberculosis Sepsis in Uganda. Int J Environ Res Public Health. 2023 Mar 13;20(6):5041.
    · extracted · source: references/10665-381036.page-434.45.json
  493. MTB/RIF for Multi-Outcomes of Patients With Presumptive Pulmonary Tuberculosis in Thailand. Value Health Reg Issues. 2020 May;21:264–71.
    · extracted · source: references/10665-381036.page-434.46.json
  494. Sedrak A, Salem AA, Amin TT, Amin W. Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt. Egypt J Hosp Med. 2022 Jul 1;88(1):2452–8.
    · extracted · source: references/10665-381036.page-434.47.json
  495. analysis. PLoS One. 2023 Jul 14;18(7):e0288605.
    · extracted · source: references/10665-381036.page-434.48.json
  496. modelling. Thorax. 2021 Mar;76(3):281–91.
    · extracted · source: references/10665-381036.page-434.50.json
  497. Lancet Glob Health. 2023 Feb;11(2):e278–86.
    · extracted · source: references/10665-381036.page-434.52.json
  498. for diagnosis of pediatric tuberculosis under national tuberculosis elimination program. Indian Journal of Community Medicine. 2023;48(1):24.
    · extracted · source: references/10665-381036.page-434.53.json
  499. treatment in the Philippines in 2017. International Journal of Tuberculosis and Lung Disease. 2022 May 1;26(5):392–8.
    · extracted · source: references/10665-381036.page-434.55.json
  500. mobile testing in high-burden peri-mining communities in South Africa. Afr J Lab Med. 2021;10(1).
    · extracted · source: references/10665-381036.page-434.56.json
  501. India. International Journal of Tuberculosis and Lung Disease. 2021 Dec 1;25(12):1013–8.
    · extracted · source: references/10665-381036.page-434.57.json
  502. Figueredo LJ de A, de Miranda SS, Dos Santos LB, Manso CGG, Soares VM, Alves S, et al. Cost analysis of smear microscopy and the xpert assay for tuberculosis diagnosis: Average turnaround time. Rev Soc Bras Med Trop. 2020;53:1–6.
    · extracted · source: references/10665-381036.page-434.58.json
  503. Lopes LN, Cardoso LL, Da Silva MS, Tonin E, Zilly A, Silva-Sobrinho RA. Rapid molecular assay for tuberculosis: Cost and contributions. Revista Baiana de Enfermagem. 2020;34.
    · extracted · source: references/10665-381036.page-434.59.json
  504. costs incurred under the National Tuberculosis Elimination Programme: A costing study from Tamil Nadu, South India. Int Health. 2021 Nov 1;13(6):536–44.
    · extracted · source: references/10665-381036.page-434.60.json
  505. up tuberculosis diagnosis using Xpert MTB/RIF testing in West Java, Indonesia. PLoS One. 2022 Mar 1;17(3 March).
    · extracted · source: references/10665-381036.page-434.61.json
  506. Santos ADS, De Oliveira RD, Lemos EF, Lima F, Cohen T, Cords O, et al. Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. Clinical Infectious Diseases. 2021 Mar
    · extracted · source: references/10665-381036.page-434.62.json
  507. Soares VM, de Almeida IN, Vater MC, Alves S, Figueredo LJ de A, Scherer L, et al. Genotype®MTBDRplus and xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: Cost analysis in a tertiary referral hospital. Rev Soc Bras Med Trop. 2020;53.
    · extracted · source: references/10665-381036.page-434.63.json
  508. pathway in Uganda. Vol. 25, International Journal of Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease; 2021. p. 61–3.
    · extracted · source: references/10665-381036.page-434.64.json
  509. Yadav RN, Verma AK, Kaushik G. Laboratory cost analysis of conventional and newer molecular tests for diagnosis of presumptive multidrug-resistant tuberculosis patients. J Glob Infect Dis. 2022 Jul 1;14(3):93–8.
    · extracted · source: references/10665-381036.page-434.65.json
  510. treatment in the Philippines in 2017. The International Journal of Tuberculosis and Lung Disease. 2022 May 1;26(5):392–8.
    · extracted · source: references/10665-381036.page-434.67.json
  511. mobile testing in high-burden peri-mining communities in South Africa. Afr J Lab Med. 2021 Nov 30;10(1).
    · extracted · source: references/10665-381036.page-434.68.json
  512. India (No 1). The International Journal of Tuberculosis and Lung Disease. 2021 Dec 1;25(12):1013–8.
    · extracted · source: references/10665-381036.page-434.69.json
  513. Figueredo LJ de A, Miranda SS de, Santos LB dos, Manso CGG, Soares VM, Alves S, et al. Cost analysis of smear microscopy and the Xpert assay for tuberculosis diagnosis: average turnaround time. Rev Soc Bras Med Trop. 2020;53.
    · extracted · source: references/10665-381036.page-434.70.json
  514. Lopes LN, Cardoso LL, Da Silva MS, Tonin E, Zilly A, Silva-Sobrinho RA. TESTE RÁPIDO MOLECULAR PARA TUBERCULOSE: CUSTO E CONTRIBUIÇÕES. Revista Baiana de Enfermagem . 2020 May 6;34.
    · extracted · source: references/10665-381036.page-434.71.json
  515. costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India. Int Health. 2021 Dec 1;13(6):536–44.
    · extracted · source: references/10665-381036.page-434.72.json
  516. up tuberculosis diagnosis using Xpert MTB/RIF testing in West Java, Indonesia. PLoS One. 2022 Mar 10;17(3):e0264912.
    · extracted · source: references/10665-381036.page-434.73.json
  517. Santos A da S, de Oliveira RD, Lemos EF, Lima F, Cohen T, Cords O, et al. Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. Clinical Infectious Diseases. 2021 Mar
    · extracted · source: references/10665-381036.page-434.74.json
  518. Soares VM, Almeida IN de, Vater MC, Alves S, Figueredo LJ de A, Scherer L, et al. Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: cost analysis in a tertiary referral hospital. Rev Soc Bras Med Trop. 2020;53.
    · extracted · source: references/10665-381036.page-434.75.json
  519. pathway in Uganda. The International Journal of Tuberculosis and Lung Disease. 2021 Jan 1;25(1):61–3.
    · extracted · source: references/10665-381036.page-434.76.json
  520. Yadav R, Verma A, Kaushik G. Laboratory cost analysis of conventional and newer molecular tests for diagnosis of presumptive multidrug-resistant tuberculosis patients. J Glob Infect Dis. 2022;14(3):93.
    · extracted · source: references/10665-381036.page-434.77.json
  521. Jo Y, Kagujje M, Johnson K, Dowdy D, Hangoma P, Chiliukutu L, et al. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. PLoS One. 2021 Sep 9;16(9):e0256531.
    · extracted · source: references/10665-381036.page-434.78.json
  522. Donkeng-Donfack VF, Tchatchueng-Mbougua JB, Abanda NN, Ongboulal SM, Djieugoue YJ, Kamdem Simo Y, et al. A cost–benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns. BMC Infect Dis. 2022 Dec 4;22(1):219.
    · extracted · source: references/10665-381036.page-434.79.json
  523. Sohn H, Puri L, Nguyen NAT, Van’t Hoog AH, Nguyen VAT, Nliwasa M, et al. Cost and affordability analysis of TB-LAMP and Xpert MTB/RIF assays as routine diagnostic tests in peripheral laboratories in Malawi and Vietnam. Journal of Global Health Science. 2019;1.
    · extracted · source: references/10665-381036.page-434.80.json
  524. Baikunje N, Behera D, Rajwanshi A, Sharma M, Sharma A, Sharma K. Comparative evaluation of loop-mediated isothermal amplification (LAMP) assay, GeneXpert MTB/Rif and multiplex PCR for the diagnosis of tubercular lymphadenitis in HIV-infected patients of North India. Mol Cell Probes. 2019 Dec;48:101459.
    · extracted · source: references/10665-381036.page-434.81.json
  525. Jaroenram W, Kampeera J, Arunrut N, Karuwan C, Sappat A, Khumwan P, et al. Graphene-based electrochemical genosensor incorporated loop-mediated isothermal amplification for rapid on-site detection of Mycobacterium tuberculosis. J Pharm Biomed Anal. 2020 Jul;186:113333.
    · extracted · source: references/10665-381036.page-434.82.json
  526. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, et al. The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. PLoS One. 2016 May 12;11(5):e0155101.
    · extracted · source: references/10665-381036.page-434.83.json
  527. decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing. PLoS One. 2023;18(8 AUGUST).
    · extracted · source: references/10665-381036.page-434.84.json
  528. decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing. PLoS One. 2023 Aug 24;18(8):e0290496.
    · extracted · source: references/10665-381036.page-434.85.json
  529. WHO. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization.2023. Available at https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023.
    · extracted · link · source: references/10665-381036.page-472.1.json
  530. WHO. Status Update: Reaching the targets in the political declaration of the United Nations General Assembly High-level Meeting on the fight against tuberculosis. September 2023. Geneva, Switzerland: World Health Organization.2023. Available at https://www.who.int/publications/m/item/WHO-UCN-TB-2023.4.
    · extracted · link · source: references/10665-381036.page-472.2.json
  531. WHO. The End TB Strategy. Geneva, Switzerland: World Health Organization.2015. Available at https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19.
    · extracted · link · source: references/10665-381036.page-472.3.json
  532. United Nations SDG. United Nations General Assembly. Transforming our world: the 2030 agenda for sustainable development.Resolution adopted by the General Assembly on 25 September 2015. New York, USA: United Nations 2030. Available at https://sdgs.un.org/2030agenda.
    · extracted · link · source: references/10665-381036.page-472.4.json
  533. WHO. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis. Rapid diagnostics for tuberculosis detection. Geneva, Switzerland: World Health Organization.2021. Available at https://www.who.int/publications/i/item/9789240029415
    · extracted · link · source: references/10665-381036.page-472.5.json
  534. Schumacher SG, Sohn H, Qin ZZ, et al. Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies. PLoS One 2016;11(3):e0151073. doi: 10.1371/journal.pone.0151073
    · extracted · doi:10.1371/journal.pone.0151073 · source: references/10665-381036.page-472.6.json
  535. WHO. Update on the use of nucleic acid amplification tests to detect TB and drug resisistant TB: rapid communication. Geneva, Switzerland: World Health Organization.2021. Available at https://www.who.int/publications/i/item/9789240020269.
    · extracted · link · source: references/10665-381036.page-472.7.json
  536. Fan L, Li D, Zhang S, et al. Parallel Tests Using Culture, Xpert MTB/RIF, and SAT-TB in Sputum Plus Bronchial Alveolar Lavage Fluid Significantly Increase Diagnostic Performance of Smear-Negative Pulmonary Tuberculosis. Front Microbiol 2018;9:1107. doi: 10.3389/fmicb.2018.01107
    · extracted · doi:10.3389/fmicb.2018.01107 · source: references/10665-381036.page-472.8.json
  537. Esmail A, Pooran A, Sabur NF, et al. An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag. J Clin Microbiol 2020;58(10) doi: 10.1128/JCM.01032-20
    · extracted · doi:10.1128/JCM.01032-20 · source: references/10665-381036.page-472.9.json
  538. Nathavitharana RP, A. OBryan, M. Edwards, M. van der Westhuizen, H.M, Voldman, B. Subramanian, A. Engel, N. McDowell, A. Steingart, K. . WHO Standard: Universal access to rapid tuberculosis diagnostics. Web Annex A. Uniting innovation and implementation: a mixed methods systematic review of implementation solutions to increase the uptake and impact of molecular WHO-recommended rapid diagnostic tests. Geneva, Switzerland: World Health Organization.2020. Available at https://iris.who.int/bitstream/handle/10665/366684/9789240071339-eng.pdf
    · extracted · link · source: references/10665-381036.page-472.10.json
  539. Engel N, Ochodo EA, Karanja PW, et al. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views. Cochrane Database Syst Rev 2022;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2
    · extracted · doi:10.1002/14651858.CD014877.pub2 · source: references/10665-381036.page-472.11.json
  540. Noyes J BA, Cargo M, Flemming K, Harden A, Harris J, Garside R, Hannes K, Pantoja T, Thomas J. Chapter 21: Qualitative evidence. In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), ed. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023): Cochrane.2023. Available at www.training.cochrane.org/handbook.
    · extracted · link · source: references/10665-381036.page-472.12.json
  541. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol 2012;12:181. doi: 10.1186/1471-2288-12-181
    · extracted · doi:10.1186/1471-2288-12-181 · source: references/10665-381036.page-472.13.json
  542. Murad MH, Chang SM, Fiordalisi CV, et al. Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. J Clin Epidemiol 2021;135:170-75. doi: 10.1016/j.jclinepi.2021.02.028
    · extracted · doi:10.1016/j.jclinepi.2021.02.028 · source: references/10665-381036.page-472.14.json
  543. StopTBPartnership. Xpert MTB/RIF and Ultra, Technical Information Note. Geneva: Stop TB Partnership, 2019. Available at https://stoptb.org/assets/documents/gdf/drugsupply/Xpert_info_note.pdf.
    · extracted · link · source: references/10665-381036.page-472.15.json
  544. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 2021;18(3):e1003583. doi: 10.1371/journal.pmed.1003583
    · extracted · doi:10.1371/journal.pmed.1003583 · source: references/10665-381036.page-472.16.json
  545. Covidence systematic review software [program]. Melbourne, Australia. : Veritas Health Innovation Available at www.covidence.org.
    · extracted · link · source: references/10665-381036.page-472.17.json
  546. Engel N, Ganesh G, Patil M, et al. Barriers to Point-of-Care Testing in India: Results from Qualitative Research across Different Settings, Users and Major Diseases. PLoS One 2015;10(8):e0135112. doi: 10.1371/journal.pone.0135112
    · extracted · doi:10.1371/journal.pone.0135112 · source: references/10665-381036.page-472.18.json
  547. Umubyeyi AN, Bonsu F, Chimzizi R, et al. The role of technical assistance in expanding access to Xpert((R)) MTB/RIF: experience in sub-Saharan Africa. Public Health Action 2016;6(1):32-4. doi: 10.5588/pha.15.0069
    · extracted · doi:10.5588/pha.15.0069 · source: references/10665-381036.page-472.19.json
  548. Eshun-Wilson I, Rohwer A, Hendricks L, et al. Being HIV positive and staying on antiretroviral therapy in Africa: A qualitative systematic review and theoretical model. PLoS One 2019;14(1):e0210408. doi: 10.1371/journal.pone.0210408
    · extracted · doi:10.1371/journal.pone.0210408 · source: references/10665-381036.page-472.20.json
  549. Rees RW, Caird J, Dickson K, et al. 'It's on your conscience all the time': a systematic review of qualitative studies examining views on obesity among young people aged 12-18 years in the UK. BMJ Open 2014;4(4):e004404. doi: 10.1136/bmjopen-2013-004404
    · extracted · doi:10.1136/bmjopen-2013-004404 · source: references/10665-381036.page-472.21.json
  550. Takala T, Hayry M. Research Ethics and Justice: The Case of Finland. Camb Q Healthc Ethics 2019;28(3):551-76. doi: 10.1017/S0963180119000471
    · extracted · doi:10.1017/S0963180119000471 · source: references/10665-381036.page-472.22.json
  551. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008;8:45. doi: 10.1186/1471-2288-8-45
    · extracted · doi:10.1186/1471-2288-8-45 · source: references/10665-381036.page-472.23.json
  552. Braun V CV. Using thematic analysis in psychology. Qualitative Research in Psychology 2006;3(2):77-101.
    · extracted · source: references/10665-381036.page-472.24.json
  553. Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci 2018;13(Suppl 1):2. doi: 10.1186/s13012-017-0688-3
    · extracted · doi:10.1186/s13012-017-0688-3 · source: references/10665-381036.page-472.25.json
  554. Lewin S, Bohren M, Rashidian A, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 2: how to make an overall CERQual assessment of confidence and create a Summary of Qualitative Findings table. Implement Sci 2018;13(Suppl 1):10. doi: 10.1186/s13012-017-0689-2
    · extracted · doi:10.1186/s13012-017-0689-2 · source: references/10665-381036.page-472.26.json
  555. Glenton C, Carlsen B, Lewin S, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 5: how to assess adequacy of data. Implement Sci 2018;13(Suppl 1):14. doi: 10.1186/s13012-017-0692-7
    · extracted · doi:10.1186/s13012-017-0692-7 · source: references/10665-381036.page-472.27.json
  556. Munthe-Kaas H, Bohren MA, Glenton C, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 3: how to assess methodological limitations. Implement Sci 2018;13(Suppl 1):9. doi: 10.1186/s13012-017-0690-9
    · extracted · doi:10.1186/s13012-017-0690-9 · source: references/10665-381036.page-472.28.json
  557. Noyes J, Booth A, Lewin S, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 6: how to assess relevance of the data. Implement Sci 2018;13(Suppl 1):4. doi: 10.1186/s13012-017-0693-6
    · extracted · doi:10.1186/s13012-017-0693-6 · source: references/10665-381036.page-472.29.json
  558. Mwaura M, Kao K, Wambugu J, et al. Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland. PLoS One 2020;15(2):e0228669. doi: 10.1371/journal.pone.0228669
    · extracted · doi:10.1371/journal.pone.0228669 · source: references/10665-381036.page-472.30.json
  559. Sereda Y, Korotych O, Klimuk D, et al. Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study. Int J Environ Res Public Health 2022;19(7) doi: 10.3390/ijerph19074370
    · extracted · doi:10.3390/ijerph19074370 · source: references/10665-381036.page-472.31.json
  560. An Y, Teo AKJ, Huot CY, et al. Barriers to childhood tuberculosis case detection and management in Cambodia: the perspectives of healthcare providers and caregivers. BMC Infect Dis 2023;23(1):80. doi: 10.1186/s12879-023-08044-y
    · extracted · doi:10.1186/s12879-023-08044-y · source: references/10665-381036.page-472.32.json
  561. Jiang WX, Li ZP, Zhao Q, et al. Impacts of a comprehensive tuberculosis control model on the quality of clinical services and the financial burden of treatment for patients with drug-resistant tuberculosis in China: a mixed-methods evaluation. Infect Dis Poverty 2021;10(1):54. doi: 10.1186/s40249-021-00832-5
    · extracted · doi:10.1186/s40249-021-00832-5 · source: references/10665-381036.page-472.33.json
  562. Juliasih NN, Soedarsono, Sari RM. Analysis of tuberculosis program management in primary health care. Infect Dis Rep 2020;12(Suppl 1):8728. doi: 10.4081/idr.2020.8728
    · extracted · doi:10.4081/idr.2020.8728 · source: references/10665-381036.page-472.34.json
  563. Kanakaraju M, Nagaraja SB, Satyanarayana S, et al. Chest Radiography and Xpert MTB/RIF(R) Testing in Persons with Presumptive Pulmonary TB: Gaps and Challenges from a District in Karnataka, India. Tuberc Res Treat 2020;2020:5632810. doi: 10.1155/2020/5632810
    · extracted · doi:10.1155/2020/5632810 · source: references/10665-381036.page-472.35.json
  564. Nagar M, Joshi A, Sahu S, et al. Concordance and Discordance of Orthopedicians with Revised National Tuberculosis Control Program with Reference to Musculoskeletal Tuberculosis: A Qualitative Inquiry. Indian J Orthop 2020;54(5):711-19. doi: 10.1007/s43465-020-00068-9
    · extracted · doi:10.1007/s43465-020-00068-9 · source: references/10665-381036.page-472.36.json
  565. Paudel S, Padmawati RS, Ghimire A, et al. Feasibility of Find cases Actively, Separate safely and Treat effectively (FAST) strategy for early diagnosis of TB in Nepal: An implementation research. PLoS One 2021;16(10):e0258883. doi: 10.1371/journal.pone.0258883
    · extracted · doi:10.1371/journal.pone.0258883 · source: references/10665-381036.page-472.37.json
  566. Pongpeeradech N, Kasetchareo Y, Chuchottaworn C, et al. Evaluation of the use of GeneXpert MTB/RIF in a zone with high burden of tuberculosis in Thailand. PLoS One 2022;17(7):e0271130. doi: 10.1371/journal.pone.0271130
    · extracted · doi:10.1371/journal.pone.0271130 · source: references/10665-381036.page-472.38.json
  567. Shrestha S, Angolkar M, Narasannavar A, et al. Perceptions and challenges among health care providers about HIV-TB co-infected children- A qualitative study. Indian Journal of Tuberculosis 2023 doi: 10.1016/j.ijtb.2023.05.018
    · extracted · doi:10.1016/j.ijtb.2023.05.018 · source: references/10665-381036.page-472.39.json
  568. Singh AR, Kumar A, Shewade HD, et al. Poor adherence to TB diagnosis guidelines among under-five children with severe acute malnutrition in central India: A missed window of opportunity? PLoS One 2021;16(3):e0248192. doi: 10.1371/journal.pone.0248192
    · extracted · doi:10.1371/journal.pone.0248192 · source: references/10665-381036.page-472.40.json
  569. Velayutham B, Jayabal L, Watson B, et al. Status of Universal Drug Susceptibility Testing in Pulmonary Tuberculosis Patients Initiated on Treatment in an Urban Setting, South India. Indian J Community Med 2023;48(1):103-07. doi: 10.4103/ijcm.ijcm_315_22
    · extracted · doi:10.4103/ijcm.ijcm_315_22 · source: references/10665-381036.page-472.41.json
  570. Doulla BE, Squire SB, MacPherson E, et al. Routine surveillance for the identification of drug resistant Tuberculosis in Tanzania: A cross-sectional study of stakeholders' perceptions. PLoS One 2019;14(2):e0212421. doi: 10.1371/journal.pone.0212421
    · extracted · doi:10.1371/journal.pone.0212421 · source: references/10665-381036.page-472.42.json
  571. Gwaza GP, Leqheka M, Mots'oane T, et al. Missed opportunities for integrated testing of HIV and tuberculosis on the GeneXpert platform in Lesotho. Afr J Lab Med 2023;12(1):2132. doi: 10.4102/ajlm.v12i1.2132
    · extracted · doi:10.4102/ajlm.v12i1.2132 · source: references/10665-381036.page-472.43.json
  572. Isangula K, Philbert D, Ngari F, et al. Implementation of evidence-based multiple focus integrated intensified TB screening to end TB (EXIT-TB) package in East Africa: a qualitative study. BMC Infect Dis 2023;23(1):161. doi: 10.1186/s12879-023-08069-3
    · extracted · doi:10.1186/s12879-023-08069-3 · source: references/10665-381036.page-472.44.json
  573. Nalugwa T, Handley M, Shete P, et al. Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. Implement Sci Commun 2022;3(1):9. doi: 10.1186/s43058-022-00260-y
    · extracted · doi:10.1186/s43058-022-00260-y · source: references/10665-381036.page-472.45.json
  574. Oga-Omenka C, Boffa J, Kuye J, et al. Understanding the gaps in DR-TB care cascade in Nigeria: A sequential mixed-method study. J Clin Tuberc Other Mycobact Dis 2020;21:100193. doi: 10.1016/j.jctube.2020.100193
    · extracted · doi:10.1016/j.jctube.2020.100193 · source: references/10665-381036.page-472.46.json
  575. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014;14:2. doi: 10.1186/1471-2334-14-2
    · extracted · doi:10.1186/1471-2334-14-2 · source: references/10665-381036.page-472.47.json
  576. England K, Masini T, Fajardo E. Detecting tuberculosis: rapid tools but slow progress. Public Health Action 2019;9(3):80-83. doi: 10.5588/pha.19.0013
    · extracted · doi:10.5588/pha.19.0013 · source: references/10665-381036.page-472.48.json
  577. Engel N, Krumeich A. Valuing Simplicity: Developing a Good Point of Care Diagnostic. Front Sociol 2020;5:37. doi: 10.3389/fsoc.2020.00037
    · extracted · doi:10.3389/fsoc.2020.00037 · source: references/10665-381036.page-472.49.json
  578. Colvin CJ, Leon N, Wills C, et al. Global-to-local policy transfer in the introduction of new molecular tuberculosis diagnostics in South Africa. Int J Tuberc Lung Dis 2015;19(11):1326-38. doi: 10.5588/ijtld.15.0262
    · extracted · doi:10.5588/ijtld.15.0262 · source: references/10665-381036.page-472.50.json
  579. Mohammed H, Oljira L, Roba KT, et al. Burden of tuberculosis and challenges related to screening and diagnosis in Ethiopia. J Clin Tuberc Other Mycobact Dis 2020;19:100158. doi: 10.1016/j.jctube.2020.100158
    · extracted · doi:10.1016/j.jctube.2020.100158 · source: references/10665-381036.page-472.51.json
  580. Naidoo P, van Niekerk M, du Toit E, et al. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests. BMC Health Serv Res 2015;15:488. doi: 10.1186/s12913-015-1145-0
    · extracted · doi:10.1186/s12913-015-1145-0 · source: references/10665-381036.page-472.52.json
  581. Nathavitharana RR, Daru P, Barrera AE, et al. FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up. Int J Tuberc Lung Dis 2017;21(9):1020-25. doi: 10.5588/ijtld.16.0794
    · extracted · doi:10.5588/ijtld.16.0794 · source: references/10665-381036.page-472.53.json
  582. Saria V. New Machine, Old Cough: Technology and Tuberculosis in Patna. Front Sociol 2020;5:18. doi: 10.3389/fsoc.2020.00018
    · extracted · doi:10.3389/fsoc.2020.00018 · source: references/10665-381036.page-472.54.json
  583. Ketema L, Dememew ZG, Assefa D, et al. Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: A mixed method study. PLoS One 2020;15(11):e0241977. doi: 10.1371/journal.pone.0241977
    · extracted · doi:10.1371/journal.pone.0241977 · source: references/10665-381036.page-472.55.json
  584. McDowell A, Raizada N, Khaparde SD, et al. "Before Xpert I only had my expertise": A qualitative study on the utilization and effects of Xpert technology among pediatricians in 4 Indian cities. PLoS One 2018;13(3):e0193656. doi: 10.1371/journal.pone.0193656
    · extracted · doi:10.1371/journal.pone.0193656 · source: references/10665-381036.page-472.56.json
  585. Mnyambwa NP, Lekule I, Ngadaya ES, et al. Assessment of GeneXpert GxAlert platform for multi-drug resistant tuberculosis diagnosis and patients' linkage to care in Tanzania. BMC Res Notes 2018;11(1):121. doi: 10.1186/s13104-018-3235-7
    · extracted · doi:10.1186/s13104-018-3235-7 · source: references/10665-381036.page-472.57.json
  586. Nalugwa T, Shete PB, Nantale M, et al. Challenges with scale-up of GeneXpert MTB/RIF(R) in Uganda: a health systems perspective. BMC Health Serv Res 2020;20(1):162. doi: 10.1186/s12913-020-4997-x
    · extracted · doi:10.1186/s12913-020-4997-x · source: references/10665-381036.page-472.58.json
  587. Newtonraj A, Venables E, Selvaraj K, et al. Xpert negative means no TB: A mixed-methods study into early implementation of Xpert in Puducherry, India. J Family Med Prim Care 2019;8(4):1379-85. doi: 10.4103/jfmpc.jfmpc_421_18
    · extracted · doi:10.4103/jfmpc.jfmpc_421_18 · source: references/10665-381036.page-472.59.json
  588. Oliwa JN, Odero SA, Nzinga J, et al. Perspectives and practices of health workers around diagnosis of paediatric tuberculosis in hospitals in a resource-poor setting - modern diagnostics meet age-old challenges. BMC Health Serv Res 2020;20(1):708. doi: 10.1186/s12913-020-05588-6
    · extracted · doi:10.1186/s12913-020-05588-6 · source: references/10665-381036.page-472.60.json
  589. Oo T, Kyaw KWY, Soe KT, et al. Magnitude and reasons for pre-diagnosis attrition among presumptive multi-drug resistant tuberculosis patients in Bago Region, Myanmar: A mixed methods study. Sci Rep 2019;9(1):7189. doi: 10.1038/s41598-019-43562-3
    · extracted · doi:10.1038/s41598-019-43562-3 · source: references/10665-381036.page-472.61.json
  590. Raizada N, McDowell A, Parija D, et al. Pathways to diagnosis of pediatric TB patients: A mixed methods study from India. Indian J Tuberc 2021;68(3):363-73. doi: 10.1016/j.ijtb.2020.12.011
    · extracted · doi:10.1016/j.ijtb.2020.12.011 · source: references/10665-381036.page-472.62.json
  591. Rendell NL, Bekhbat S, Ganbaatar G, et al. Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. PeerJ 2017;5:e3567. doi: 10.7717/peerj.3567
    · extracted · doi:10.7717/peerj.3567 · source: references/10665-381036.page-472.63.json
  592. Vijayageetha M, Kumar AM, Ramakrishnan J, et al. Tuberculosis screening among pregnant women attending a tertiary care hospital in Puducherry, South India: is it worth the effort? Glob Health Action 2019;12(1):1564488. doi: 10.1080/16549716.2018.1564488
    · extracted · doi:10.1080/16549716.2018.1564488 · source: references/10665-381036.page-472.64.json
  593. Medina-Marino A, de Vos L, Bezuidenhout D, et al. "I got tested at home, the help came to me": acceptability and feasibility of home-based TB testing of household contacts using portable molecular diagnostics in South Africa. Trop Med Int Health 2021;26(3):343-54. doi: 10.1111/tmi.13533
    · extracted · doi:10.1111/tmi.13533 · source: references/10665-381036.page-472.65.json
  594. Phyo AM, Kumar AMV, Soe KT, et al. Contact Investigation of Multidrug-Resistant Tuberculosis Patients: A Mixed-Methods Study from Myanmar. Trop Med Infect Dis 2019;5(1) doi: 10.3390/tropicalmed5010003
    · extracted · doi:10.3390/tropicalmed5010003 · source: references/10665-381036.page-472.66.json
  595. McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. Int J Tuberc Lung Dis 2016;20(4):536-43. doi: 10.5588/ijtld.15.0562
    · extracted · doi:10.5588/ijtld.15.0562 · source: references/10665-381036.page-472.67.json
  596. Royce S, Khann S, Yadav RP, et al. Identifying multidrug resistance in previously treated tuberculosis patients: a mixed-methods study in Cambodia. Int J Tuberc Lung Dis 2014;18(11):1299-306. doi: 10.5588/ijtld.14.0116
    · extracted · doi:10.5588/ijtld.14.0116 · source: references/10665-381036.page-472.68.json
  597. Cattamanchi A, Berger CA, Shete PB, et al. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis 2020;18:100136. doi: 10.1016/j.jctube.2019.100136
    · extracted · doi:10.1016/j.jctube.2019.100136 · source: references/10665-381036.page-472.69.json
  598. Shewade HD, Kokane AM, Singh AR, et al. Provider reported barriers and solutions to improve testing among tuberculosis patients 'eligible for drug susceptibility test': A qualitative study from programmatic setting in India. PLoS One 2018;13(4):e0196162. doi: 10.1371/journal.pone.0196162
    · extracted · doi:10.1371/journal.pone.0196162 · source: references/10665-381036.page-472.70.json
  599. Davids M, Dheda K, Pant Pai N, et al. A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests. PLoS One 2015;10(10):e0141453. doi: 10.1371/journal.pone.0141453
    · extracted · doi:10.1371/journal.pone.0141453 · source: references/10665-381036.page-472.71.json
  600. de Camargo KR, Jr., Guedes CR, Caetano R, et al. The adoption of a new diagnostic technology for tuberculosis in two Brazilian cities from the perspective of patients and healthcare workers: a qualitative study. BMC Health Serv Res 2015;15:275. doi: 10.1186/s12913-015-0941-x
    · extracted · doi:10.1186/s12913-015-0941-x · source: references/10665-381036.page-472.72.json
  601. Engel N, Davids M, Blankvoort N, et al. Compounding diagnostic delays: a qualitative study of point-of-care testing in South Africa. Trop Med Int Health 2015;20(4):493-500. doi: 10.1111/tmi.12450
    · extracted · doi:10.1111/tmi.12450 · source: references/10665-381036.page-472.73.json
  602. Hoang TT, Nguyen NV, Dinh SN, et al. Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health 2015;15:980. doi: 10.1186/s12889-015-2338-5
    · extracted · doi:10.1186/s12889-015-2338-5 · source: references/10665-381036.page-472.74.json
  603. Ismail IM, Kibballi Madhukeshwar A, Naik PR, et al. Magnitude and Reasons for Gaps in Tuberculosis Diagnostic Testing and Treatment Initiation: An Operational Research Study from Dakshina Kannada, South India. J Epidemiol Glob Health 2020;10(4):326-36. doi: 10.2991/jegh.k.200516.001
    · extracted · doi:10.2991/jegh.k.200516.001 · source: references/10665-381036.page-472.75.json
  604. Jaroslawski S, Pai M. Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Glob Health 2012;2(1):39-50. doi: 10.1016/j.jegh.2011.12.001
    · extracted · doi:10.1016/j.jegh.2011.12.001 · source: references/10665-381036.page-472.76.json
  605. Joshi B, Lestari T, Graham SM, et al. The implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: A mixed-methods analysis. PLoS One 2018;13(8):e0201731. doi: 10.1371/journal.pone.0201731
    · extracted · doi:10.1371/journal.pone.0201731 · source: references/10665-381036.page-472.77.json
  606. Stime KJ, Garrett N, Sookrajh Y, et al. Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa. BMC Health Serv Res 2018;18(1):363. doi: 10.1186/s12913-018-3154-2
    · extracted · doi:10.1186/s12913-018-3154-2 · source: references/10665-381036.page-472.78.json
  607. Adam P, Pai M. Implementation of Xpert((R)) MTB/RIF in high-burden countries: voices from the field matter. Public Health Action 2019;9(3):78-79. doi: 10.5588/pha.19.0055
    · extracted · doi:10.5588/pha.19.0055 · source: references/10665-381036.page-472.79.json
  608. Adepoyibi T, Lilis L, Greb H, et al. Which attributes within target product profiles for tuberculosis diagnostics are the most important to focus on? Int J Tuberc Lung Dis 2018;22(4):425-28. doi: 10.5588/ijtld.17.0312
    · extracted · doi:10.5588/ijtld.17.0312 · source: references/10665-381036.page-472.80.json
  609. Albert H, Nathavitharana RR, Isaacs C, et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016;48(2):516-25. doi: 10.1183/13993003.00543-2016
    · extracted · doi:10.1183/13993003.00543-2016 · source: references/10665-381036.page-472.81.json
  610. Ardizzoni E, Fajardo E, Saranchuk P, et al. Implementing the Xpert(R) MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries. PLoS One 2015;10(12):e0144656. doi: 10.1371/journal.pone.0144656
    · extracted · doi:10.1371/journal.pone.0144656 · source: references/10665-381036.page-472.82.json
  611. Boulanger RF, Komparic A, Dawson A, et al. Developing and Implementing new TB Technologies: Key Informants' Perspectives on the Ethical Challenges. J Bioeth Inq 2020;17(1):65-73. doi: 10.1007/s11673-019-09954-w
    · extracted · doi:10.1007/s11673-019-09954-w · source: references/10665-381036.page-472.83.json
  612. Brown S, Leavy JE, Jancey J. Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries: A Systematic Review. Glob Health Sci Pract 2021;9(3):698-710. doi: 10.9745/GHSP-D-21-00121
    · extracted · doi:10.9745/GHSP-D-21-00121 · source: references/10665-381036.page-472.84.json
  613. Cash RA. Ethical issues in adapting new technologies for rapid diagnosis. Indian J Med Ethics 2013;10(4):254-5. doi: 10.20529/IJME.2013.077
    · extracted · doi:10.20529/IJME.2013.077 · source: references/10665-381036.page-472.85.json
  614. Charoensook P, Upala P, Anuwatnonthakate A, et al. Pulmonary tuberculosis screening and quality of life among migrant workers, Northern Thailand. J Infect Dev Ctries 2018;12(12):1052-61. doi: 10.3855/jidc.10596
    · extracted · doi:10.3855/jidc.10596 · source: references/10665-381036.page-472.86.json
  615. Chawla KS, Kanyama C, Mbewe A, et al. Policy to practice: impact of GeneXpert MTB/RIF implementation on the TB spectrum of care in Lilongwe, Malawi. Trans R Soc Trop Med Hyg 2016;110(5):305-11. doi: 10.1093/trstmh/trw030
    · extracted · doi:10.1093/trstmh/trw030 · source: references/10665-381036.page-472.87.json
  616. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012;102(10):805-7. doi: 10.7196/samj.5851
    · extracted · doi:10.7196/samj.5851 · source: references/10665-381036.page-472.88.json
  617. Cowan J, Greenberg Cowan J, Barnhart S, et al. A qualitative assessment of challenges to tuberculosis management and prevention in Northern Ethiopia. Int J Tuberc Lung Dis 2013;17(8):1071-5. doi: 10.5588/ijtld.12.0240
    · extracted · doi:10.5588/ijtld.12.0240 · source: references/10665-381036.page-472.89.json
  618. Daftary A, Furin J, Zelnick JR, et al. TB and women: a call to action. Int J Tuberc Lung Dis 2020;24(12):1312-15. doi: 10.5588/ijtld.20.0414
    · extracted · doi:10.5588/ijtld.20.0414 · source: references/10665-381036.page-472.90.json
  619. da Silva Antunes R, Pinto M, Trajman A. Patient costs for the diagnosis of tuberculosis in Brazil: comparison of Xpert MTB/RIF and smear microscopy. Int J Tuberc Lung Dis 2014;18(5):547-51. doi: 10.5588/ijtld.13.0637
    · extracted · doi:10.5588/ijtld.13.0637 · source: references/10665-381036.page-472.91.json
  620. de Haas P, Nhung NV, Hng NT, et al. Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults. Int J Tuberc Lung Dis 2023;27(1):19-27. doi: 10.5588/ijtld.22.0161
    · extracted · doi:10.5588/ijtld.22.0161 · source: references/10665-381036.page-472.92.json
  621. Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis 2015;211 Suppl 2(Suppl 2):S29-38. doi: 10.1093/infdis/jiu821
    · extracted · doi:10.1093/infdis/jiu821 · source: references/10665-381036.page-472.93.json
  622. de Vries G, Tsolova S, Anderson LF, et al. Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences. BMC Public Health 2017;17(1):334. doi: 10.1186/s12889-017-4216-9
    · extracted · doi:10.1186/s12889-017-4216-9 · source: references/10665-381036.page-472.94.json
  623. Dominique JK, Ortiz-Osorno AA, Fitzgibbon J, et al. Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context. Clin Infect Dis 2015;61Suppl 3(Suppl 3):S119-25. doi: 10.1093/cid/civ552
    · extracted · doi:10.1093/cid/civ552 · source: references/10665-381036.page-472.95.json
  624. Gray CM, Katamba A, Narang P, et al. Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study. J Clin Microbiol 2016;54(8):1984-91. doi: 10.1128/JCM.03036-
    · extracted · doi:10.1128/JCM.03036- · source: references/10665-381036.page-472.96.json
  625. Griffin AM, Caviedes L, Gilman R, et al. Field and laboratory preparedness: challenges to rolling out new multidrug-resistant tuberculosis diagnostics. Rev Panam Salud Publica 2009;26(2):120-7. doi: 10.1590/s1020-49892009000800004
    · extracted · doi:10.1590/s1020-49892009000800004 · source: references/10665-381036.page-472.97.json
  626. Jindal HA, Malik JS. GeneXpert brings new hope for challenges to tuberculosis 2050. Indian J Tuberc 2014;61(2):171-2.
    · extracted · source: references/10665-381036.page-472.98.json
  627. Kedia. Utilization of GeneXpert MTB/RIF in the Southern Department of Haiti. Annals of Global Health 2015;81(1):128.
    · extracted · source: references/10665-381036.page-472.99.json
  628. Kondo M, Simon MS, Westblade LF, et al. Implementation of infectious diseases rapid molecular diagnostic tests and antimicrobial stewardship program involvement in acute-care hospitals. Infect Control Hosp Epidemiol 2021;42(5):609-11. doi: 10.1017/ice.2020.1230
    · extracted · doi:10.1017/ice.2020.1230 · source: references/10665-381036.page-472.100.json
  629. Lemaire JF, Casenghi M. New diagnostics for tuberculosis: fulfilling patient needs first. J Int AIDS Soc 2010;13:40. doi: 10.1186/1758-2652-13-40
    · extracted · doi:10.1186/1758-2652-13-40 · source: references/10665-381036.page-472.101.json
  630. Lorent N. Early diagnosis and care of tuberculosis through community-based active case-finding in urban slums of Phnom Penh, Cambodia. ProQuest Information & Learning 2016;77
    · extracted · source: references/10665-381036.page-472.102.json
  631. Maraba N, Hoffmann CJ, Chihota VN, et al. Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. PLoS One 2018;13(7):e0199687. doi: 10.1371/journal.pone.0199687
    · extracted · doi:10.1371/journal.pone.0199687 · source: references/10665-381036.page-472.103.json
  632. Mbelele PM, Mohamed SY, Sauli E, et al. Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults. Int J Mycobacteriol 2018;7(4):299-309. doi: 10.4103/ijmy.ijmy_135_18
    · extracted · doi:10.4103/ijmy.ijmy_135_18 · source: references/10665-381036.page-472.104.json
  633. Mistry N, Rangan S, Dholakia Y, et al. Durations and Delays in Care Seeking, Diagnosis and Treatment Initiation in Uncomplicated Pulmonary Tuberculosis Patients in Mumbai, India. PLoS One 2016;11(3):e0152287. doi: 10.1371/journal.pone.0152287
    · extracted · doi:10.1371/journal.pone.0152287 · source: references/10665-381036.page-472.105.json
  634. Mohapatra PR. Rapid molecular detection of tuberculosis. N Engl J Med 2011;364(2):184; author reply 84-5. doi: 10.1056/NEJMc1011919
    · extracted · doi:10.1056/NEJMc1011919 · source: references/10665-381036.page-472.106.json
  635. Moyenga I, Roggi A, Sulis G, et al. The impact of Xpert(R) MTB/RIF depends on service coordination: experience in Burkina Faso. Int J Tuberc Lung Dis 2015;19(3):285-7. doi: 10.5588/ijtld.14.0629
    · extracted · doi:10.5588/ijtld.14.0629 · source: references/10665-381036.page-472.107.json
  636. Mpagama SG, Mbelele PM, Chongolo AM, et al. Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation. BMC Public Health 2019;19(1):395. doi: 10.1186/s12889-019-6720-6
    · extracted · doi:10.1186/s12889-019-6720-6 · source: references/10665-381036.page-472.108.json
  637. Narayan G, Vasudevan K, Rajagopal A, et al. Active Screening for Pulmonary Tuberculosis Among Jail Inmates: A Mixed Method Study From Puducherry, South India. Cureus 2023;15(5):e39749. doi: 10.7759/cureus.39749
    · extracted · doi:10.7759/cureus.39749 · source: references/10665-381036.page-472.109.json
  638. Nathavitharana R. Challenges facing TB control in india focusing on the role of Xpert MTB/RIF in the public and private sector. American Journal of Tropical Medicine and Hygiene 2014;1:167.
    · extracted · source: references/10665-381036.page-472.110.json
  639. Njovu. Integrated testing for TB, VL and HIV using GeneXpert in Tanzania Mainland: Data extracts from Gene Xpert machines. Tanzania Journal of Health Research 2022;23(Supplement 1):178-79.
    · extracted · source: references/10665-381036.page-472.111.json
  640. Noe A, Ribeiro RM, Anselmo R, et al. Knowledge, attitudes and practices regarding tuberculosis care among health workers in Southern Mozambique. BMC Pulm Med 2017;17(1):2. doi: 10.1186/s12890-016-0344-8
    · extracted · doi:10.1186/s12890-016-0344-8 · source: references/10665-381036.page-472.112.json
  641. Abbott 2019a Abbott. Abbott RealTime MTB. https://www.molecular.abbott/int/en/products/infectious-disease/realtime-mtb 2019.
    · extracted · link · source: references/10665-381036.page-550.1.json
  642. Abbott 2019b Abbott. Abbott RealTime RIF/INH. https://www.molecular.abbott/int/en/products/infectious-disease/realtime-mtb-rif-inh-resistance 2019.
    · extracted · link · source: references/10665-381036.page-550.2.json
  643. Almeida Da Silva 2011 Almeida Da Silva PE and Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011;66(7):1417-1430.
    · extracted · source: references/10665-381036.page-550.3.json
  644. Bruker-Hain Diagnostics 2019a Bruker-Hain Diagnostics. FluoroType MTB. https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/fluorotype-mtb.html 2019.
    · extracted · link · source: references/10665-381036.page-550.4.json
  645. Bruker-Hain Diagnostics 2019b Bruker-Hain Diagnostics. FluoroType MDRTB. https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/fluorotype -mtbdr.html 2019.
    · extracted · link · source: references/10665-381036.page-550.5.json
  646. Burdz 2003 Burdz TV, Wolfe J, Kabani A. Evaluation of sputum decontamination methods for Mycobacterium tuberculosis using viable colony counts and flow cytometry. Diagn Microbiol Infect Dis , 2003; 47 :503-9.
    · extracted · source: references/10665-381036.page-550.6.json
  647. Chihota 2010 Chihota VN, Grant AD, Fielding K, Ndibongo B, van Zyl A, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis , 2010; 14: 1024-1031.
    · extracted · source: references/10665-381036.page-550.7.json
  648. Dowdy 2008 Dowdy DW, Lourenco MC, Cavalcante SC, Saraceni V, King B, et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One, 2008; 3: e4057.
    · extracted · source: references/10665-381036.page-550.8.json
  649. Chu H and Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59(12):1331-1332.
    · extracted · source: references/10665-381036.page-550.10.json
  650. Cochrane 2008 The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 2008.
    · extracted · source: references/10665-381036.page-550.11.json
  651. Dicks 2019 Dicks KV and Stout JE. Molecular Diagnostics for Mycobacterium tuberculosis Infection [Annual Review of Medicine]. 2019;70(1):77-90.
    · extracted · source: references/10665-381036.page-550.12.json
  652. Friedrich 2011 Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial.
    · extracted · source: references/10665-381036.page-550.13.json
  653. Journal of Clinical Microbiology 2011;49(8):2827–31.
    · extracted · source: references/10665-381036.page-550.14.json
  654. GLI 2014 Global Laboratory Initiative. Mycobacteriology Laboratory Manual, 2014. https://www.who.int/tb/laboratory/mycobacteriology-laboratory-manual.pdf (accessed 10 March 2019).
    · extracted · link · source: references/10665-381036.page-550.15.json
  655. Horne 2019 Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2019, Issue 6. Art No. CD009593.
    · extracted · source: references/10665-381036.page-550.16.json
  656. Miotto 2017 Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in <em>Mycobacterium tuberculosis. Eur Resp J 2017;50(6):1701354.
    · extracted · source: references/10665-381036.page-550.17.json
  657. Miotto 2018 Miotto P, Cabibbe AM, Borroni E, Degano M, Cirillo DM. Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. J Clin Microbiol. 2018; 56(5): e01599-17.
    · extracted · source: references/10665-381036.page-550.18.json
  658. Moher 2009 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
    · extracted · source: references/10665-381036.page-550.19.json
  659. Nathavitharana 2017 Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM.
    · extracted · source: references/10665-381036.page-550.20.json
  660. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. The European respiratory journal 2017;49(1):1601075. DOI: 10.1183/13993003.01075-2016
    · extracted · doi:10.1183/13993003.01075-2016 · source: references/10665-381036.page-550.21.json
  661. Reitsma 2005 Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58(10):982-990.
    · extracted · source: references/10665-381036.page-550.22.json
  662. Schünemann 2020 guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology 2020. [DOI: 10.1016/j.jclinepi.2019.12.020]
    · extracted · doi:10.1016/j.jclinepi.2019.12.020 · source: references/10665-381036.page-550.23.json
  663. Schünemann 2020 guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2020;pii: S0895-4356(19)30674-2. [DOI: 10.1016/j.jclinepi.2019.12.021]
    · extracted · doi:10.1016/j.jclinepi.2019.12.021 · source: references/10665-381036.page-550.24.json
  664. Smith 2012 Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.. Int J Tuberc Lung Dis 2012;16(2):203-205.
    · extracted · source: references/10665-381036.page-550.25.json
  665. Somoskovi 2001 Somoskovi A, Parsons LM, Salfinger M.. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.. Respiratory research 2001;2(3):164-168.
    · extracted · source: references/10665-381036.page-550.26.json
  666. Subbaraman 2016 Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, et al.. The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysis.
    · extracted · source: references/10665-381036.page-550.27.json
  667. PLOS Medicine 2016;13(10):e1002149.
    · extracted · source: references/10665-381036.page-550.28.json
  668. Clinical Infectious Diseases 2016;62 (8):995–1001.
    · extracted · source: references/10665-381036.page-550.30.json
  669. Theron 2016 Clinical Infectious Diseases 2016;62 (8):995–1001.
    · extracted · source: references/10665-381036.page-550.31.json
  670. Theron 2018 Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False positive Xpert MTB/RIF results in re-tested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. Journal of Clinical Microbiology 2018;56(3):pii: e01696-17.
    · extracted · source: references/10665-381036.page-550.32.json
  671. UNITAID 2017 UNITAID. TUBERCULOSIS: Diagnostics Technology Landscape. UNITAID 2017.
    · extracted · source: references/10665-381036.page-550.33.json
  672. Wang 2019 Wang MG, Xue M, Wu SQ, Zhang MM, Wang Y, Liu Q et al. Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance. Infection, Genetics and Evolution 2019; 71: 54-59.
    · extracted · source: references/10665-381036.page-550.34.json
  673. Whiting 2011 Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al.. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-536.
    · extracted · source: references/10665-381036.page-550.35.json
  674. WHO 2014 World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, World Health Organization 2014.
    · extracted · source: references/10665-381036.page-550.36.json
  675. WHO 2018 World Health Organization. Global Tuberculosis Report 2017. Geneva, World Health Organization 2017.
    · extracted · source: references/10665-381036.page-550.37.json
  676. WHO 2018 World Health Organization. Treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis 2018.
    · extracted · source: references/10665-381036.page-550.38.json
  677. Abimbola, T. O., Marston, B. J., Date, A. A., Blandford, J. M., Sangrujee, N., & Wiktor, S. Z. (2012). Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 60(1), 1–7. https://doi.org/10.1097/QAI.0b013e318246538fAdelman, M. W., McFarland, D. A., Tsegaye, M., Aseffa, A., Kempker, R. R., & Blumberg, H. M. (2018).
    · extracted · doi:10.1097/QAI.0b013e318246538fAdelman · source: references/10665-381036.page-566.1.json
  678. Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics. Open Forum Infectious Diseases, 5(1), 1–8. https://doi.org/10.1093/ofid/ofx269Andrews, J. R., Lawn, S. D., Rusu, C., Wood, R., Noubary, F., Bender, M. A., Horsburgh, C. R., Losina, E., Freedberg, K. A., & Walensky, R. P. (2012). The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: A model-based analysis. Aids, 26(8), 987–995. https://doi.org/10.1097/QAD.0b013e3283522d47Boyer, S., March, L., Kouanfack, C., Laborde-Balen, G., Marino, P., Aghokeng, A. F., Mpoudi-Ngole, E., Koulla-Shiro, S., Delaporte, E., Carrieri, M. P., Spire, B., Laurent, C., & Moatti, J. P. (2013).
    · extracted · doi:10.1093/ofid/ofx269Andrews · source: references/10665-381036.page-566.2.json
  679. https://doi.org/10.1186/1471-2334-13-352Whitfield, M. G., Marras, S. A. E., Warren, R. M., Van Rie, A., Rice, J., Wangh, L. J., & Kreiswirth, B. N. (2020). Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-61286-7Zwerling, A. A., Sahu, M., Ngwira, L. G., Khundi, M., Harawa, T., Corbett, E. L., Chaisson, R. E., & Dowdy, D. W. (2015). Screening for tuberculosis among adults newly diagnosed with HIV in Sub-Saharan Africa: A cost-effectiveness analysis. Journal of Acquired Immune Deficiency Syndromes, 70(1), 83– 90. https://doi.org/10.1097/QAI.0000000000000712
    · extracted · doi:10.1186/1471-2334-13-352Whitfield · source: references/10665-381036.page-566.4.json
  680. Albert, H., Nathavitharana, R. R., Isaacs, C., Pai, M., Denkinger, C. M., & Boehme, C. C. (2016). Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? [10.1183/13993003.00543-2016].
    · extracted · doi:10.1183/13993003.00543-2016 · source: references/10665-381036.page-594.1.json
  681. European Respiratory Journal, 48, 516-525. Bainomugisa, A., Gilpin, C., Coulter, C., & Marais, B. J. (2020). New Xpert MTB/XDR: added value and future in the field. European Respiratory Journal, 56(5), 2003616.
    · extracted · source: references/10665-381036.page-594.2.json
  682. Beisel, U., Umlauf, R., Hutchinson, E., & Chandler, C. I. (2016). The complexities of simple technologies: re-imagining the role of rapid diagnostic tests in malaria control efforts.
    · extracted · source: references/10665-381036.page-594.3.json
  683. Malaria Journal, 15, 64. Cattamanchi, A., Berger, C. A., Shete, P. B., Turyahabwe, S., Joloba, M., Moore, D. A. J., et al. (2020). Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 18, 100136.
    · extracted · source: references/10665-381036.page-594.4.json
  684. Colvin, C. J., Leon, N., Wills, C., van Niekerk, M., Bissell, K., & Naidoo, P. (2015). Global-to-local policy transfer in the introduction of new molecular tuberculosis diagnostics in South Africa. The International Journal of Tuberculosis and Lung Disease, 19(11), 1326-1338.
    · extracted · source: references/10665-381036.page-594.5.json
  685. Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., et al. (2020).
    · extracted · source: references/10665-381036.page-594.6.json
  686. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 382(10), 893-902. Covidence. (2017). Covidence systematic review software. Melbourne: Veritas Health Innovation.
    · extracted · source: references/10665-381036.page-594.7.json
  687. Creswell, J., Codlin, A. J., Andre, E., Micek, M. A., Bedru, A., Carter, E. J., et al. (2014).
    · extracted · source: references/10665-381036.page-594.8.json
  688. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infectious Diseases, 14(1), 2. Di Tanna, G. L., Khaki, A. R., Theron, G., McCarthy, K., Cox, H., Mupfumi, L., et al. (2019).
    · extracted · source: references/10665-381036.page-594.9.json
  689. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health, 7(2), e191-e199. Engel, N., Davids, M., Blankvoort, N., Pai, N. P., Dheda, K., & Pai, M. (2015). Compounding diagnostic delays: a qualitative study of point-of-care testing in South Africa. Tropical medicine & international health, 20(4), 493-500.
    · extracted · source: references/10665-381036.page-594.10.json
  690. Engel, N., Wachter, K., Pai, M., Gallarda, J., Boehme, C., Celentano, I., et al. (2016). Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform. BMJ Global Health, 1(4).
    · extracted · source: references/10665-381036.page-594.11.json
  691. England, K., Masini, T., & Fajardo, E. (2019). Detecting tuberculosis: rapid tools but slow progress. Public Health Action, 9(3), 80-83.
    · extracted · source: references/10665-381036.page-594.12.json
  692. Eshun-Wilson, I., Rohwer, A., Hendricks, L., Oliver, S., & Garner, P. (2019). Being HIV positive and staying on antiretroviral therapy in Africa: A qualitative systematic review and theoretical model. PLOS ONE, 14(1), e0210408.
    · extracted · source: references/10665-381036.page-594.13.json
  693. Haraka, F., & al., E. (2019). Impact of diagnostic test Xpert MTB/RIF® on health outcomes for tuberculosis. Paper presented at the World Health Organization-convened Guideline Development Group Meeting on "Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance", 3-6 December 2019.
    · extracted · source: references/10665-381036.page-594.14.json
  694. Hoang, T., Nguyen, N., Dinh, S., Nguyen, H., Cobelens, F., Thwaites, G., et al. (2015).
    · extracted · source: references/10665-381036.page-594.15.json
  695. Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health, 15(1), 980. Jaroslawski, S., & Pai, M. (2012). Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. Journal of Epidemiology and Global Health, 2, 39-50.
    · extracted · source: references/10665-381036.page-594.16.json
  696. Joshi, B., Lestari, T., Graham, S. M., Baral, S. C., Verma, S. C., Ghimire, G., et al. (2018). The implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: A mixed-methods analysis. PLOS ONE, 13(8), e0201731.
    · extracted · source: references/10665-381036.page-594.17.json
  697. Kelly-Cirino, C. D., Nkengasong, J., Kettler, H., Tongio, I., Gay-Andrieu, F., Escadafal, C., et al. (2019). Importance of diagnostics in epidemic and pandemic preparedness. BMJ Global Health, 4(Suppl 2), e001179.
    · extracted · source: references/10665-381036.page-594.18.json
  698. Lewin, S., Glenton, C., Munthe-Kaas, H., Carlsen, B., Colvin, C. J., Gülmezoglu, M., et al. (2015). Using Qualitative Evidence in Decision Making for Health and Social Interventions: An Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses (GRADE-CERQual). PLOS Medicine, 12(10), e1001895.
    · extracted · source: references/10665-381036.page-594.19.json
  699. McDowell, A., & Pai, M. (2016). Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. Int J Tuberc Lung Dis, 20(4), 536-543.
    · extracted · source: references/10665-381036.page-594.20.json
  700. McDowell, A., Raizada, N., Khaparde, S. D., Rao, R., Sarin, S., Kalra, A., et al. (2018). “Before Xpert I only had my expertise”: A qualitative study on the utilization and effects of Xpert technology among pediatricians in 4 Indian cities. PLOS ONE, 13(3), e0193656.
    · extracted · source: references/10665-381036.page-594.21.json
  701. Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7), e1000097.
    · extracted · source: references/10665-381036.page-594.22.json
  702. Mwaura, M., Kao, K., Wambugu, J., Trollip, A., Sikhondze, W., Omesa, E., et al. (2020).
    · extracted · source: references/10665-381036.page-594.23.json
  703. Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland. PLOS ONE, 15(2), e0228669. Naidoo, P., van Niekerk, M., du Toit, E., Beyers, N., & Leon, N. (2015). Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients’ experiences in the era of rapid molecular diagnostic tests. BMC Health Services Research, 15(1), 488.
    · extracted · source: references/10665-381036.page-594.24.json
  704. Nalugwa, T., Shete, P. B., Nantale, M., Farr, K., Ojok, C., Ochom, E., et al. (2020). Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective. BMC Health Services Research, 20(1), 162.
    · extracted · source: references/10665-381036.page-594.25.json
  705. Newtonraj, A., Venables, E., Selvaraj, K., Kundu, D., Purty, A. J., Manikandan, M., et al. (2019).
    · extracted · source: references/10665-381036.page-594.26.json
  706. Xpert negative means no TB: A mixed-methods study into early implementation of Xpert in Puducherry, India. J Family Med Prim Care, 8(4), 1379-1385. Noyes, J., Booth, A., Cargo, M., Flemming, K., Harden, A., Harris, J., et al. (2020). Chapter 21: Qualitative evidence. In J. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. Page & V. Welch (Eds.), Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020): Cochrane.
    · extracted · source: references/10665-381036.page-594.27.json
  707. Oliwa, J. N., Odero, S. A., Nzinga, J., van Hensbroek, M. B., Jones, C., English, M., et al. (2020). Perspectives and practices of health workers around diagnosis of paediatric tuberculosis in hospitals in a resource-poor setting - modern diagnostics meet age-old challenges. BMC health services research, 20(1), 708-708.
    · extracted · source: references/10665-381036.page-594.28.json
  708. Pai, M., Schumacher, S. G., & Abimbola, S. (2018). Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Global Health, 3(2).
    · extracted · source: references/10665-381036.page-594.29.json
  709. Phyo, A. M., Kumar, A. M. V., Soe, K. T., Kyaw, K. W. Y., Thu, A. S., Wai, P. P., et al. (2019).
    · extracted · source: references/10665-381036.page-594.30.json
  710. Contact Investigation of Multidrug-Resistant Tuberculosis Patients: A Mixed-Methods Study from Myanmar. Tropical medicine and infectious disease, 5(1), 3. Pooran, A., Theron, G., Zijenah, L., Chanda, D., Clowes, P., Mwenge, L., et al. (2019). Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. The Lancet Global Health, 7(6), e798-e807.
    · extracted · source: references/10665-381036.page-594.31.json
  711. R. de Camargo, K., R. Guedes, C., Caetano, R., Menezes, A., & Trajman, A. (2015). The adoption of a new diagnostic technology for tuberculosis in two Brazilian cities from the perspective of patients and healthcare workers: a qualitative study. BMC Health Services Research, 15(1), 275.
    · extracted · source: references/10665-381036.page-594.32.json
  712. Rees, R. W., Caird, J., Dickson, K., Vigurs, C., & Thomas, J. (2014). ‘It’s on your conscience all the time’: a systematic review of qualitative studies examining views on obesity among young people aged 12–18 years in the UK. BMJ Open, 4(4), e004404.
    · extracted · source: references/10665-381036.page-594.33.json
  713. Rendell, N. L., Bekhbat, S., Ganbaatar, G., Dorjravdan, M., Pai, M., & Dobler, C. C. (2017).
    · extracted · source: references/10665-381036.page-594.34.json
  714. Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. PeerJ, 5, e3567. Royce, S., Khann, S., Yadav, R. P., Mao, E. T., Cattamanchi, A., Sam, S., et al. (2014).
    · extracted · source: references/10665-381036.page-594.35.json
  715. Identifying multidrug resistance in previously treated tuberculosis patients: a mixed-methods study in Cambodia. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 18(11), 1299-1306. Shewade, H. D., Kokane, A. M., Singh, A. R., Parmar, M., Verma, M., Desikan, P., et al. (2018).
    · extracted · source: references/10665-381036.page-594.36.json
  716. Provider reported barriers and solutions to improve testing among tuberculosis patients ‘eligible for drug susceptibility test’: A qualitative study from programmatic setting in India. PLOS ONE, 13(4), e0196162. Stime, K. J., Garrett, N., Sookrajh, Y., Dorward, J., Dlamini, N., Olowolagba, A., et al. (2018).
    · extracted · source: references/10665-381036.page-594.37.json
  717. Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa. BMC Health Serv Res, 18(1), 363. Vijayageetha, M., Kumar, A. M., Ramakrishnan, J., Sarkar, S., Papa, D., Mehta, K., et al. (2019).
    · extracted · source: references/10665-381036.page-594.38.json
  718. Tuberculosis screening among pregnant women attending a tertiary care hospital in Puducherry, South India: is it worth the effort? Global health action, 12(1), 1564488-1564488. World Health, O. (2015). Implementing the end TB strategy: the essentials. Geneva: World Health Organization.
    · extracted · source: references/10665-381036.page-594.39.json
  719. World Health Organization. (2020a). Global Tuberculosis Report 2020 Geneva: World Health World Health Organization. (2020b). WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection. Geneva: World Health World Health Organization. (2020c). WHO consolidated guidelines on tuberculosis. Module 4: treatment Geneva: World Health Organization.
    · extracted · source: references/10665-381036.page-594.40.json
  720. Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to September 05, 2020> Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Tuberculosis, Multidrug-Resistant/ or Tuberculosis, Pulmonary/ or Mycobacterium tuberculosis/(Tuberculosis or MDR-TB or XDR-TB or tuberculous).ti. or (Tuberculosis or MDR-TB or XDR-TB or tuberculous).ab. 1 or 2 exp Point-of-Care Systems/Reagent Kits, Diagnostic/4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 3 and 12 "Patient Acceptance of Health Care"/ or acceptability.mp.
    · extracted · source: references/10665-381036.page-594.41.json
  721. Health Equity/ or equity.mp. or Health Services Accessibility/Patient Preference/ or preferences.mp. Patient Satisfaction/ or Attitude to Health/"Attitude of Health Personnel"/ or providers experience*.mp. Critical Pathways/14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 13 and 24 Interviews as Topic/ or interview*.mp. or Interview/survey*.mp. or Health Surveys/ or Health Care Surveys/ or "Surveys and Questionnaires"/Qualitative Research/Focus group discussion*.mp. or Focus Groups/"mixed methods".ti. or "mixed methods".ab. or "mixed-methods".ti. or "mixed-methods".ab. 26 or 27 or 28 or 29 or 30 13 and 31 25 or 32 limit 33 to yr="2007 -Current" "systematic review"/(metaanalysis or meta-analysis).mp. 35 or 36 13 and 37 limit 38 to yr="2007 -Current"
    · extracted · source: references/10665-381036.page-594.42.json
  722. Database: Embase <1996 to 2020 Week 36> tuberculosis/ or tuberculosis.mp. drug resistant tuberculosis.mp. or drug resistant tuberculosis/multidrug resistant tuberculosis.mp. or multidrug resistant tuberculosis/MDR-TB.mp.
    · extracted · source: references/10665-381036.page-594.43.json
  723. Cinahl (EBSCOHost) Limiters - Published Date: 20070101-20201231 S15 TX interview* OR TX ( survey* or questionnaire* ) OR TX ( qualitative research or qualitative study or qualitative methods or mixed methods ) S14 S8 AND S12 S13 S8 AND S12 S12 S9 OR S10 OR S11 S11 TX ( barriers or challenges ) OR TX critical pathway OR TX facilitator* S10 TX patient preference* OR TX ( patient satisfaction or patients experiences or patients perceptions or patients attitudes )
    · extracted · source: references/10665-381036.page-594.46.json
  724. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016; 48: 516–25. https://doi.org/10.1183/13993003.00543-2016 PMID: 27418550
    · extracted · doi:10.1183/13993003.00543-2016 · source: references/10665-381036.page-628.1.json
  725. Cazabon, D., Pande, T., Kik, S., Van Gemert, W., Sohn, H., Denkinger, C., Qin, Z. Z., Waning, B., & Pai, M. (2018).
    · extracted · source: references/10665-381036.page-628.2.json
  726. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016. Gates open research, 2, 35. https://doi.org/10.12688/gatesopenres.12842.2
    · extracted · doi:10.12688/gatesopenres.12842.2 · source: references/10665-381036.page-628.3.json
  727. Xpert® Retrieved November 28, 2020, from https://www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-XDR
    · extracted · link · source: references/10665-381036.page-628.5.json
  728. Engel, N., Ochodo, E., Wanjiku Karanja, P., Schmidt, B.M., Janssen, R., Steingart, K.R., Oliver, S. (2020). User perspectives on cartridge-based nucleic acid amplification tests of low-complexity for tuberculosis and tuberculosis drug resistance.
    · extracted · source: references/10665-381036.page-628.6.json
  729. Mwaura, M., Kao, K., Wambugu, J., Trollip, A., Sikhondze, W., Omesa, E., Dlamini, S., Mzizi, N., Dlamini, M., Sibandze, B., Dlamini, B., Albert, H., Dondorp, W., & Engel, N. (2020). Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland. PloS one, 15(2), e0228669. https://doi.org/10.1371/journal.pone.0228669
    · extracted · doi:10.1371/journal.pone.0228669 · source: references/10665-381036.page-628.7.json
  730. Stop TB Partnership. (2020). High Burden Countries. Retrieved November 29, 2020, from http://www.stoptb.org/countries/tbdata.asp
    · extracted · link · source: references/10665-381036.page-628.8.json
  731. World Health Organization. (2020). Global Tuberculosis Report 2020. Geneva: World Health Organization.
    · extracted · source: references/10665-381036.page-628.9.json
  732. Bainomugisa 2020 Bainomugisa A, Gilpin C, Coulter C, Marais BJ. New Xpert MTB/XDR: added value and future in the field.
    · extracted · source: references/10665-381036.page-656.1.json
  733. European Respiratory Journal 2020;56:2003616.
    · extracted · source: references/10665-381036.page-656.2.json
  734. Bisimwa 2020 Bisimwa BC, Nachega JB, Warren RM, Theron G, Metcalfe JZ, Shah M, et al. Xpert MTB/RIF-detected rifampicin resistance is a sub-optimal surrogate for multidrug resistant tuberculosis in Eastern Democratic Republic of the Congo: diagnostic and clinical implications. Clinical Infectious Diseases 2020;ciaa873.
    · extracted · source: references/10665-381036.page-656.3.json
  735. Brossier 2011 Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
    · extracted · source: references/10665-381036.page-656.4.json
  736. Antimicrobial agents and chemotherapy 2011;55(1):355-60.
    · extracted · source: references/10665-381036.page-656.5.json
  737. Cepheid package insert 2020 Cepheid. Xpert® MTB/XDR. GXMTB/XDR-10. Package insert 2020.
    · extracted · source: references/10665-381036.page-656.6.json
  738. Chakravorty 2017 Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. Molecular Biology 2017;8(4):e00812-17.
    · extracted · source: references/10665-381036.page-656.7.json
  739. Covidence 2017 Covidence systematic review software. Available at www.covidence.org [Computer program]. Melbourne: Veritas Health Innovation, 2017.
    · extracted · link · source: references/10665-381036.page-656.8.json
  740. GRADEpro GDT [Computer program]. Version accessed 29 October 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
    · extracted · source: references/10665-381036.page-656.10.json
  741. Gopalakrishna 2016 Gopalakrishna G, Langendam MW, Scholten RJ, Bossuyt PM, Leeflang MM. Defining the clinical pathway in Cochrane diagnostic test accuracy reviews. BMC Med Res Methodol. 2016;16(1):153.
    · extracted · source: references/10665-381036.page-656.11.json
  742. Heyckendorf 2017 Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, et al. What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy 2018;62(2):e01550-17.
    · extracted · source: references/10665-381036.page-656.12.json
  743. Kohli 2020 Kohli M, MacLean E, Pai M, Schumacher SG, Denkinger, CM. Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: A systematic review and meta-analysis.
    · extracted · source: references/10665-381036.page-656.13.json
  744. European Respiratory Journal 2020.
    · extracted · source: references/10665-381036.page-656.14.json
  745. Macaskill 2010 Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results.
    · extracted · source: references/10665-381036.page-656.15.json
  746. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: srdta.cochrane.org/.
    · extracted · source: references/10665-381036.page-656.16.json
  747. Moher 2009 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLOS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097]
    · extracted · doi:10.1371/journal.pmed1000097 · source: references/10665-381036.page-656.17.json
  748. Reitsma 2005 Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
    · extracted · source: references/10665-381036.page-656.18.json
  749. Rutjes 2005 Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem. 2005 Aug;51(8):1335-41 Schünemann 2008 Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336(7653):1106-10.
    · extracted · source: references/10665-381036.page-656.19.json
  750. Schünemann 2016 Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, et al; GRADE Working Group.
    · extracted · source: references/10665-381036.page-656.20.json
  751. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology 2016;76:89-98. [DOI: 10.1016/j.jclinepi.2016.01.032]
    · extracted · doi:10.1016/j.jclinepi.2016.01.032 · source: references/10665-381036.page-656.21.json
  752. Schünemann 2020a 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology 2020;122:129-41. [DOI: 10.1016/j.jclinepi.2019.12.020]
    · extracted · doi:10.1016/j.jclinepi.2019.12.020 · source: references/10665-381036.page-656.22.json
  753. Schünemann 2020b 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2020;122:142-52. [DOI: 10.1016/j.jclinepi.2019.12.021]
    · extracted · doi:10.1016/j.jclinepi.2019.12.021 · source: references/10665-381036.page-656.23.json
  754. Sulis 2020 Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLOS Medicine. 2020 17(1):e1003023 Takwoingi 2015 Takwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Statistical Methods in Medical Research 2015;26(4):1896-1911.Whiting 2011 Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
    · extracted · source: references/10665-381036.page-656.24.json
  755. WHO Consolidated Guidelines (Module 3) 2020 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection; June 2020. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection (accessed 1 July 2020).
    · extracted · source: references/10665-381036.page-656.25.json
  756. WHO Consolidated Guidelines (Module 4) 2020 World Health Organization. Global tuberculosis report 2020. who.int/tb/publications/global_report/en/ (accessed 19 October 2020).
    · extracted · source: references/10665-381036.page-656.26.json
  757. WHO Critical concentrations 2018 World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. (WHO/CDS/TB/2018.5). License: CC BY-NC-SA 3.0 IGO. who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/(accessed 16 July 2020).
    · extracted · source: references/10665-381036.page-656.27.json
  758. WHO Definitions and reporting 2020 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014 and January 2020). who.int/tb/publications/definitions/en/ (accessed 24 July 2020).
    · extracted · source: references/10665-381036.page-656.28.json
  759. for drug resistance Loci included in gDST reference Cepheid China (yes) retrospective1 530 (47.9%) ≥ 15 years2 Benin (no) Cameroon (no) Rwanda (no) 621 (48.3%) ≥ 15 years 13.3% Benin; 37.2% Rwanda FIND 2020 New Delhi (yes)
    · extracted · source: references/10665-381036.page-673.1.json
  760. Moldova (yes) Mumbai (yes) 611 (80.9%) ≥ 18 years 17.5% overall, 87.1% South Africa Abbreviations: NA: not applicable; NR: not reported; RR: rifampicin resistance Footnotes 1. In some cases, the reference standard was performed before and in other cases after the index test. 2. One participant was 13 years old.
    · extracted · source: references/10665-381036.page-673.2.json
  761. World Health Organization. Global Tuberculosis Report 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1.
    · extracted · link · source: references/10665-381036.page-705.1.json
  762. World Health Organization. Xpert MTB/RIF implementation manual Technical and operational ‘how-to’: practical considerations 2014. http://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1.
    · extracted · link · source: references/10665-381036.page-705.2.json
  763. World Health Organization. Rapid Implementation of the Xpert MTB/RIF diagnostic test Technical and Operational ‘How-to’Practical considerations 2011. http://apps.who.int/iris/bitstream/handle/10665/44593/9789241501569_eng.pdf?sequence=1.
    · extracted · link · source: references/10665-381036.page-705.3.json
  764. World Health Organization. Monitoring of Xpert MTB/RIF roll-out 2016. https://www.who.int/tb/areas-of-work/laboratory/mtb-rif-rollout/en/.
    · extracted · link · source: references/10665-381036.page-705.4.json
  765. Chakravorty S, Simmons AM, Rowneki M et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio 2017; 8: e00812-17.
    · extracted · source: references/10665-381036.page-705.5.json
  766. World Health Organization. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistsant Tuberculosis (MDR-TB) - Policy Statement 2008. http://www.who.int/tb/features_archive/policy_statement.pdf?ua=1.
    · extracted · link · source: references/10665-381036.page-705.6.json
  767. Hain Lifescience. Genotype MTBDRplus VER 2.0 Instructions for Use 2015. https://www.ghdonline.org/uploads/MTBDRplusV2_0212_304A-02-02.pdf.
    · extracted · link · source: references/10665-381036.page-705.7.json
  768. Whitfield MG, Soeters HM, Warren RM et al. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0133869.
    · extracted · source: references/10665-381036.page-705.8.json
  769. Chang KC, Yew WW, Zhang Y. Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis: a Systematic Review with Meta-Analyses. Antimicrob Agents Chemother 2011; 55: 4499-505.
    · extracted · source: references/10665-381036.page-705.9.json
  770. Whitfield MG, Streicher EM, Dolby T et al. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2016; 99: 128-30.
    · extracted · source: references/10665-381036.page-705.10.json
  771. Chedore P, Bertucci L, Wolfe J et al. Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide. J Clin Microbiol 2010; 48: 300-1.
    · extracted · source: references/10665-381036.page-705.11.json
  772. Whitfield MG, Warren RM, Streicher EM et al. Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. J Clin Microbiol 2015; 53: 3633-5.
    · extracted · source: references/10665-381036.page-705.12.json
  773. Scorpio A, LindholmLevy P, Heifets L et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3.
    · extracted · source: references/10665-381036.page-705.13.json
  774. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-7.
    · extracted · source: references/10665-381036.page-705.14.json
  775. Streicher EM, Maharaj K, York T et al. Rapid Sequencing of the Mycobacterium tuberculosis pncA Gene for Detection of Pyrazinamide Susceptibility. J Clin Microbiol 2014; 52: 4056-7.
    · extracted · source: references/10665-381036.page-705.15.json
  776. Sekiguchi J, Nakamura T, Miyoshi-Akiyama T et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin Microbiol 2007; 45: 2802-7.
    · extracted · source: references/10665-381036.page-705.16.json
  777. Köser CU, Cirillo DM, Miotto P. How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide. Antimicrob Agents Chemother 2020; 64: e01003-20.
    · extracted · source: references/10665-381036.page-705.17.json
  778. Schünemann HJ, Mustafa R, Brozek J et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 2016; 76: 89-98.
    · extracted · source: references/10665-381036.page-705.18.json
  779. Schünemann HJ, Oxman AD, Brozek J et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-10.
    · extracted · source: references/10665-381036.page-705.19.json
  780. Schünemann HJ, Mustafa RA, Brozek J et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol 2020; 122: 129-41.
    · extracted · source: references/10665-381036.page-705.20.json
  781. Schünemann HJ, Mustafa RA, Brozek J et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol 2020; 122: 142-52.
    · extracted · source: references/10665-381036.page-705.21.json
  782. Khan MT, Malik SI, Ali S et al. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan. Microbial drug resistance (Larchmont, NY) 2018; 24: 1417-21.
    · extracted · source: references/10665-381036.page-705.22.json
  783. Calderón RI, Velásquez GE, Becerra MC et al. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis 2017; 21: 894-901.
    · extracted · source: references/10665-381036.page-705.23.json
  784. Pang Y, Zhang Z, Wang Y et al. Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother 2017; 61.
    · extracted · source: references/10665-381036.page-705.24.json
  785. Ando H, Mitarai S, Kondo Y et al. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2010; 16: 1164-8.
    · extracted · source: references/10665-381036.page-705.25.json
  786. Driesen M, Kondo Y, de Jong BC et al. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clin Microbiol Infect 2018; 24: 60-4.
    · extracted · source: references/10665-381036.page-705.26.json
  787. Willby MJ, Wijkander M, Havumaki J et al. Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing. Antimicrob Agents Chemother 2017; 62: e01871-17.
    · extracted · source: references/10665-381036.page-705.27.json
  788. Matsumoto T, Ogata H, Toyota E et al. [Clinical evaluation of a line probe assay kit for the identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis]. Kekkaku 2013; 88: 291-6.
    · extracted · source: references/10665-381036.page-705.28.json
  789. Mitarai S, Kato S, Ogata H et al. Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2012; 50: 884-90.
    · extracted · source: references/10665-381036.page-705.29.json
  790. Rienthong S, Boonin C, Chaiyasirinrote B et al. Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand. Int J Tuberc Lung Dis 2015; 19: 817-22.
    · extracted · source: references/10665-381036.page-705.30.json
  791. Moher D, Liberati A, Tetzlaff J et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6.
    · extracted · source: references/10665-381036.page-705.31.json
  792. Global Tuberculosis Report 2022. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO
    · extracted · source: references/10665-381036.page-769.1.json
  793. Karmakar M, Ragonnet R, Ascher DB, Trauer JM, Denholm JT. Estimating tuberculosis drug resistance amplification rates in high-burden settings. BMC Infect Dis. 2022 Jan 24;22(1):82.
    · extracted · source: references/10665-381036.page-769.2.json
  794. The End TB Strategy. Geneva: World Health Organization; WHO/HTM/TB/2015.19. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19(Accessed 6 April 2023)
    · extracted · link · source: references/10665-381036.page-769.3.json
  795. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
    · extracted · source: references/10665-381036.page-769.4.json
  796. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022 Nov;20(11):685–701.
    · extracted · source: references/10665-381036.page-769.5.json
  797. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705–18.
    · extracted · source: references/10665-381036.page-769.6.json
  798. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022 (WHO/UCN/TB/2022.2). Licence: CC BY-NC-SA 3.0 IGO
    · extracted · source: references/10665-381036.page-769.7.json
  799. Lindsay McKenna. The 2021 Tuberculosis Treatment Pipeline Report. Treatment Action Group. Available from: https://www.treatmentactiongroup.org/wp-content/uploads/2021/11/pipeline_TB_Treatment_2021_final.pdf (Accessed 16 April 2023)
    · extracted · link · source: references/10665-381036.page-769.8.json
  800. Van Rie A, Walker T, de Jong B, Rupasinghe P, Rivière E, Dartois V, et al. Balancing access to BPaLM regimens and risk of resistance. The Lancet Infectious Diseases. 2022 Oct;22(10):1411–2.
    · extracted · source: references/10665-381036.page-769.9.json
  801. The CRyPTIC Consortium and the 100 000 Genomes Project. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018 Sep 26;NEJMoa1800474-14.
    · extracted · source: references/10665-381036.page-769.10.json
  802. Dale K, Globan M, Horan K, Sherry N, Ballard S, Tay EL, et al. Whole genome sequencing for tuberculosis in Victoria, Australia: A genomic implementation study from 2017 to 2020. The Lancet Regional Health - Western Pacific. 2022 Nov;28:100556.
    · extracted · source: references/10665-381036.page-769.11.json
  803. Nilgiriwala K, Rabodoarivelo MS, Hall MB, Patel G, Mandal A, Mishra S, et al. Genomic Sequencing from Sputum for Tuberculosis Disease Diagnosis, Lineage Determination, and Drug Susceptibility Prediction. Diekema DJ, editor. J Clin Microbiol. 2023 Mar 23;61(3):e01578-22.
    · extracted · source: references/10665-381036.page-769.12.json
  804. Whiting PF. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med. 2011 Oct 18;155(8):529.
    · extracted · source: references/10665-381036.page-769.13.json
  805. Brankin AE, Fowler PW. Inclusion of minor alleles improves catalogue-based prediction of fluoroquinolone resistance in Mycobacterium tuberculosis. JAC Antimicrob Resist 2023 Apr 4;5(2)
    · extracted · source: references/10665-381036.page-769.14.json
  806. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO Web Annex B.17. A Systematic and Scoping Review of the Economic Evidence around Targeted Next Generation Sequencing (tNGS) for the Diagnosis of Drug-Resistant Tuberculosis (DR-TB)
    · extracted · source: references/10665-381036.page-769.15.json
  807. US list pricing as of October, 2018 Chan WS et al (2020) with AFB smear-negative or MTB detected low/very low tNGS (MinION and MiSeq)
    · extracted · source: references/10665-381036.page-786.2.json
  808. Moldova tNGS (iSeq100) and Budget impact analysis (BIA) Cost per 5-year period for population Published sources, manufacturer costing data, publicly available costing data Rowlinson MC and Musser KA (2022)1 tNGS and WGS (both in-house)
    · extracted · source: references/10665-381036.page-786.6.json
  809. In-house laboratory costs 1. The paper by Rowlinson MC and Musser KA (2020) is a report
    · extracted · source: references/10665-381036.page-786.7.json
  810. Malaria Tanzania Children with uncomplicated P. falciparum malaria tNGS (Second Generation Sequencing) Cost per specimen Cost per step Wales et al (2017)
    · extracted · source: references/10665-381036.page-789.6.json
  811. HIV-infected patients in US with baseline CD4 counts of 0.250x10^9 cells/L. tNGS (Genotypic resistance testing)
    · extracted · source: references/10665-381036.page-789.8.json
  812. Koh WJ, Ko Y, Kim CK, Park KS, and Lee NY. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med. 2012;32:264–9.
    · extracted · source: references/10665-381036.page-805.1.json
  813. Zaheen A, and Bloom BR. Tuberculosis in 2020 - New Approaches to a Continuing Global Health Crisis. N Engl J Med. 2020 Apr 2;382(14):e26. doi: 10.1056/NEJMp2000325. PMID: 32242354.
    · extracted · doi:10.1056/NEJMp2000325 · source: references/10665-381036.page-805.2.json
  814. Barbier M, Wirth T. The Evolutionary History, Demography, and Spread of the Mycobacterium tuberculosis Complex. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.TBTB2-0008-2016. PMID: 27726798.World Health Organization (WHO). Global Tuberculosis Report 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports [Accessed 11th November 2022].
    · extracted · link · doi:10.1128/microbiolspec.TBTB2-0008-2016 · source: references/10665-381036.page-805.3.json
  815. Viney K, Linh NW, and Gegia M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. European Respiratory Journal. 2021;57:1-5. Doi: 10.1183/13993003.00361-2021.
    · extracted · doi:10.1183/13993003.00361-2021 · source: references/10665-381036.page-805.4.json
  816. World Health Organization (WHO). Tuberculosis fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis [Accessed 1st June 2022].
    · extracted · link · source: references/10665-381036.page-805.5.json
  817. Dean AS, et al (2022). 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis 22(7):E191-E196 (https://doi.org/10.1016/S1473-3099(21)00808-2).
    · extracted · doi:10.1016/S1473-3099(21)00808-2 · source: references/10665-381036.page-805.6.json
  818. Monedero-Recuero I, Gegia M, Wares DF, Chadha SS, and Mirzayev F. Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape. Int J Infect Dis. 2021 Jul;108:557-567. doi: 10.1016/j.ijid.2021.06.022. Epub 2021 Jun 15. PMID: 34139370.
    · extracted · doi:10.1016/j.ijid.2021.06.022 · source: references/10665-381036.page-805.7.json
  819. Andama A, Somoskovi A, Mandel B, Bell D, and Gutierrez C. Improving diagnosis and case management of patients with tuberculosis: A review of gaps, needs and potential solutions in accessing laboratory diagnostics. Infect Genet Evol. 2019 Aug;72:131-140. doi: 10.1016/j.meegid.2018.08.030. Epub 2018 Oct 13. PMID: 30326281.
    · extracted · doi:10.1016/j.meegid.2018.08.030 · source: references/10665-381036.page-805.8.json
  820. Furin J, Cox H, and Pai M. Tuberculosis. Lancet. 2019 Apr 20;393(10181):1642-1656. doi:
    · extracted · source: references/10665-381036.page-805.9.json
  821. 1016/S0140-6736(19)30308-3. Epub 2019 Mar 20. PMID: 30904262. 10) Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, and Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole genome sequences. Genome Med 2015;7:51.
    · extracted · source: references/10665-381036.page-805.10.json
  822. Penn-Nicholson A, Gomathi SN, Ugarte-Gil C, Meaza A, Lavu E, Patel P, Choudhury B, Rodrigues C, Chadha S, Kazi M, Macé A, Nabeta P, Boehme C, Gangakhedkar RR, Sarin S, Tesfaye E, Gotuzzo E, du Cros P, Tripathy S, Ruhwald M, Singh M, Denkinger CM, Schumacher SG; Truenat Trial Consortium; and Members of the Truenat Trial Consortium. A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. Eur Respir J. 2021 Nov 4;58(5):2100526. doi: 10.1183/13993003.00526-2021. PMID: 34049948; PMCID: PMC8607906.
    · extracted · doi:10.1183/13993003.00526-2021 · source: references/10665-381036.page-805.11.json
  823. Jang JG, and Chung JH. (2020). Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam University journal of medicine, 37(4), 277–285. https://doi.org/10.12701/yujm.2020.00626.
    · extracted · doi:10.12701/yujm.2020.00626 · source: references/10665-381036.page-805.12.json
  824. World Health Organization. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Jun 5]. https://apps.who.int/iris/handle/10665/330395.
    · extracted · link · source: references/10665-381036.page-805.13.json
  825. Ling DI, Zwerling A, and Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. European Respirology, 2008;32:1165-1174.
    · extracted · source: references/10665-381036.page-805.14.json
  826. Pai M, Nicol MP, and Boehme CC. Tuberculosis Diagnostics: State of the Art and Future Directions. American Society for Microbiology. 2016;4:5.
    · extracted · source: references/10665-381036.page-805.15.json
  827. Cirillo DM, Miotto P, and Tortoli E. Evolution of Phenotypic and Molecular Drug Susceptibility Testing. Adv Exp Med Biol. 2017;1019:221-246. doi: 10.1007/978-3-319-64371-7_12. PMID: 29116638.
    · extracted · doi:10.1007/978-3-319-64371-7_12 · source: references/10665-381036.page-805.16.json
  828. Hepple, et al. Implementation of liquid culture for tuberculosis diagnosis in a remote setting: lessons learned. Int J Tuberc Lung Dis. 2011;15(3):405–407.
    · extracted · source: references/10665-381036.page-805.17.json
  829. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) [Internet]. Geneva: World Health Organization; 2008 [cited 2020 Jul 14]. https://www.who.int/tb/laboratory/line_probe_assays/en/.
    · extracted · link · source: references/10665-381036.page-805.18.json
  830. Lin M, Chen YW, Li YR, Long LJ, Qi LY, Cui TT, Wu SY, Lin JY, Wu T, Yang YC, Yuan WH, Wu GY, Lan QW, Liu JQ, Li YP, Yu ZY, and Guo XG. Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clin Chim Acta. 2022 Aug 1;533:183-218. doi: 10.1016/j.cca.2022.06.020. Epub 2022 Jul 2. PMID: 35792161.
    · extracted · doi:10.1016/j.cca.2022.06.020 · source: references/10665-381036.page-805.19.json
  831. Theron G, Peter J, Richardson M, Barnard M, Donegan S, and Warren R, et al. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014; (10):CD010705.
    · extracted · source: references/10665-381036.page-805.20.json
  832. Satta G, Lipman M, Smith GP, Arnold C, Kon OM, and McHugh TD. Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential? Clin Microbiol Infect. 2018 Jun;24(6):604-609. doi: 10.1016/j.cmi.2017.10.030. Epub 2017 Nov 3. PMID: 29108952.
    · extracted · doi:10.1016/j.cmi.2017.10.030 · source: references/10665-381036.page-805.21.json
  833. Behjati S, and Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013 Dec;98(6):236-8. doi: 10.1136/archdischild-2013-304340. Epub 2013 Aug 28. PMID: 23986538; PMCID: PMC3841808.
    · extracted · doi:10.1136/archdischild-2013-304340 · source: references/10665-381036.page-805.22.json
  834. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, and Butcher PD. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med 2016;14:46.
    · extracted · source: references/10665-381036.page-805.23.json
  835. Bragg L, and Tyson GW. Metagenomics using next-generation sequencing. Methods Mol Biol. 2014;1096:183-201. doi: 10.1007/978-1-62703-712-9_15. PMID: 24515370.
    · extracted · doi:10.1007/978-1-62703-712-9_15 · source: references/10665-381036.page-805.24.json
  836. Cabibbe AM, Spitaleri A, Battaglia S, Colman RE, Suresh A, Uplekar S, Rodwell TC, and Cirillo DM. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol. 2020 Sep 22;58(10):e00632-20. doi: 10.1128/JCM.00632-20. PMID: 32727827; PMCID: PMC7512157.
    · extracted · doi:10.1128/JCM.00632-20 · source: references/10665-381036.page-805.25.json
  837. Moher D, Liberati A, Tetzlaff J, Altman DG, and PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed.), 339, b2535. https://doi.org/10.1136/bmj.b2535.
    · extracted · doi:10.1136/bmj.b2535 · source: references/10665-381036.page-805.26.json
  838. Slatko BE, Gardner AF, and Ausubel FM. Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol. 2018 Apr;122(1):e59. doi: 10.1002/cpmb.59. PMID: 29851291; PMCID: PMC6020069.
    · extracted · doi:10.1002/cpmb.59 · source: references/10665-381036.page-805.27.json
  839. Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, aand Engelthaler DM. 2016. Rapid drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates directly from clinical samples by use of amplicon sequencing: a proof-of-concept study. J Clin Microbiol. 54:2058–2067.
    · extracted · source: references/10665-381036.page-805.28.json
  840. Mitchell SL, and Simner PJ. Next-Generation Sequencing in Clinical Microbiology: Are We There Yet? Clin Lab Med. 2019 Sep;39(3):405-418. doi: 10.1016/j.cll.2019.05.003. PMID: 31383265.
    · extracted · doi:10.1016/j.cll.2019.05.003 · source: references/10665-381036.page-805.29.json
  841. World Health Organization (WHO). The use of next-generation sequencing technologies for the detection of mutations associated with rug resistance in Mycobacterium tuberculosis complex: technical guide. Available from: https://apps.who.int/iris/bitstream/handle/10665/274443/WHO-CDS-TB-2018.19-eng.pdf?sequence=1&isAllowed=y [Accessed 20th June 2022].
    · extracted · link · source: references/10665-381036.page-805.30.json
  842. Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B, Gouws-Williams E, Ghys PD; WHO–UNAIDS Network for HIV Isolation Characterisation. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019 Feb;19(2):143-155. doi: 10.1016/S1473-3099(18)30647-9. Epub 2018 Nov 30. Erratum in: Lancet Infect Dis. 2020 Mar;20(3):e27. PMID: 30509777.
    · extracted · doi:10.1016/S1473-3099(18)30647-9 · source: references/10665-381036.page-805.31.json
  843. Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol. 2018 Feb;16(2):80-90. doi: 10.1038/nrmicro.2017.128. Epub 2017 Nov 7. PMID: 29109555.
    · extracted · doi:10.1038/nrmicro.2017.128 · source: references/10665-381036.page-805.32.json
  844. Michaud CM. Global Burden of Infectious Diseases. Encyclopedia of Microbiology. 2009:444–54. doi: 10.1016/B978-012373944-5.00185-1. Epub 2009 Feb 17. PMCID: PMC7150259.
    · extracted · doi:10.1016/B978-012373944-5.00185-1 · source: references/10665-381036.page-805.33.json
  845. Peteranderl C, Herold S, Schmoldt C. Human Influenza Virus Infections. Semin Respir Crit Care Med. 2016 Aug;37(4):487-500. doi: 10.1055/s-0036-1584801. Epub 2016 Aug 3. PMID: 27486731; PMCID: PMC7174870.
    · extracted · doi:10.1055/s-0036-1584801 · source: references/10665-381036.page-805.34.json
  846. The National Institute for Health Research (NHS). Guidance notes for registering a systematic review protocol with PROSPERO. Available from: https://www.crd.york.ac.uk/prospero/documents/Registering%20a%20review%20on%20PROSPERO.pdf [Accessed 22nd June 2022].
    · extracted · link · source: references/10665-381036.page-805.35.json
  847. International Monetary Fund (IMF). Inflation rate, average consumer prices. Available from: https://www.imf.org/external/datamapper/PCPIPCH@WEO/OEMDC [Accessed 12th December 2022].
    · extracted · link · source: references/10665-381036.page-805.36.json
  848. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, and ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(2), 231–250. https://doi.org/10.1016/j.jval.2013.02.002.
    · extracted · doi:10.1016/j.jval.2013.02.002 · source: references/10665-381036.page-805.37.json
  849. Tafess K, Ng TTL, Lao HY, Leung KSS, Tam KKG, Rajwani R, Tam STY, Ho LPK, Chu CMK, Gonzalez D, Sayada C, Ma OCK, Nega BH, Ameni G, Yam WC, and Siu GKH. Targeted-Sequencing Workflows for Comprehensive Drug Resistance Profiling of Mycobacterium tuberculosis Cultures Using Two Commercial Sequencing Platforms: Comparison of Analytical and Diagnostic Performance, Turnaround Time, and Cost. Clin Chem. 2020 Jun 1;66(6):809-820. doi: 10.1093/clinchem/hvaa092. PMID: 32402055.
    · extracted · doi:10.1093/clinchem/hvaa092 · source: references/10665-381036.page-805.38.json
  850. Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Crudu V, Cohen T, and Menzies NA. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. Int J Tuberc Lung Dis. 2022 Oct 1;26(10):963-969. doi: 10.5588/ijtld.22.0104. PMID: 36163669.
    · extracted · doi:10.5588/ijtld.22.0104 · source: references/10665-381036.page-805.39.json
  851. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, and Rodwell TC. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019 Apr 30;16(4):e1002794. doi: 10.1371/journal.pmed.1002794.
    · extracted · doi:10.1371/journal.pmed.1002794 · source: references/10665-381036.page-805.40.json
  852. Rowlinson MC, and Musser KA. Current Methods and Role of Next-Generation Sequencing in the Diagnosis of Antimicrobial Resistance in Tuberculosis. Clinical Microbiology Newsletter. 2022 Jan;44:1-12.doi: https://doi.org/10.1016/j.clinmicnews.2021.12.001.
    · extracted · doi:10.1016/j.clinmicnews.2021.12.001 · source: references/10665-381036.page-805.41.json
  853. Chan WS, Au CH, Chung Y, Leung HCM, Ho DN, Wong EYL, Lam TW, Chan TL, Ma ESK, and Tang BSF. Rapid and economical drug resistance profiling with Nanopore MinION for clinical specimens with low bacillary burden of Mycobacterium tuberculosis. BMC Res Notes. 2020 Sep 18;13(1):444. doi: 10.1186/s13104-020-05287-9. PMID: 32948225; PMCID: PMC7501614.
    · extracted · doi:10.1186/s13104-020-05287-9 · source: references/10665-381036.page-805.42.json
  854. Gliddon HD, Frampton D, Munsamy V, Heaney J, Pataillot-Meakin T, Nastouli E, Pym AS, Steyn AJC, Pillay D, and McKendry RA. A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing. Microbiol Spectr. 2021 Dec 22;9(3):e0061021. doi: 10.1128/Spectrum.00610-21. Epub 2021 Nov 24. PMID: 34817282; PMCID: PMC8612157.
    · extracted · doi:10.1128/Spectrum.00610-21 · source: references/10665-381036.page-805.43.json
  855. He G, Li Y, Chen X, Chen J, and Zhang W. Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. Int J Infect Dis. 2020 Jul;96:68-72. doi: 10.1016/j.ijid.2020.04.043. Epub 2020 Apr 24. PMID: 32339719.
    · extracted · doi:10.1016/j.ijid.2020.04.043 · source: references/10665-381036.page-805.44.json
  856. Pankhurst LJ, Del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fermont JM, Gascoyne-Binzi DM, Kohl TA, Kong C, Lemaitre N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith EG, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook DW; and COMPASS-TB Study Group. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med. 2016 Jan;4(1):49-58. doi: 10.1016/S2213-2600(15)00466-X. Epub 2015 Dec 4. PMID: 26669893; PMCID: PMC4698465.
    · extracted · doi:10.1016/S2213-2600(15)00466-X · source: references/10665-381036.page-805.45.json
  857. Vogel M, Utpatel C, Corbett C, Kohl TA, Iskakova A, Ahmedov S, Antonenka U, Dreyer V, Ibrahimova A, Kamarli C, Kosimova D, Mohr V, Sahalchyk E, Sydykova M, Umetalieva N, Kadyrov A, Kalmambetova G, Niemann S, and Hoffmann H. Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country. Sci Rep. 2021 Jul 28;11(1):15333. doi: 10.1038/s41598-021-94297-z. PMID: 34321545; PMCID: PMC8319420.
    · extracted · doi:10.1038/s41598-021-94297-z · source: references/10665-381036.page-805.46.json
  858. Alleweldt F, Kara Ş, Best K, Aarestrup FM, Beer M, Bestebroer TM, Campos J, Casadei G, Chinen I, Van Domselaar G, Dominguez C, Everett HE, Fouchier RA, Grant K, Green J, Höper D, Johnston J, Koopmans MP, Oude Munnink BB, Myers R, Nadon C, Patel A, Pohlmann A, Pongolini S, Reimer A, Thiessen S, Wylezich C. Economic evaluation of whole genome sequencing for pathogen identification and surveillance - results of case studies in Europe and the Americas 2016 to 2019. Euro Surveill. 2021 Mar;26(9):1900606. doi: 10.2807/1560-7917.ES.2021.26.9.1900606. PMID: 33663647; PMCID: PMC7934224.
    · extracted · doi:10.2807/1560-7917.ES.2021.26.9.1900606 · source: references/10665-381036.page-805.47.json
  859. Dimitrov KM, Sharma P, Volkening JD, Goraichuk IV, Wajid A, Rehmani SF, Basharat A, Shittu I, Joannis TM, Miller PJ, Afonso CL. A robust and cost-effective approach to sequence and analyze complete genomes of small RNA viruses. Virol J. 2017 Apr 7;14(1):72. doi: 10.1186/s12985-017-0741-5. PMID: 28388925; PMCID: PMC5384157.
    · extracted · doi:10.1186/s12985-017-0741-5 · source: references/10665-381036.page-805.48.json
  860. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001 Mar 20;134(6):440-50. doi: 10.7326/0003-4819-134-6-200103200-00008. PMID: 11255519.
    · extracted · doi:10.7326/0003-4819-134-6-200103200-00008 · source: references/10665-381036.page-805.49.json
  861. Gachogo RW, Mwai DN, Onyambu FG. Cost analysis of implementing HIV drug resistance testing in Kenya: a case study of a service delivery site at a tertiary level hospital in Kenya. F1000Res. 2020 Jul 29;9:793. doi: 10.12688/f1000research.23379.1. PMID: 32983418; PMCID: PMC7495211.
    · extracted · doi:10.12688/f1000research.23379.1 · source: references/10665-381036.page-805.50.json
  862. Riaz N, Leung P, Barton K, Smith MA, Carswell S, Bull R, Lloyd AR, Rodrigo C. Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants. BMC Genomics. 2021 Mar 2;22(1):148. doi: 10.1186/s12864-021-07460-1. PMID: 33653280; PMCID: PMC7923462.
    · extracted · doi:10.1186/s12864-021-07460-1 · source: references/10665-381036.page-805.51.json
  863. Merel P, Pellegrin I, Garrigue I, Caumont A, Schrive MH, Birac V, Bonot P, Fleury H. Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis. J Virol Methods. 2001 Oct;98(1):9-16. doi: 10.1016/s0166-0934(01)00338-x. PMID: 11543879.
    · extracted · doi:10.1016/s0166-0934(01)00338-x · source: references/10665-381036.page-805.52.json
  864. Chaturbhuj DN, Nirmalkar AP, Paranjape RS, Tripathy SP. Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samples. PLoS One. 2014 Feb 12;9(2):e87441. doi: 10.1371/journal.pone.0087441. PMID: 24533056; PMCID: PMC3922725.
    · extracted · doi:10.1371/journal.pone.0087441 · source: references/10665-381036.page-805.53.json
  865. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One. 2012;7(5):e36494. doi: 10.1371/journal.pone.0036494. Epub 2012 May 4. PMID: 22574170; PMCID: PMC3344889.
    · extracted · doi:10.1371/journal.pone.0036494 · source: references/10665-381036.page-805.54.json
  866. Ekici H, Rao SD, Sönnerborg A, Ramprasad VL, Gupta R, Neogi U. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. J Antimicrob Chemother. 2014 Dec;69(12):3349-55. doi: 10.1093/jac/dku278. Epub 2014 Jul 31. PMID: 25085657.
    · extracted · doi:10.1093/jac/dku278 · source: references/10665-381036.page-805.55.json
  867. Kunasol C, Dondorp AM, Batty EM, Nakhonsri V, Sinjanakhom P, Day NPJ, Imwong M. Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers. Sci Rep. 2022 Apr 1;12(1):5563. doi: 10.1038/s41598-022-09474-5. PMID: 35365711; PMCID: PMC8974807.
    · extracted · doi:10.1038/s41598-022-09474-5 · source: references/10665-381036.page-805.56.json
  868. Patel N, Ferns BR, Nastouli E, Kozlakidis Z, Kellam P, and Morris S. Cost analysis of standard Sanger sequencing versus next generation sequencing in the ICONIC study. The Lancet Meeting Abstracts. 2016 Nov 25.
    · extracted · source: references/10665-381036.page-805.57.json
  869. Taylor SM, Parobek CM, Aragam N, Ngasala BE, Mårtensson A, Meshnick SR, Juliano JJ. Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. J Infect Dis. 2013 Dec 15;208(12):1998-2006. doi: 10.1093/infdis/jit392. Epub 2013 Aug 1. PMID: 23908494; PMCID: PMC3836461.
    · extracted · doi:10.1093/infdis/jit392 · source: references/10665-381036.page-805.58.json
  870. Wales C, Corpus G, Chang C. Hepatitis C Virus Genotyping Using Next-Generation Sequencing: An Efficient Alternative to Sanger Sequencing. Arch Pathol Lab Med. 2017 Mar;141(3):323-324. doi: 10.5858/arpa.2016-0338-LE. PMID: 28234569.
    · extracted · doi:10.5858/arpa.2016-0338-LE · source: references/10665-381036.page-805.59.json
  871. Tiberi S, Utjesanovic N, Galvin J, et. al. Drug resistant TB – latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases. 2022.
    · extracted · source: references/10665-381036.page-848.1.json
  872. World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
    · extracted · source: references/10665-381036.page-848.2.json
  873. Farhat M, Fresch L, Calderon R, Loerger T, Snyder M, Meehan C, et al. GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications. 2019;10(2128).
    · extracted · source: references/10665-381036.page-848.3.json
  874. World Health Organization. Global Tuberculosis Report 2016. Geneva: World Health Organization; 2016.
    · extracted · source: references/10665-381036.page-848.4.json
  875. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide Geneva: World Health Organization; 2018. Report No.: Licence: CC BY-NCSA 3.0 IGO Contract No.: WHO/CDS/TB/2018.19.
    · extracted · source: references/10665-381036.page-848.5.json
  876. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021. Contract No.: Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · source: references/10665-381036.page-848.6.json
  877. Klaic M, Kapp S, Hudson P, Chapman W, Denehy L, Story D, et al. Implementability of healthcare interventions: an overview of reviews and development of a conceptual framework. Implement Sci. 2022;17(1):10.
    · extracted · source: references/10665-381036.page-848.7.json
  878. Engel N, Ochodo EA, Karanja PW, Schmidt BM, Janssen R, Steingart KR, et al. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views. Cochrane Database Syst Rev. 2022;4(4):CD014877.
    · extracted · source: references/10665-381036.page-848.8.json
  879. Mounier-Jack S, Mayhew SH, Mays N. Integrated care: learning between high-income, and low-and middle-income country health systems. Health Policy Plan. 2017;32(suppl_4):iv6-iv12.
    · extracted · source: references/10665-381036.page-848.9.json
  880. Lehmann U, Gilson L. Actor interfaces and practices of power in a community health worker programme: a South African study of unintended policy outcomes. Health Policy Plan. 2013;28(4):358-66.
    · extracted · source: references/10665-381036.page-848.10.json
  881. Orgill M, Gilson L, Chitha W, Michel J, Erasmus E, Marchal B, et al. A qualitative study of the dissemination and diffusion of innovations: bottom up experiences of senior managers in three health districts in South Africa. Int J Equity Health. 2019;18(1):53.
    · extracted · source: references/10665-381036.page-848.11.json
  882. Walker L, Gilson L. 'We are bitter but we are satisfied': nurses as street-level bureaucrats in South Africa. Soc Sci Med. 2004;59(6):1251-61.
    · extracted · source: references/10665-381036.page-848.12.json
  883. Erasmus E. The use of street-level bureaucracy theory in health policy analysis in low- and middle-income countries: a meta-ethnographic synthesis. Health Policy Plan. 2014;29 Suppl 3:iii70-8.
    · extracted · source: references/10665-381036.page-848.13.json
  884. Erasmus E, Gilson L. How to start thinking about investigating power in the organizational settings of policy implementation. Health policy and planning. 2008;23: 361-68.
    · extracted · source: references/10665-381036.page-848.14.json
  885. What if any concerns do you have about the equity of the tNGS rapid diagnostic technology in your country context? For example, with reference to the extent to which the benefit of the technology reaches those who need it most?
    · extracted · source: references/10665-381036.page-848.19.json
  886. What would need to change in your country context to enable the tNGS technology to have an optimal positive impact on clinical care for TB patients. What is your sense of how likely (feasible)
    · extracted · source: references/10665-381036.page-848.20.json
  887. Tiberi S, Utjesanovic N, Galvin J, et. al. Drug resistant TB – latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases. 2022.
    · extracted · source: references/10665-381036.page-861.1.json
  888. World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
    · extracted · source: references/10665-381036.page-861.2.json
  889. Farhat M, Fresch L, Calderon R, Loerger T, Snyder M, Meehan C, et al. GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications. 2019;10(2128).
    · extracted · source: references/10665-381036.page-861.3.json
  890. World Health Organization. Global Tuberculosis Report 2016. Geneva: World Health Organization; 2016.
    · extracted · source: references/10665-381036.page-861.4.json
  891. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide Geneva: World Health Organization; 2018. Report No.: Licence: CC BY-NCSA 3.0 IGO Contract No.: WHO/CDS/TB/2018.19.
    · extracted · source: references/10665-381036.page-861.5.json
  892. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021. Contract No.: Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · source: references/10665-381036.page-861.6.json
  893. Klaic M, Kapp S, Hudson P, Chapman W, Denehy L, Story D, et al. Implementability of healthcare interventions: an overview of reviews and development of a conceptual framework. Implement Sci. 2022;17(1):10.
    · extracted · source: references/10665-381036.page-861.7.json
  894. Engel N, Ochodo EA, Karanja PW, Schmidt BM, Janssen R, Steingart KR, et al. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views. Cochrane Database Syst Rev. 2022;4(4):CD014877.
    · extracted · source: references/10665-381036.page-861.8.json
  895. Mounier-Jack S, Mayhew SH, Mays N. Integrated care: learning between high-income, and low-and middle-income country health systems. Health Policy Plan. 2017;32(suppl_4):iv6-iv12.
    · extracted · source: references/10665-381036.page-861.9.json
  896. ehmann U, Gilson L. Actor interfaces and practices of power in a community health worker programme: a South African study of unintended policy outcomes. Health Policy Plan. 2013;28(4):358-66.
    · extracted · source: references/10665-381036.page-861.10.json
  897. Orgill M, Gilson L, Chitha W, Michel J, Erasmus E, Marchal B, et al. A qualitative study of the dissemination and diffusion of innovations: bottom up experiences of senior managers in three health districts in South Africa. Int J Equity Health. 2019;18(1):53.
    · extracted · source: references/10665-381036.page-861.11.json
  898. Walker L, Gilson L. 'We are bitter but we are satisfied': nurses as street-level bureaucrats in South Africa. Soc Sci Med. 2004;59(6):1251-61.
    · extracted · source: references/10665-381036.page-861.12.json
  899. Erasmus E. The use of street-level bureaucracy theory in health policy analysis in low- and middle-income countries: a meta-ethnographic synthesis. Health Policy Plan. 2014;29 Suppl 3:iii70-8.
    · extracted · source: references/10665-381036.page-861.13.json
  900. Erasmus E, Gilson L. How to start thinking about investigating power in the organizational settings of policy implementation. Health policy and planning. 2008;23: 361-68.
    · extracted · source: references/10665-381036.page-861.14.json
  901. Youssef A, Chaudhary ZK, Wiljer D, Mylopoulos M, Sockalingam S. Mapping Evidence of Patients' Experiences in Integrated Care: A Scoping Review. Gen Hosp Psychiatry. 2019;61:1-9.
    · extracted · source: references/10665-381036.page-861.15.json
  902. Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X
    · extracted · doi:10.1016/S0140-6736(17)32130-X · source: references/10665-381036.page-894.1.json
  903. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLOS Medicine 2016;13(10):e1002152. doi: 10.1371/journal.pmed.1002152
    · extracted · doi:10.1371/journal.pmed.1002152 · source: references/10665-381036.page-894.2.json
  904. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. American journal of epidemiology 1974;99(2):131-8. doi: 10.1093/oxfordjournals.aje.a121593 [published Online First: 1974/02/01]
    · extracted · doi:10.1093/oxfordjournals.aje.a121593 · source: references/10665-381036.page-894.3.json
  905. Small PM, Fujiwara PI. Management of Tuberculosis in the United States. New England Journal of Medicine 2001;345(3):189-200. doi: 10.1056/nejm200107193450307
    · extracted · doi:10.1056/nejm200107193450307 · source: references/10665-381036.page-894.4.json
  906. Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiology spectrum 2016;4(5) doi: 10.1128/microbiolspec.TBTB2-0023-2016 [published Online First: 2016/10/21]
    · extracted · doi:10.1128/microbiolspec.TBTB2-0023-2016 · source: references/10665-381036.page-894.5.json
  907. World Health Organization.The End TB Strategy. Geneva, 2015.
    · extracted · source: references/10665-381036.page-894.6.json
  908. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2006;10(11):1192-204. [published Online First: 2006/11/30]
    · extracted · source: references/10665-381036.page-894.7.json
  909. Sørensen AL, Nagai S, Houen G, et al. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infection and immunity 1995;63(5):1710-17. doi: 10.1128/iai.63.5.1710-1717.1995
    · extracted · doi:10.1128/iai.63.5.1710-1717.1995 · source: references/10665-381036.page-894.8.json
  910. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356(9235):1099-104. doi: 10.1016/s0140-6736(00)02742-2 [published Online First: 2000/09/29]
    · extracted · doi:10.1016/s0140-6736(00)02742-2 · source: references/10665-381036.page-894.9.json
  911. Rangaka MX, Diwakar L, Seldon R, et al. Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. Clinical Infectious Diseases 2007;44(12):1639-46. doi: 10.1086/518234
    · extracted · doi:10.1086/518234 · source: references/10665-381036.page-894.10.json
  912. Tagmouti S, Slater M, Benedetti A, et al. Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review. Annals of the American Thoracic Society 2014;11(8):1267-76. doi: 10.1513/AnnalsATS.201405-188OC [published Online First: 2014/09/05]
    · extracted · doi:10.1513/AnnalsATS.201405-188OC · source: references/10665-381036.page-894.11.json
  913. Campos-Neto A, Rodrigues-Junior V, Pedral-Sampaio DB, et al. Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. Tuberculosis 2001;81(5-6):353-8.
    · extracted · source: references/10665-381036.page-894.12.json
  914. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS ONE [Electronic Resource] 2013;8(5):e64215.
    · extracted · source: references/10665-381036.page-894.13.json
  915. Kiselev VI, Baranovskii PM, Rudykh IV, et al. Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis. [Russian]. Problemy tuberkuleza i boleznei legkikh 2009(2):11-16.
    · extracted · source: references/10665-381036.page-894.14.json
  916. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. The Lancet Respiratory Medicine 2017;5(4):259-68.
    · extracted · source: references/10665-381036.page-894.15.json
  917. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. European Respiratory Journal 2016;47(3):919-28.
    · extracted · source: references/10665-381036.page-894.16.json
  918. Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. The Lancet Infectious diseases 2021 doi: 10.1016/s1473-3099(21)00261-9 [published Online First: 2021/10/05]
    · extracted · doi:10.1016/s1473-3099(21)00261-9 · source: references/10665-381036.page-894.17.json
  919. Hamada Y, den Boon S, Maria Cirillo D, et al. Framework for the evaluation of new tests for tuberculosis infection. European Respiratory Journal 2021:2004078. doi: 10.1183/13993003.04078-2020
    · extracted · doi:10.1183/13993003.04078-2020 · source: references/10665-381036.page-894.18.json
  920. World Health Organization. Use of tuberculosis release assays (IGRAs) in low and middle-income countries. World Heal Organ Policy Statement. Published online 2011. doi:WHO/HTM/TB/2011.18.
    · extracted · source: references/10665-381036.page-894.19.json
  921. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
    · extracted · doi:10.1186/s13643-016-0384-4 · source: references/10665-381036.page-894.20.json
  922. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009 [published Online First: 2011/10/19]
    · extracted · doi:10.7326/0003-4819-155-8-201110180-00009 · source: references/10665-381036.page-894.21.json
  923. Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Research Policy and Systems 2018;16(1):45. doi: 10.1186/s12961-018-0320-2
    · extracted · doi:10.1186/s12961-018-0320-2 · source: references/10665-381036.page-894.22.json
  924. Stogova NA. Use of a sample with recombinant tuberculosis antigen (Diaskintest®) in the differential diagnosis of lung diseases of lower lobe localization. Tuberculosis and socially infectious diseases 2020
    · extracted · source: references/10665-381036.page-894.23.json
  925. Stogova NA Immunological skin tests in differential diagnostics disseminated processes in the lungs. PULMONOLOGIYA . 2020; 30 (4): 446-452. (In Russ.) Https://doi.org/10.18093/0869-0189-2020-30-4-446-452.
    · extracted · doi:10.18093/0869-0189-2020-30-4-446-452 · source: references/10665-381036.page-894.24.json
  926. S.L. Nakonechnaya VAA, Yu.L. Mizernitsky. COMPARATIVE EVALUATION OF THE RESULTS OF THE MANTU AND DIASKIN TEST WITH THE LABORATORY TEST QuantiFERON® - Gold In-Tube IN CHILDREN WITH TUBERCULOSIS AND CHILDREN WITH CHRONIC NON-SPECIFIC LUNG DISEASES. Tuberculosis and socially infectious diseases 2020(3):20-25.
    · extracted · source: references/10665-381036.page-894.25.json
  927. Xu M, Lu W, Li T, et al. Sensitivity, specificity, and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China: two randomized, self-controlled, parallel-group phase 2b trials. Clin Infect Dis 2021;22:22. doi: 10.1093/cid/ciab472
    · extracted · doi:10.1093/cid/ciab472 · source: references/10665-381036.page-894.26.json
  928. L.А. Bаryshnikovа RHF, D.A. Kudlay, A.P. Alekseev, M.N. Kabaeva. The technological concept of in vitro gamma-interferon tests to identify effector T cells that respond to stimulation with the Mycobacterium tuberculosis antigen and their use among children. Pacific Medical Journal 2021(2)
    · extracted · source: references/10665-381036.page-894.27.json
  929. Dotsenko Ya. I. SMA, Bilogortseva O. I., Pobedyonna G. P. POSSIBILITIES OF MODERN DIAGNOSTICS AND PROPHYLAXIS OF TUBERCULOSIS IN MEDICAL WORKERS OF ANTI-TUBERCULOSIS MEDICAL CENTERS (Ukrainian). Ukrainian Journal of Occupational Health 2015;1(42)
    · extracted · source: references/10665-381036.page-894.28.json
  930. Aggerbeck H, Ruhwald M, Hoff ST, et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS ONE [Electronic Resource] 2018;13(9):e0204554.
    · extracted · source: references/10665-381036.page-894.29.json
  931. Aggerbeck H, Ruhwald M, Hoff ST, et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. International Journal of Tuberculosis & Lung Disease 2019;23(1):38-44.
    · extracted · source: references/10665-381036.page-894.30.json
  932. Aksenova V, Barishnikova L, Klevno N, et al. New screening and diagnostic options of various traits of TB infection among children and adolescents in Russia. Curr Pediatr 2011; 10: 16– 22.
    · extracted · source: references/10665-381036.page-894.31.json
  933. Baryshnikova LA, Aksenova VA, Klevno NI. Detection and differential diagnostics of tuberculosis in children and adolescents. Tuberk i Bolezn lëgkih 2017; 95: 34–9.
    · extracted · source: references/10665-381036.page-894.32.json
  934. Borodulina EA, Akhmerova TE, Yeremenko ES, Amsova EA, Titugina A. Features of Diagnostics of Tuberculosis in children using Diaskintest. Èpidemiologiâ i vakcinoprofilaktika 2014; 6: 51–5.
    · extracted · source: references/10665-381036.page-894.33.json
  935. Borodulina EA, Lebedeva NO, Povalyaeva L V, Tsygancov IL, Borodulin BE. Tuberculin diagnostics in pulmonary Tuberculosis combined with HIV-infection. Kazan Med J 2012; 93: 576–9.
    · extracted · source: references/10665-381036.page-894.34.json
  936. Slogotskaya L, Bogorodskaya E, Ivanova D, et al. Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow. PLoS ONE [Electronic Resource] 2018;13(12):e0208705.
    · extracted · source: references/10665-381036.page-894.35.json
  937. Dovgalyuk IF, Starshinova AA, Zubareva S V. Possibilities of application of Diaskintest in the practical work of the paediatrician. Pediatr J named after GNSperansky 2013; 92: 65–8.
    · extracted · source: references/10665-381036.page-894.36.json
  938. Fedorovykh VS, Markelov YM, Karbauskene SI, Bakunovich T V. Results on Tuberculosis detection in children and adolescents in Karelian Republic and evaluation tests with preparation ‘Diaskintest’ in risk groups for Tuberculosis. Proc Petrozavodsk State Univ 2014; 6: 62–6.
    · extracted · source: references/10665-381036.page-894.37.json
  939. Iablonskiy PK, Dovgaljuk IF, Starshinova AA, Iakunova O. Role of modern immunological tests in diagnostics of Tuberculosis in children. Med Immunol 2013; 15: 37–44.
    · extracted · source: references/10665-381036.page-894.38.json
  940. Kabanets NN, Filinyuk OV, Urazova OI, Morozova KS, Kolokolova OV. Comparative evaluation of immunological tests for children at risk in the Tomsk Region. Bull Sib Med 2016; 15: 30–8.
    · extracted · source: references/10665-381036.page-894.39.json
  941. Kibrik BS, Melnikov VP. The results of allergen Tuberculosis recombinant usage among healthy population, people with social contacts and TB patients. Tuberc Soc Signif Dis 2015; 1: 36–9.
    · extracted · source: references/10665-381036.page-894.40.json
  942. Koretskaya NM, Bolshakova IA, Chushkina AA. Comparative evaluation of the results of Mantoux test with 2 TE PPD-L and Diaskintest in medical university students. Sib Med J 2012; 112: 97– 9.
    · extracted · source: references/10665-381036.page-894.41.json
  943. Laushkina ZA, Krasnov VA, Petrenko TI. Immunological tests in differential diagnostics of Pulmonary Tuberculosis. Tuberk i Bolezn Legk 2017; 95: 26–30.
    · extracted · source: references/10665-381036.page-894.42.json
  944. Losovskaya ME, Belushkov VV, Gurina OP, et al. The comparison of laboratory tests Quantiferon, Tubinferon and Diaskintest in children with tuberculosis infection. Russ Clin Lab Diagnostics 2016; 61: 838–42.
    · extracted · source: references/10665-381036.page-894.43.json
  945. Lozovskaya ME, Belushkov VV, Gurina OP, Vasilyeva YB, Klochkova LV. Comparative evaluation of innovative diagnostic tests for latent and active TВ infection in children. Pediatr 2014; 5: 46– 50.
    · extracted · source: references/10665-381036.page-894.44.json
  946. Ministry of Health, and Social Development of the Russian Federation. Order of the Ministry of Health and Social Development of the Russian Federation of October 29, 2009 N 855 ‘On Amendments to Appendix N 4 to the Order of the Ministry of Health of Russia of March 21, 2003 N 109’. 2009. https://www.garant.ru/products/ipo/prime/doc/4089228/ (accessed Feb 7, 2020).
    · extracted · link · source: references/10665-381036.page-894.45.json
  947. Mishin V, Morozov I, Grigor’yev Y, et al. A diagnostic and clinical significance of the intradermal Mantoux test and Diaskintest in young healthy individuals and people with Pulmonary Tuberculosis. Russ Infect Dis 2016; 14: 56–62.
    · extracted · source: references/10665-381036.page-894.46.json
  948. Nikitina IY, Karpina NL, Kasimceva O V., Gergert VY, Ergeshov A, Lyadova I V. Comparative performance of QuantiFERON-TB Gold versus skin test with tuberculosis recombinant allergen (Diaskintest) among patients with suspected pulmonary tuberculosis in Russia. Int J Infect Dis 2019; 86: 18–24.
    · extracted · source: references/10665-381036.page-894.47.json
  949. Salina T, Morozova TI. Immunological methods in differential diagnostics. Tuberk i Bolezn lëgkih 2011; 88: 50–3.
    · extracted · source: references/10665-381036.page-894.48.json
  950. Salina TY, Morozova TI, Kudlay DA. Results of the skin test of diaskintest in pulmonary tuberculosis patients caused by different genotypes of M. tuberculosis. Tuberc Lung Dis 2019; 97: 66–7.
    · extracted · source: references/10665-381036.page-894.49.json
  951. Samorodov NA, Kibishev VM, Tilova LA, et al. Analysis of the results of the use of recombinant TB allergen ‘Diaskintest’ in patients with respiratory diseases. J New Med Technol eEdition 2019; 13: 114–9.
    · extracted · source: references/10665-381036.page-894.50.json
  952. Senin AM, Eismont N V, Golubev DN. ‘Diaskintest’ as evaluation of activity of the disease in patients with Tuberculosis and HIV co-infection. Vestn Sovrem Klin Med 2016; 9: 101–7.
    · extracted · source: references/10665-381036.page-894.51.json
  953. Shovkun LA, Romantseva NE, D KE. Diagnostics of the active and latent Tubercular infection among children and teenagers using Diaskintest preparation. Med Vestn Ûga Ross 2014; 1: 124–9.
    · extracted · source: references/10665-381036.page-894.52.json
  954. Slogotskaya LI, Litvinov VI, Seltsovsky PP, et al. A skin test with recombinant allergen of Mycobacterium Tuberculosis (Diaskintest) to detect Tuberculosis in HIV patients. Pulmonologiya 2011; 1: 60–4.
    · extracted · source: references/10665-381036.page-894.53.json
  955. Slogotskaya LV, Ivanova DA, Kochetkov YA, Kulikovskaya NV, Vaneeva TV, Filippov AV. Comparative results of the skin test with the preparation containing the recombinant protein CFP-10-ESAT-6 and the laboratory test Quantiferon-GIT. Tuberk i Bolezn lëgkih 2012; 89: 27–32.
    · extracted · source: references/10665-381036.page-894.54.json
  956. Slogotskaya LV, Kochetkov YA, Filippova AV. Diaskintest is a new method to detect Tuberculosis. Tuberk i Bolezn lëgkih 2011; 88: 17–22.
    · extracted · source: references/10665-381036.page-894.55.json
  957. Slogotskaya LV, Sentchichina O, Bogorodskaya EM. Sensitivity of the test with the Tuberculosis allergen, containing recombinant protein ESAT6-CFP10, in new cases of Tuberculosis in children and adolescents in Moscow. Tuberc Soc Signif Dis 2013; 1: 37–44.
    · extracted · source: references/10665-381036.page-894.56.json
  958. Starshinova AA, Istomina EV, Zinchenko YS, et al. Diagnostic value of specific immune complexes in detection of active Tuberculosis infection. Med Immunol 2019; 21: 269–78.
    · extracted · source: references/10665-381036.page-894.57.json
  959. Starshinova AA, Zinchenko YS, Istomina E V., et al. Diagnosis of Latent Tuberculosis Infection in Personnel of Various Institutions and Determination of the Risk Group for Tuberculosis. Bioprep Prev Diagnosis, Treat 2019; 19: 178–84.
    · extracted · source: references/10665-381036.page-894.58.json
  960. Vaganova US, Russkih OE. Ways of rising detectability of Tuberculosis among health workers. J Pharm Qual Assur 2015; 2: 61–7.
    · extracted · source: references/10665-381036.page-894.59.json
  961. A S. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. Int J Mycobacteriology 2018;7:32-9.
    · extracted · source: references/10665-381036.page-894.60.json
  962. Zhang H, Wang L, Li F, et al. Induration or erythema diameter not less than 5 mm as results of recombinant fusion protein ESAT6-CFP10 skin test for detecting M. tuberculosis infection. BMC Infect Dis 2020;20(1):685. doi: 10.1186/s12879-020-05413-9 [published Online First: 2020/09/20]
    · extracted · doi:10.1186/s12879-020-05413-9 · source: references/10665-381036.page-894.61.json
  963. Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clinical Microbiology & Infection 2016;22(10):889.e9-89.e16.
    · extracted · source: references/10665-381036.page-894.62.json
  964. Badaro R, Machado BAS, Duthie MS, et al. The single recombinant M. tuberculosis protein DPPD provides enhanced performance of skin testing among HIV-infected tuberculosis patients. AMB Express 2020;10(1):133. doi: 10.1186/s13568-020-01068-6 [published Online First: 2020/08/02]
    · extracted · doi:10.1186/s13568-020-01068-6 · source: references/10665-381036.page-894.63.json
  965. Levi DT. Modern tuberculin preparation — methods of receiving, control, standardization and use. Moscow, Russia, 1987.
    · extracted · source: references/10665-381036.page-894.64.json
  966. Starshinova A, Zhuravlev V, Dovgaluk I, et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. International Journal of Mycobacteriology 2018;7(1):32-39.
    · extracted · source: references/10665-381036.page-894.65.json
  967. Zwerling A, Behr MA, Verma A, et al. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLOS Medicine 2011;8(3):e1001012. doi: 10.1371/journal.pmed.1001012
    · extracted · doi:10.1371/journal.pmed.1001012 · source: references/10665-381036.page-894.66.json
  968. Starshinova AA, Istomina EV, Belyaeva EN, Yablonsky PK. Detection of latent tuberculosis infection in various units of an anti‑TB facility. Med Alliance 2018;4:11‑8.
    · extracted · source: references/10665-381036.page-894.67.json
  969. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.
    · extracted · link · source: references/10665-381036.page-894.68.json
  970. Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X
    · extracted · doi:10.1016/S0140-6736(17)32130-X · source: references/10665-381036.page-933.1.json
  971. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLOS Medicine 2016;13(10):e1002152. doi: 10.1371/journal.pmed.1002152
    · extracted · doi:10.1371/journal.pmed.1002152 · source: references/10665-381036.page-933.2.json
  972. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. American journal of epidemiology 1974;99(2):131-8. doi: 10.1093/oxfordjournals.aje.a121593 [published Online First: 1974/02/01]
    · extracted · doi:10.1093/oxfordjournals.aje.a121593 · source: references/10665-381036.page-933.3.json
  973. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva, Switzerland: WHO, 2020.
    · extracted · source: references/10665-381036.page-933.4.json
  974. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27(1):3-20. doi: 10.1128/cmr.00034-13 [published Online First: 2014/01/08]
    · extracted · doi:10.1128/cmr.00034-13 · source: references/10665-381036.page-933.5.json
  975. World Health Organization.The End TB Strategy. Geneva, 2015.
    · extracted · source: references/10665-381036.page-933.6.json
  976. Froeschle JE, Ruben FL, Bloh AM. Immediate Hypersensitivity Reactions after Use of Tuberculin Skin Testing. Clinical Infectious Diseases 2002;34(1):e12-e13. doi: 10.1086/324587
    · extracted · doi:10.1086/324587 · source: references/10665-381036.page-933.7.json
  977. Campos-Neto A, Rodrigues-Junior V, Pedral-Sampaio DB, et al. Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. Tuberculosis 2001;81(5-6):353-8.
    · extracted · source: references/10665-381036.page-933.8.json
  978. Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. The Lancet Infectious diseases 2021 doi: 10.1016/s1473-3099(21)00261-9 [published Online First: 2021/10/05]
    · extracted · doi:10.1016/s1473-3099(21)00261-9 · source: references/10665-381036.page-933.9.json
  979. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. The Lancet Respiratory Medicine 2017;5(4):259-68.
    · extracted · source: references/10665-381036.page-933.10.json
  980. Kiselev VI, Baranovskiĭ PM, Rudykh IV, et al. [Clinical trials of the new skin test Diaskintest for the diagnosis of tuberculosis]. Probl Tuberk Bolezn Legk 2009(2):11-6. [published Online First: 2009/04/23]
    · extracted · source: references/10665-381036.page-933.11.json
  981. Aggerbeck H, Ruhwald M, Hoff ST, et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS ONE [Electronic Resource] 2018;13(9):e0204554.
    · extracted · source: references/10665-381036.page-933.12.json
  982. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf Accessed 11 September 2020.
    · extracted · link · source: references/10665-381036.page-933.13.json
  983. Europen Medial Agency. Serious adverse reaction. https://www.ema.europa.eu/en/glossary/serious-adverse-reaction accessed 3 December 2021.
    · extracted · link · source: references/10665-381036.page-933.14.json
  984. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
    · extracted · doi:10.1186/s13643-016-0384-4 · source: references/10665-381036.page-933.15.json
  985. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi: 10.1136/bmj.l4898
    · extracted · doi:10.1136/bmj.l4898 · source: references/10665-381036.page-933.16.json
  986. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. doi: 10.1136/bmj.i4919
    · extracted · doi:10.1136/bmj.i4919 · source: references/10665-381036.page-933.17.json
  987. Chou R, Aronson N, Atkins D, et al. Assessing Harms When Comparing Medical Interventions. 2008 Nov 18. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK47098/.
    · extracted · link · source: references/10665-381036.page-933.18.json
  988. Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Research Policy and Systems 2018;16(1):45. doi: 10.1186/s12961-018-0320-2
    · extracted · doi:10.1186/s12961-018-0320-2 · source: references/10665-381036.page-933.19.json
  989. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8(5):e1001026. doi: 10.1371/journal.pmed.1001026 [published Online First: 2011/05/12]
    · extracted · doi:10.1371/journal.pmed.1001026 · source: references/10665-381036.page-933.20.json
  990. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS ONE [Electronic Resource] 2013;8(5):e64215.
    · extracted · source: references/10665-381036.page-933.21.json
  991. Aggerbeck H, Ruhwald M, Hoff ST, et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. International Journal of Tuberculosis & Lung Disease 2019;23(1):38-44.
    · extracted · source: references/10665-381036.page-933.22.json
  992. Bergstedt W, Tingskov PN, Thierry-Carstensen B, et al. First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS ONE [Electronic Resource] 2010;5(6):e11277.
    · extracted · source: references/10665-381036.page-933.23.json
  993. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. European Respiratory Journal 2016;47(3):919-28.
    · extracted · source: references/10665-381036.page-933.24.json
  994. Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clinical Microbiology & Infection 2016;22(10):889.e9-89.e16.
    · extracted · source: references/10665-381036.page-933.25.json
  995. Li F, Xu M, Zhou L, et al. Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial. Clinical & Vaccine Immunology: CVI 2016;23(9):767-73.
    · extracted · source: references/10665-381036.page-933.26.json
  996. Xu M, Lu W, Li T, et al. Sensitivity, specificity, and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China: two randomized, self-controlled, parallel-group phase 2b trials. Clin Infect Dis 2021;22:22. doi: 10.1093/cid/ciab472
    · extracted · doi:10.1093/cid/ciab472 · source: references/10665-381036.page-933.27.json
  997. Aksenova VA, Klevno NI, Baryshnikova LA, et al. Diaskintest for tuberculosis in children and adolescents. [Russian]. Problemy tuberkuleza i boleznei legkikh 2009(10):13-16.
    · extracted · source: references/10665-381036.page-933.28.json
  998. Belushkov V.V. LME, Novik G.A., Gurina O.P., Shibakova N.D. IMPORTANCE OF DIASKINTEST AND QUANTIFERON TEST IN THE DIAGNOSTICS OF TUBERCULOSIS IN CHILDREN (in Russian) FUNDAMENTAL RESEARCH 2012;7:34-39.
    · extracted · source: references/10665-381036.page-933.29.json
  999. Bаrminа N, Bаryshnikovа L. Ways to enhance the efficiency of tuberculosis prevention in the children exposed to tuberculous infection illustrated by the example of Perm Kray (in Tuberculosis and Lung Diseases 2018;96(9):50-56.
    · extracted · source: references/10665-381036.page-933.30.json
  1000. M.I. Borisova AEG, T.R. Suleimanova. Skin test with allergen tuberculosis recombinant in pregnant women (in Russian). Tuberculosis and socially significant diseases 2017;4
    · extracted · source: references/10665-381036.page-933.31.json
  1001. Slogotskaya L, Litvinov V, Seltsovsky P, et al. A skin test with recombinant allergen of Mycobacterium tuberculosis (Diaskintest®) to detect tuberculosis in HIV patients (in Pulmonologiya 2011(1):60-64.
    · extracted · source: references/10665-381036.page-933.32.json
  1002. Slogotskaya L.V. FV, Kochetkov Ya.A., Sel’tsovsky P.P.., Litvinov V.I. The efficacy of application of diaskintest in patients presenting with extrapulmonary localization of tuberculosis and concomitant HIV infection or without it (in Russian) Immunology 2011;3
    · extracted · source: references/10665-381036.page-933.33.json
  1003. Streltsova Elena Nikolaevna ROA, Bespalova Alevtina Olegovna. Comparative clinical studies of the use of the Diaskintest skin test and the Mantoux test in patients with pulmonary tuberculosis (in Russian) Astrakhan Medical Journal 2011;1
    · extracted · source: references/10665-381036.page-933.34.json
  1004. Korolyuk A.M. VAG, Krivokhizh V.N. POSSIBLE CAUSES AND MECHANISMS OF EMERGENCY ADVERSE REACTIONS OF IMMEDIATE TYPE TO GENETIC TUBERCULOSIS ALLERGENS IN CHILDREN (in Russian). Phthisiology and Pulmonology 2017;1(14)
    · extracted · source: references/10665-381036.page-933.35.json
  1005. Rutkovsky L.I. KII, Chekalina O.E. ANALYSIS OF ADVERSE REACTIONS TO A SAMPLE WITH AN ALLERGEN TUBERCULOSIS RECOMBINANT IN CHILDREN (in Russian). Abstracts Nationwide scientific forum of students with international participation «Student science – 2020» 2020;3
    · extracted · source: references/10665-381036.page-933.36.json
  1006. Yarovaya Yu.A. AVI, Egorova T.Yu., Petlenko I.S. OPTIONS OF GENERAL REACTIONS TO THE DIASKINTEST SAMPLE (in Russian) Medicine: theory and practice 2019;4
    · extracted · source: references/10665-381036.page-933.37.json
  1007. Dotsenko Ya. I. SMA, Bilogortseva O. I., Pobedyonna G. P. POSSIBILITIES OF MODERN DIAGNOSTICS AND PROPHYLAXIS OF TUBERCULOSIS IN MEDICAL WORKERS OF ANTI-TUBERCULOSIS MEDICAL CENTERS (Ukrainian). Ukrainian Journal of Occupational Health 2015;1(42)
    · extracted · source: references/10665-381036.page-933.38.json
  1008. Xia L, Liu XH, Zhao ZY, et al. Safety Evaluation of Recombinant Fusion Protein RP22 as a Skin Test Reagent for Tuberculosis Diagnosis: A Phase I Clinical Trial. Infectious Diseases & Therapy 2021;10(2):925-37.
    · extracted · source: references/10665-381036.page-933.39.json
  1009. Du WX, Chen BW, Lu JB, et al. Preclinical study and phase I clinical safety evaluation of recombinant Mycobacterium tuberculosis ESAT6 protein. Medical Science Monitor Basic Research 2013;19:146-52.
    · extracted · source: references/10665-381036.page-933.40.json
  1010. Sun QF, Xu M, Wu JG, et al. Efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis: a phase II trial. Medical Science Monitor 2013;19:969-77.
    · extracted · source: references/10665-381036.page-933.41.json
  1011. Arend SM, Franken WP, Aggerbeck H, et al. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis 2008;88(3):249-61.
    · extracted · source: references/10665-381036.page-933.42.json
  1012. Lillebaek T, Bergstedt W, Tingskov PN, et al. Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique. Tuberculosis 2009;89(2):158-62.
    · extracted · source: references/10665-381036.page-933.43.json
  1013. Wu X, Zhang L, Zhang J, et al. Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection. Clinical & Experimental Immunology 2008;152(1):81-7.
    · extracted · source: references/10665-381036.page-933.44.json
  1014. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine 2016; 13(10): e1002152.
    · extracted · source: references/10665-381036.page-974.1.json
  1015. World Health Organization. Global tuberculosis report 2020: World Health Organization; 2020.
    · extracted · source: references/10665-381036.page-974.2.json
  1016. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? The International Journal of Tuberculosis and Lung Disease 2006; 10(11): 1192-204.
    · extracted · source: references/10665-381036.page-974.3.json
  1017. SAGE. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections, 2017.
    · extracted · source: references/10665-381036.page-974.4.json
  1018. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal 2011; 37(1): 88-99.
    · extracted · source: references/10665-381036.page-974.5.json
  1019. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. American journal of respiratory and critical care medicine 2011; 183(1): 88-95.
    · extracted · source: references/10665-381036.page-974.6.json
  1020. Steffen RE, Caetano R, Pinto M, et al. Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS one 2013; 8(4): e59546.
    · extracted · source: references/10665-381036.page-974.7.json
  1021. Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. The Lancet Infectious Diseases 2021.
    · extracted · source: references/10665-381036.page-974.8.json
  1022. Starshinova A, Zhuravlev V, Dovgaluk I, et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. International journal of mycobacteriology 2018; 7(1): 32.
    · extracted · source: references/10665-381036.page-974.9.json
  1023. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2015; 4(1): 1-9.
    · extracted · source: references/10665-381036.page-974.10.json
  1024. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: Oxford university press; 2015.
    · extracted · source: references/10665-381036.page-974.11.json
  1025. Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Scientific reports 2020; 10(1): 1-12.
    · extracted · source: references/10665-381036.page-974.12.json
  1026. Аксенова ВА, Барышникова Л, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы современной педиатрии 2011; 10(4).
    · extracted · source: references/10665-381036.page-974.13.json
  1027. Куликов А, Зинчук И, Проценко М, Крысанов И. Диаскинтест для скрининга детей и подростков на туберкулезную инфекцию: подходы к ценообразованию и анализ затраты–эффективность. Туберкулез и болезни легких 2009; 9: 41-6.
    · extracted · source: references/10665-381036.page-974.14.json
  1028. Ягудина Р, Зинчук И. Фармакоэкономическое исследование лекарственных средств для диагностики туберкулезной инфекции. Фармакоэкономика Современная фармакоэкономика и фармакоэпидемиология 2013; 6(1).
    · extracted · source: references/10665-381036.page-974.15.json
  1029. Солодун ИЮ, Эва ХМ, Башлакова ЕЕ, Ермолаева ТН, Давыдовская МВ, Евдошенко ЕП. Клинико-экономический анализ применения метода диагностики туберкулезной инфекции у детей и подростков с использованием аллергена туберкулезного рекомбинантного. Проблемы стандартизации в здравоохранении 2017; (3-4).
    · extracted · source: references/10665-381036.page-974.16.json
  1030. Чугаев Ю, Камаева Н, Цветков А, Кудлай Д, Черняев И. ИННОВАЦИОННЫЕ РЕКОМБИНАНТНЫЕ ТЕХНОЛОГИИ ВЫЯВЛЕНИЯ И ДИАГНОСТИКИ ТУБЕРКУЛЕЗА У ДЕТЕЙ И ПОДРОСТКОВ: ДОСТИЖЕНИЯ И ПРОБЛЕМЫ. Pediatriya named after GN Speransky 2020; 96(6).
    · extracted · source: references/10665-381036.page-974.17.json
  1031. Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR, Marks SM, Linas BP. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model. JAMA internal medicine 2017; 177(12): 1755-64.
    · extracted · source: references/10665-381036.page-974.18.json
  1032. Auguste P, Tsertsvadze A, Pink J, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technology Assessment 2016; 20(38): 1-678.
    · extracted · source: references/10665-381036.page-974.19.json
  1033. Jo Y, Shrestha S, Gomes I, et al. Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas. Clinical Infectious Diseases 2021; 73(9): e3476-e82.
    · extracted · source: references/10665-381036.page-974.20.json
  1034. Capocci S, Smith C, Morris S, et al. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. European Respiratory Journal 2015; 46(1): 165-74.
    · extracted · source: references/10665-381036.page-974.21.json
  1035. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. American journal of respiratory and critical care medicine 2011; 184(5): 590-601.
    · extracted · source: references/10665-381036.page-974.22.json
  1036. Campbell JR, Johnston JC, Ronald LA, et al. Screening for latent tuberculosis infection in migrants with CKD: a cost-effectiveness analysis. American Journal of Kidney Diseases 2019; 73(1): 39-50.
    · extracted · source: references/10665-381036.page-974.23.json
  1037. Abubakar I, Lalvani A, Southern J, et al. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health technology assessment (Winchester, England) 2018; 22(56): 1.
    · extracted · source: references/10665-381036.page-974.24.json
  1038. del Campo MT, Fouad H, Solís-Bravo MM, Sánchez-Uriz MA, Mahíllo-Fernández I, Esteban J. Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers. Infection Control & Hospital Epidemiology 2012; 33(12): 1226-34.
    · extracted · source: references/10665-381036.page-974.25.json
  1039. Eralp MN, Scholtes S, Martell G, Winter R, Exley AR. Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice. BMJ open 2012; 2(2): e000630.
    · extracted · source: references/10665-381036.page-974.26.json
  1040. Mandalakas AM, Hesseling AC, Gie RP, Schaaf H, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013; 68(3): 247-55.
    · extracted · source: references/10665-381036.page-974.27.json
  1041. Kim H, Hanrahan C, Martinson N, Golub J, Dowdy D. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. The International Journal of Tuberculosis and Lung Disease 2018; 22(12): 1435-42.
    · extracted · source: references/10665-381036.page-974.28.json
  1042. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013; 68(3): 230-9.
    · extracted · source: references/10665-381036.page-974.29.json
  1043. Verma G, Chuck A, Jacobs P. Tuberculosis screening for long-term care: a cost-effectiveness analysis. The International journal of tuberculosis and lung disease 2013; 17(9): 1170-7.
    · extracted · source: references/10665-381036.page-974.30.json
  1044. La’Marcus TW, Coleman MS, de la Motte Hurst C, et al. A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC public health 2015; 15(1): 1-14.
    · extracted · source: references/10665-381036.page-974.31.json
  1045. Nijhawan AE, Iroh PA, Brown LS, Winetsky D, Porsa E. Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. BMC infectious diseases 2016; 16(1): 1-11.
    · extracted · source: references/10665-381036.page-974.32.json
  1046. Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. The European Journal of Health Economics 2017: 405-15.
    · extracted · source: references/10665-381036.page-974.33.json
  1047. Mullie GA, Schwartzman K, Zwerling A, N’Diaye DS. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC medicine 2017; 15(1): 1-15.
    · extracted · source: references/10665-381036.page-974.34.json
  1048. Sohn H, Kim H, Lee S. Cost-effectiveness of contact screening strategies for tuberculosis among high-school adolescents in South Korea. The International Journal of Tuberculosis and Lung Disease 2018; 22(5): 496-503.
    · extracted · source: references/10665-381036.page-974.35.json
  1049. Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F. Cost-effectiveness of latent tuberculosis infection screening before immigration to low-incidence countries. Emerging infectious diseases 2019; 25(4): 661.
    · extracted · source: references/10665-381036.page-974.36.json
  1050. Loureiro RB, Maciel ELN, Caetano R, et al. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PloS one 2019; 14(11): e0225197.
    · extracted · source: references/10665-381036.page-974.37.json
  1051. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. The Lancet infectious diseases 2011; 11(6): 435-44.
    · extracted · source: references/10665-381036.page-974.38.json
  1052. Shah M, Miele K, Choi H, et al. QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC infectious diseases 2012; 12(1): 1-10.
    · extracted · source: references/10665-381036.page-974.39.json
  1053. Swaminath A, Bhadelia N, Wang YC. Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflammatory bowel diseases 2013; 19(11): 2444-9.
    · extracted · source: references/10665-381036.page-974.40.json
  1054. Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PloS one 2017; 12(10): e0186778.
    · extracted · source: references/10665-381036.page-974.41.json
  1055. Li J, Yip BH, Leung C, et al. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: a cost-effectiveness analysis in an intermediate disease burden area. PloS one 2018; 13(1): e0189531.
    · extracted · source: references/10665-381036.page-974.42.json
  1056. Png ME, Yoong J, Ong CWM, Fisher D, Bagdasarian N. A screening strategy for latent tuberculosis in healthcare workers: Cost-effectiveness and budget impact of universal versus targeted screening. Infection Control & Hospital Epidemiology 2019; 40(3): 341-9.
    · extracted · source: references/10665-381036.page-974.43.json
  1057. Al Abri S, Kowada A, Yaqoubi F, Al Khalili S, Ndunda N, Petersen E. Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman. International Journal of Infectious Diseases 2020; 92: S72-S7. Section A: Systematic literature reviews Literature review For the primary systematic literature review (new skin tests), the search included papers from inception until 30 July 2021. Since the previous review included papers published until 20 October 2020, our updated search excluded studies published before October 2020.
    · extracted · source: references/10665-381036.page-974.44.json
  1058. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine 2016; 13(10): e1002152.
    · extracted · source: references/10665-381036.page-1068.1.json
  1059. Wysocki AD, Villa TCS, Arakawa T, et al. Latent tuberculosis infection diagnostic and treatment cascade among contacts in primary health care in a city of Sao Paulo State, Brazil: cross-sectional study. PloS one 2016; 11(6): e0155348.
    · extracted · source: references/10665-381036.page-1068.2.json
  1060. National Health System. National latent TB infection testing and treatment programme. 2021. https://www.england.nhs.uk/tuberculosis-programme/area-for-action-8-national-latent-tb-infection-testing-and-treatment-programme/ (accessed 12 October, 2021 2021).
    · extracted · link · source: references/10665-381036.page-1068.3.json
  1061. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. The Lancet Infectious Diseases 2016; 16(11): 1269-78.
    · extracted · source: references/10665-381036.page-1068.4.json
  1062. Loureiro RB, Maciel ELN, Caetano R, et al. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PloS one 2019; 14(11): e0225197.
    · extracted · source: references/10665-381036.page-1068.5.json
  1063. Vynnycky E, Fine P. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiology & Infection 1997; 119(2): 183-201.
    · extracted · source: references/10665-381036.page-1068.6.json
  1064. Pai M, Zwerling A, Menzies D. Systematic review: T-cell–based assays for the diagnosis of latent tuberculosis infection: an update. Annals of internal medicine 2008; 149(3): 177-84.
    · extracted · source: references/10665-381036.page-1068.7.json
  1065. Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Scientific reports 2020; 10(1): 1-12.
    · extracted · source: references/10665-381036.page-1068.8.json
  1066. World Health Organization. Global tuberculosis report 2020: World Health Organization; 2020.
    · extracted · source: references/10665-381036.page-1068.9.json
  1067. Mugwagwa T, Abubakar I, White PJ. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling. Thorax 2021; 76(3): 281-91.
    · extracted · source: references/10665-381036.page-1068.10.json
  1068. Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. The Lancet Infectious Diseases 2021.
    · extracted · source: references/10665-381036.page-1068.11.json
  1069. Abubakar I, Lalvani A, Southern J, et al. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health technology assessment (Winchester, England) 2018; 22(56): 1.
    · extracted · source: references/10665-381036.page-1068.12.json
  1070. Tuberculosis N. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. National Institute for Health and Care Excellence 2011.
    · extracted · source: references/10665-381036.page-1068.13.json
  1071. Mandalakas AM, Hesseling AC, Gie RP, Schaaf H, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013; 68(3): 247-55.
    · extracted · source: references/10665-381036.page-1068.14.json
  1072. Qiagen. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA package insert. Qiagen Hilden, Germany; 2022.
    · extracted · source: references/10665-381036.page-1068.15.json
  1073. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value in Health 2016; 19(8): 929-35.
    · extracted · source: references/10665-381036.page-1068.16.json
  1074. Steffen RE, Caetano R, Pinto M, et al. Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS one 2013; 8(4): e59546.
    · extracted · source: references/10665-381036.page-1068.17.json
  1075. Kim H, Hanrahan C, Martinson N, Golub J, Dowdy D. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. The International Journal of Tuberculosis and Lung Disease 2018; 22(12): 1435-42.
    · extracted · source: references/10665-381036.page-1068.18.json
  1076. White P, Jit M. What is the Cost-Effectiveness of Latent Tuberculosis Infection (LTBI) Treatment with Different Regimens. London: Imperial College Consultants; 2015.
    · extracted · source: references/10665-381036.page-1068.19.json
  1077. Gomez G, Dowdy DW, Bastos M, et al. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. BMC infectious diseases 2016; 16(1): 1-13.
    · extracted · source: references/10665-381036.page-1068.20.json
  1078. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PloS one 2013; 8(1): e54587.
    · extracted · source: references/10665-381036.page-1068.21.json
  1079. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013; 68(3): 230-9.
    · extracted · source: references/10665-381036.page-1068.22.json
  1080. Maher D, Chaulet P, Spinaci S, Harries A. Treatment of tuberculosis: guidelines for national programmes. Treatment of tuberculosis: guidelines for national programmes Second edition 1997; (Ed. 2): 1-77.
    · extracted · source: references/10665-381036.page-1068.23.json
  1081. Horsburgh Jr CR. Priorities for the treatment of latent tuberculosis infection in the United States. New England journal of medicine 2004; 350(20): 2060-7.
    · extracted · source: references/10665-381036.page-1068.24.json